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II 
Abstract 
 
 
Arthrogryposis, Renal dysfunction, and Cholestasis (ARC) syndrome is a multisystem 
disorder caused by mutations in genes encoding two proteins VPS33B or VIPAR, which 
appear to be critical regulators of cell polarity. VPS33B and VIPAR may function as 
part of a multi-protein complex that interacts with an active form of RAB11A and is 
involved in the transcriptional regulation of E-cadherin.  
VPS33B and VIPAR are shown to interact at a protein level forming a stable binary 
complex. A novel interacting partner of VIPAR was identified, PLOD3, a post-
translational modification enzyme with lysyl hydroxylase (LH), collagen 
galactosyltransferase (GT), and glucosyltransferase (GGT) activities (Wang et al., 
2012). In mIMCD-3 polarized cell lines VPS33B and VIPAR are involved in PLOD3 
trafficking from the TGN compartment via RAB11A positive vesicles. Study of the 
topology of this ternary protein complex evidenced that VIPAR is a transmembrane 
protein with its luminal N-terminal interacting with PLOD3 and its cytosolic C-terminal 
being involved in the interaction with VPS33B. VPS33B/VIPAR mediates the 
trafficking of PLOD3 from the TGN to collagen carrier structures where the binding of 
PLOD3 with collagen takes place. The PLOD3-collagen binding is required for 
collagen trafficking and an abnormal accumulation of intracellular collagen, associated 
with failure in PLOD3 delivery to collagen, is observed in Vipar knockdown mIMCD-3 
cells. 
Abnormal collagen modifications and trafficking in Vps33b/Vipar deficiency can 
explain the down-regulation of E-cadherin that characterises some polarized cell types 
in ARC and the cell model for this syndrome. These findings establish a role for 
VPS33B/VIPAR in the intracellular trafficking of collagen.  
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CHAPTER ONE: 
INTRODUCTION 
 
 
 
 
 
 
 
 
 2 
1.1 - ARC syndrome 
 
 
Arthrogryposis, renal dysfunction and cholestasis (ARC) syndrome (OMIM 208085) is 
a rare autosomal recessive disease typically characterised by neurogenic arthrogryposis, 
renal tubular dysfunction and neonatal cholestatic jaundice. Other features of the disease 
may vary from one patient to another, these include: severe metabolic acidosis, 
worsening nephrogenic diabetes insipidus, and low gamma glutamyl transpeptidase 
(γGT) activity (Gissen et al., 2004). 
In most cases, clinical features are accompanied by ichthyosis, platelet α-granule 
biogenesis defect (that often leads to bleeding tendency) and severe failure to thrive. 
Other clinical features include mild dysmorphic features and absent corpus callosum 
(Gissen et al., 2006). 
Patients with ARC rarely exceed the age of one year due to recurrent infections that lead 
to dehydration and acidosis (Tanaka et al., 1992). Those surviving longer develope liver 
cirrhosis and developmental delay (Eastham et al., 2001). A typical phenotype of a 
patient with ARC is shown in figure 1.1.  
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Figure 1.1 - Typical features of a patient with ARC syndrome can be seen, including 
joint contractures, dry skin and jaundice.  
 
 
 
The two organs most affected by ARC syndrome are the liver and kidney. 
Immunostaining of liver and kidney biopsy samples from ARC patients have been 
performed using antibodies against markers that localise exclusively to the apical 
membrane of the aforementioned organs (Bull et al., 2006; Gissen et al., 2004). These 
markers include the carcinoembryonic antigen (CEA) and γ-GT (Gamma-glutamyl 
transpeptidase) for both liver and kidney, and dipeptidyl peptidase (CD26) for 
immunostaining of kidney only. Gissen et al (2004) observed that in individuals with 
ARC apical markers were mislocalised in the cytoplasm and/or basolateral domain. This 
was clearly distinct from the expression pattern found in age-matched control kidney 
and liver samples. As an example, immunostaining of CD26 in kidney biopsies from 
ARC patients and age-matched controls is reported in figure 1.2. 
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Figure 1.2 - Immunostaining of kidney biopsies from ARC patients and age matched 
controls. Staining was performed with an antibody against CD26. The zoomed-in 
micrograph shows immunostaining of CD26 at the apical membrane in the age-
mathched controls but mislocalised to the cytoplasm in ARC kidney cells. Figure 
modified from (Gissen et al., 2004). 
 
 
 
1.2 - VPS33B and ARC 
 
 
Although the first case of ARC syndrome was reported in 1973 (Lutz-Richner and 
Landolt., 1973), the molecular basis of the disease was discovered only in 2004 when 
the genetic locus of ARC was mapped to chromosome 15q26.1. Different germline 
mutations were found in VPS33B (Vacuolar protein sorting 33B) gene (Gissen et al., 
2004). Subsequent analysis of the ARC patients DNA suggested that germline 
mutations in VPS33B account for ~75 % of all reported cases (Cullinane et al., 2009; 
Gissen et al., 2006). This evidence suggested that other genes are involved in the 
 5 
aetiology of ARC and their defects might cause the disease in the absence of mutations 
in VPS33B. The VPS33B genomic sequence (NC_000015.9) is 24,060 bp in length and 
is composed of 23 exons. Alternative splicing is predicted to produce nine transcript 
variants, four of which result in a protein product (figure 1.3). The longest processed 
mRNA (1,854 bp) encodes the VPS33B protein (NP_061138.3), which consists of 617 
amino acids and has a molecular weight of 70.6 kDa.  
The function of VPS33B has not yet been fully characterised in humans but the yeast 
homolog Vps33p is known to belong to the Sec1/Munc18 (SM) family of proteins 
(Peterson and Emr, 2001). SM proteins play an important role in conferring specificity 
to membrane fusion events by binding t-SNAREs of the syntaxin family (Chen et al., 
2002; Gallwitz and Jahn, 2003; Toonen and Verhage, 2003). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 6 
 
Figure 1.3 - VPS33B splice variants analysed with Ensemble http://www.ensembl.org/ 
Boxes are exons. Lines connecting boxes are introns. Filled boxes are coding 
sequences, and unfilled boxes are UTR (UnTranslated Region). 
A gold coloured transcript is identical between Ensembl automated annotation and 
VEGA/Havana (http://vega.sanger.ac.uk/index.html) manual curation. A red transcript 
comes from either the Ensembl automatic annotation pipeline 
(http://www.ensembl.org/info/docs/genebuild/genome_annotation.html) or manual 
curation by the VEGA/Havana project. Blue transcripts are non-coding. 
Nonsense-mediated decay transcripts contain nonsense mutations that prevent the 
expression of truncated or erroneous proteins. This type of transcript is annotated 
by VEGA/Havana. The dashed line indicates the Sec1 domain; it characterizes most of 
the coding sequence of the transcripts that result in a protein product. 
 
 
 
Vps33p is a Class C vacuole protein sorting protein whose role is crucial for vacuolar 
biogenesis in Saccharomyces cerevisiae (Peterson and Emr, 2001). As a result Vps33p 
mutants show severe defects in endocytosis (Subramanian et al., 2004) associated with 
a block in intracellular trafficking of proteins. This is shown by a missorting of vacuolar 
hydrolases and abnormal secretion (Banta et al., 1990). 
 7 
Two homologues of the yeast Vps33p have been identified in higher organisms: 
VPS33A and VPS33B (Gissen et al., 2005). Just like their yeast homolog, both VPS33A 
and VPS33B contain a Sec1 like domain (figure 1.3) that makes them part of the SM 
family of proteins. This suggests that VPS33B might play a crucial role in vesicular 
trafficking in mammalian organisms and that ARC phenotype may be secondary to 
abnormal organelle biogenesis (Gissen et al., 2005). 
The function of VPS33A is however different from VPS33B. This suggestion comes 
from the hypo-pigmented phenotype of the buff (bf) mouse that carries a mutation in 
VPS33A. The buff mouse is considered a model for Hermansky - Pudlak syndrome 
(Chintala et al., 2009). Both VPS33B and VPS33A genes are ubiquitously expressed. In 
addition VPS33B is highly expressed in testis and has a low level of expression in the 
lung (Carim et al., 2000). VPS33A and VPS33B share only 31% identity and 51% 
similarity, which can explain the different functions performed by the two encoded 
proteins (Gissen et al., 2005). This is also consistent with the common origin of the 
genes and subsequent divergence.  
The crystal structure of VPS33B is not yet known, therefore it is difficult to correlate 
mutations identified in patients with ARC patients with changes in the three-
dimensional folding of the protein, its stability, or the binding affinity for possible 
interactors. However, prediction studies have been performed using the previously 
reported crystal structure of the interaction between neuronal-SEC1 and Syntaxin1 
proteins in rat (Gissen et al., 2005; Misura et al., 2000). In this regard, it is important to 
underline that VPS33B and SEC1 share only 15% of identity (section 3.1). This 
prediction studies suggest that L30P, a missense mutation that causes a severe ARC 
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phenotype, might interfere with the N-terminal binding site for t-SNARE by disrupting 
protein-protein interactions (Gissen et al., 2005). 
According to recent studies (Bach et al., 2008; Wong et al., 2011) VPS33B is 
autophosphorylated on a tyrosine residue. The tyrosine phosphatase PtpA of 
M.tuberculosis directly interacts and dephosphorylates VPS33B on its tyrosine residue 
and this blocks the phagosome maturation in M.tuberculosis-infected macrophages. 
 
 
 
1.3 - VIPAR and ARC 
 
 
Two different studies demonstrate that VPS33B interacts with a protein encoded by the 
gene initially termed C14orf133 (Cullinane et al., 2010; Zhu et al., 2009). Thus the gene 
was named VIPAR (VPS33B-interacting protein involved in polarity and apical protein 
restriction) (NC_000014.8) (Cullinane et al., 2010) but confusingly was also carrying 
names VPS16B and hSPE-39 (Spermatogenesis-defective protein homologue 39) 
because its role in vesicular trafficking during spermatogenesis (L'Hernault and 
Faundez, 2011; Zhu et al., 2009). The final and official name of the gene is VIPAS39, 
which is a combination of VIPAR and Spe39. In this thesis VIPAS39 is used for the 
name of the gene while VIPAR for the name of the protein. The genomic sequence of 
VIPAS39 is 30,966 bp long. Alternative splicing results in twelve transcript variants 
among which seven are decoded to produce a protein (figure 1.4). The first four variants 
(named VIPAS39-005, -001. -201, -003) encode the same protein of 493 amino acids 
(isoform 1) and between them differ in the 5' UTR (figure 1.4). Variant VIPAS39-002 
and -004 lack an alternate in-frame exon in the 5' coding region compared to variant 
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VIPAS39-005. The resulting protein contains 444 amino acids (isoform 2) and is shorter 
than isoform 1 (figure 1.4). 
 
Figure 1.4 - VIPAS39 splice variants analysed with Ensembl (http://www.ensembl.org/) 
Boxes are exons. Lines connecting boxes are introns. Filled boxes are coding sequence, 
and unfilled boxes are UTR (UnTranslated Region). 
A gold coloured transcript is identical between Ensembl automated annotation and 
VEGA/Havana (http://vega.sanger.ac.uk/index.html) manual curation. 
A red transcript comes from either the Ensembl automatic annotation pipeline 
(http://www.ensembl.org/info/docs/genebuild/genome_annotation.html) or the manual 
curation by the VEGA/Havana project. Blue transcripts are non-coding. 
The protein coding variants generate two different isoforms of VIPAS39 indicated in 
figure. 
 
 
 
The precise role of the VPS33B/VIPAR in vesicular trafficking is not completely 
understood. Studies of in-vitro interaction have shown that the C. elegans homologue of 
VIPAR interacts with both VPS33A and VPS33B (Zhu et al., 2009). However 
experiments performed in our laboratory did not reveal appreciable evidence for 
interaction between VPS33A and VIPAR (Smith et al., 2012). The same in-vitro study 
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(Zhu et al., 2009) has shown that VIPAR is part of the homotypic fusion and vacuole 
protein sorting (HOPS) complex (section 1.4.4.4.1) which regulates vesicle docking 
through its interaction with SNARE proteins. Published data from our laboratory 
suggest that VIPAR may interact with VPS18 (the core protein of the HOPS complex) 
only in the absence of VPS33B. Therefore the VPS33B–VIPAR complex is unlikely to 
be part of the HOPS complex (Smith et al., 2012). The homolog of VIPAR in 
Drosophila (FOB) is thought to play an important role in the fusion of phagosomes with 
late endosomes/lysosomes in fly macrophages (Akbar et al., 2011). Defects in 
Drosophila’s immune response to non-pathogenic bacteria support this hypothesis. 
Other studies have shown that VPS33B/VIPAR might be involved in the trafficking 
from the trans-Golgi network in Dami cells (human megakaryocytic cell line) (Urban et 
al., 2012). Furthermore electron micrographs of enterocytes derived from 
vps33b morpholino-injected Zebrafish larvae showed dilated stacks of Golgi cisternae 
in these cells (Matthews et al., 2005). Further evidence of the possible role of VIPAR in 
Golgi trafficking comes from bioinformatics analysis of VIPAR using the Pfam and 
SMART databases. This found a large Golgin subfamily A member 5 domain in the 
VIPAR protein sequence (figure 1.5). Golgin family members are coiled-coil motif 
proteins known to interact with Rab GTPases and mediate tethering of vesicles to Golgi 
membranes and cisternal membranes to each other (Burguete et al., 2008; Satoh et al., 
2003) 
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Figure 1.5 - Analysis of VIPAR protein sequence using Pfam (A) and SMART (B) 
databases predict a large Golgin subfamily A member 5 domain along its sequence. 
 
 
An abnormal expression and distribution of E-cadherin, one of the major components of 
adherens junctions, was highlighted in a patient with ARC (Cullinane et al., 2010). The 
same abnormality occurs in mouse inner medullary collecting duct (mIMCD-3) cell 
lines knockdown for VPS33B and VIPAR. It was found that in the knockdown cell lines 
E-cadherin was transcriptionally down-regulated. (Cullinane et al., 2010). Co-
localisation and co-immunoprecipitation experiments performed in this study suggest 
that the VPS33B-VIPAR complex interacts with RAB11A and regulates indirectly the 
expression of E-cadherin at adherens junctions. (Cullinane et al., 2010) 
The mislocalisation of proteins normally present in the apical portion of the renal 
tubular and bile canalicular membranes (showed by immunostaining of CEA, γGT, 
CEACAM5, BSEP) may be able to explain cholestasis, dehydration and urinary waste 
of amino acids and sugars in ARC patients. In addition E-cadherin down-regulation 
with consequent disruption of the adherens and tight junctions may be associated with 
malformation of luminal structures such as bile ducts and renal tubules (Cullinane et al., 
2010; Zhao et al., 2010).
A
B 
VIPAS39 
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1.4 - Insights into vesicular transport 
 
 
1.4.1 - Endocytic and biosynthetic pathway: the central role of TGN 
 
 
Bioinformatics analysis in combination with published data discussed above and 
clinical features of individuals with ARC, suggests that one of the roles of VPS33B and 
VIPAR is to mediate vesicular trafficking and epithelial polarisation through the 
transport of proteins to the apical surface.  
Proteins are transported in membrane-bound vesicular structures through and between 
different cellular compartments. Intracellular transport of proteins is divided into two 
routes according to the direction of the transport in relation to the cell membrane (Ang 
and Folsch, 2012; Erickson and Bocock, 2007; Gissen and Maher, 2007; Keller and 
Simons, 1997). They are known as the biosynthetic and endocytic pathways. In the 
biosynthetic route the de novo synthesised proteins are transferred from the cytosolic 
ribosomes to the Endoplasmic Reticulum (ER) where the correct folding of the proteins 
occurs (Sannerud et al., 2003). The cargo proteins are then packed into transport 
vesicles and sent towards Golgi cisternae (first cis and then trans Golgi) for post-
translational modifications. In the Golgi apparatus the proteins are “labelled” with a 
sorting signal that determines their final destination within the cell (Gissen and Maher, 
2007). In the endocytic pathway, molecules are internalised from the extracellular space 
and plasma membrane. Subsequently the cargo molecules, encapsulated in endocytotic 
vesicles, are transported to early sorting endosomes. In the early endosomes the 
molecule can either be recycled back to the plasma membrane or transferred to late 
endosomes and then delivered to lysosomes for degradation (figure 1.6) (De Matteis and 
Luini, 2008; Gissen and Maher, 2007; Gruenberg and Maxfield, 1995; Sachse et al., 
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2002). The trans Golgi network (TGN) is a major sorting station that directs newly 
synthesised proteins from earlier Golgi compartments to different destinations (figure 
1.6) (De Matteis and Luini, 2008; Gu et al., 2001). Apart from this central role in the 
secretory pathway, the TGN also receives extracellular materials from the endocytic 
pathway. The main cellular compartments that receive material from TGN include: the 
apical plasma membrane (1), the basolateral plasma membrane (2), recycling 
endosomes (3), early endosomes (4), late endosomes (5) and specialised compartments 
such as secretory granules (6) in secretory cells (figure 1.6) (Gu et al., 2001). Different 
components of trafficking machinery (such as coat proteins) are involved in ensuring 
that the vesicles are delivered to different destinations. Clathrin-coated vesicles mediate 
the transport between TGN and endosomes. The recruitment of clathrin on membranes, 
as well as the recognition of sorting signals in cargo molecules, is mediated by adaptor-
coat proteins (AP). Three-dimensional tomographic studies have shown that TGN is 
composed of tubules emanating from the last two trans-Golgi cisternae and only the 
tubules deriving from the last cisterna are clathrin coated (Gu et al., 2001). Proteins are 
transported from TGN to endosomes by clathrin/AP-1-coated vesicles. 
The AP-1 complex is a heterotetramer consisting of two large subunits termed γ and β, a 
medium-sized subunit (µ1), and a small subunit (ς1) (Orzech et al., 2001). The β-
subunit is particularly important for clathrin binding (Shih et al., 1995), while the γ-
adaptin is most likely involved in targeting (Page and Robinson, 1995). The µ1-subunit 
is formed of two chains: µ1A, the ubiquitous chain, probably involved in the recognition 
of tyrosine-based sorting signals encoded by cargo proteins (Kirchhausen, 1999), and 
the recently identified epithelium-specific µ1B. µ1B was found to be expressed in 
various polarised epithelial cell lines and is implicated in basolateral targeting of 
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specific receptors (Folsch et al., 1999) (section 1.4.2). The function of the ς subunit is
unknown.  
 
Figure 1.6 - In the biosynthetic route newly synthesised proteins derived from earlier 
Golgi compartments (I) are sorted from TGN towards different destinations (1–5). The 
exit routes from the TGN include those towards the apical plasma membrane (1), the 
basolateral plasma membrane (2), recycling endosomes (3), early endosomes (4), late 
endosomes (5) and specialized compartments such as secretory granules (6) in 
secretory cells. The TGN also receives also extracellular materials from the endocytic 
pathway (II–IV) and sends it back to earlier Golgi compartments (7). Figure modified 
from (De Matteis and Luini, 2008). 
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1.4.2 - Polarized cells and vesicular trafficking 
 
 
The fundamental feature of cell polarity is the division of the plasma membrane into 
two discrete domains, one apical and one basolateral, each characterised by a particular 
distribution of proteins and lipids. The maintenance of two biochemically and 
functionally distinct domains in the membrane is tailored to the particular functions of 
each domain (Schuck and Simons, 2004). Examples of polarised cells include neurons, 
migrating cells and the growing bud in Saccharomyces cerevisiae. However, the best-
studied type of cell polarity is found in epithelia, which are the most common type of 
tissue in animals. The epithelial apical membrane faces the luminal compartment and is 
specialised primarily in secretion or absorption (Rodriguez-Boulan and Nelson, 1989). 
The basolateral domain faces the extracellular fluid compartment and specialises in the 
establishment of cell-cell contacts, recognition and transduction of signals. 
Polarised protein trafficking in epithelial cells is triggered by signals embedded within 
the sequence of the proteins themselves. The intracellular trafficking machinery, after 
reading and interpreting these sorting signals, segregates and packages membrane 
proteins into specialised transport vesicles destined for apical or basolateral delivery. 
Once the polarity is established, highly specialised cell machinery is required for its 
maintenance; membrane proteins are brought to their appropriate sites of action and 
recycled from one domain to the other. The biosynthetic and endocytic pathways 
coexist in every type of cell. In polarised cells there is another particular route, called 
transcytosis (Bastaki et al., 2002). In this route, vesicles containing macromolecules are 
transferred from one domain of the plasma membrane to the opposite one. This 
mechanism is a strategy that polarised cells employ to interconnect different sides of the 
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cell, maintaining at the same time the different composition of these microenvironments 
(Schuck and Simons, 2004).  
The cytoskeleton has a crucial role in generating and maintaining apical and basolateral 
polarity in epithelial cells. Microtubules play an essential role for the organisation of the 
apical membrane, whereas the actin cytoskeleton has a role in basolateral polarity 
(Rodriguez-Boulan E et al ., 2005). 
A large number of diseases, including ARC syndrome, are known to be associated with 
failure of normal protein sorting to the correct cell surface or intracellular compartment 
(Carmosino et al., 2010). 
 
 
 
1.4.3 - Steps in vesicular transport: from budding to fusion 
  
 
Vesicular transport of a cargo protein from a donor to an acceptor compartment can be 
summarised into 3 major steps (Carmosino et al., 2010). In the first step the trafficking 
vesicle is assembled at the donor compartment (figure 1.7A). A specific v-SNARE is 
bound to the membrane of the donor compartment in proximity to a transmembrane 
receptor that has exclusive affinity for the cargo protein (Kirchhausen, 2000). This is the 
zone of the membrane where the vesicle budding is going to occur. The cargo protein is 
recognised by the transmembrane receptor and therefore internalised into the budding 
vesicle. The coat protein complexes assemble at the membrane that starts to increase its 
curvature and form a vesicle-like structure (Bonifacino and Lippincott-Schwartz, 2003). 
This process is mediated by Rab proteins, such as Rab1 and Rab9 (Bonifacino and 
Lippincott-Schwartz, 2003). Budding of transport intermediates from cellular 
membranes involves a variety of molecular machinery including protein coats, 
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membrane-sculpting domains such as ENTHs (epsin N-terminal homology) and BARs 
(Bin/Amphiphysin/Rvs), enzymes that translocate or modify lipids, actin nucleating 
promoting factors (NPFs), and molecular motors participate in membrane deformation 
(Farsad and De Camilli, 2003; Idrissi et al., 2012). Once the vesicle has budded from 
the donor compartment it moves along the actin cytoskeleton (Stamnes, 2002) (figure 
1.7B) that guides the protein to the acceptor compartment. Motor proteins, GTP bound 
Rabs (such as Rab6 and Rab33) and Rab effector molecules are required in this process 
(Stenmark and Olkkonen, 2001). The vesicle loses its coat and becomes tethered to the 
acceptor compartment by the combination of tethering factors, such as the Homotypic 
fusion and vacuole protein sorting (HOPS) complex and Rab proteins (such as Rab1 and 
Rab5) (Yu and Hughson, 2010). Successively the t-SNARE at the acceptor 
compartment and the v-SNARE at the vesicle, assemble into a four-helix bundle called 
the “trans-SNARE complex” which promotes fusion (section 1.4.4.1) (Jahn and 
Scheller, 2006). This process is assisted by Rabs (such as Rab3 and Rab9) and 
Sec1/Munc18 (SM) proteins, as well as a number of other proteins (Sudhof and 
Rothman, 2009). The cargo protein is then released into the acceptor compartment 
(figure 1.7C). 
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Figure 1.7 - Steps in vesicular transport of a cargo protein from a donor to an acceptor 
compartment. (A) Assembly of the trafficking vesicle. (B) Intracellular trafficking. (C) 
Fusion of the vesicle to the target membrane. 
 
 
 
1.4.4 - Vesicular trafficking machinery 
 
 
As mentioned above, VPS33B belongs to the SM family of proteins that confer 
specificity to fusion events by binding t-SNAREs of the syntaxin family (Dulubova et 
al., 2003; Toonen and Verhage, 2003). Altogether SNAREs, SM and other docking and 
fusion proteins generate very complex intracellular machinery. 
 
 
 
1.4.4.1 - SNARE proteins 
 
 
SNARE proteins (soluble N-ethylmaleimide-sensitive-factor attachment protein 
receptor) are central components of the membrane fusion machinery in cells. They 
directly mediate intracellular membrane fusion through the binding of SNAREs located 
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at the donor membrane to SNAREs placed at the acceptor membrane (Chen and 
Scheller, 2001; Jahn et al., 2003; Ungar and Hughson, 2003). 
SNAREs were first biochemically identified in 1984 when Rothman and colleagues 
isolated an N-ethylmaleimide sensitive factor (NSF) and an adaptor protein called 
soluble NSF attachment protein (SNAP), both required for efficient transport of proteins 
in-vitro (Balch et al., 1984). The receptors of those molecules were first isolated from 
brain tissues and were termed SNAREs (SNAP receptors) (Sollner et al., 1993). Since 
then SNARE proteins have been found to be involved in every membrane trafficking 
event (Chen and Scheller, 2001; Jahn et al., 2003; Kavalali, 2002; Pelham, 2001). 
Rothman and colleagues (Sollner et al., 1993) named v-SNARE (v- vesicle) the SNARE 
protein located at the donor compartment, and t-SNARE (t- target) the SNARE protein 
located at the acceptor compartment. Another nomenclature categorises SNAREs into 
R-SNAREs (R- arginine) and Q-SNAREs (Q- glutamine) because of a single key amino 
acid residue located in the middle of the SNARE domain: most v-SNAREs have an 
arginine residue while t-SNAREs have a glutamine (Fasshauer et al., 1998). 
The structure of SNARE proteins is characterised by a unique SNARE motif of about 
60-70 amino acid residues (Fasshauer et al., 1998). The SNARE motif consists of a 
repeating heptad pattern of hydrophobic residues organised in a α-helical structure. 
Four α-helices assemble into a helix bundle that is stabilised by hydrophobic residues 
facing the core of the bundle (Antonin et al., 2002; Poirier et al., 1998; Sutton et al., 
1998). The central arginines and glutamines form an ionic layer composed of a 
hydrogen-bonded network in which three Q-SNAREs bind to one R-SNARE. The R/Q 
nomenclature is a result of the polar layer identification (Fasshauer et al., 1998). 
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Q-SNAREs are further classified into Qa, Qb, or Qc subgroups according to the 
positions of the SNARE motif in the four-helix structure (Bock et al., 2001). As 
previously mentioned, the formation of the trans-SNARE complex is the driving force 
that brings together the two membranes, mediating their fusion. After fusion has 
occurred, the trans-SNARE complex is converted into a very stable cis complex where 
SNAREs are associated within the same membrane (Bock et al., 2001). The NSF/SNAP 
chaperone system utilises the energy of ATP hydrolysis to disassemble the cis-SNARE 
complex (figure 1.7C) (May et al., 2001). Thus SNAREs are recycled for another round 
of membrane fusion events.  
Originally SNARE proteins were thought to be the component that confers specificity to 
the fusion reaction. This hypothesis, known as the SNARE hypothesis, was based on the 
identification of numerous SNARE proteins in eukaryotic cells that were thought to be 
required in distinct fusion processes (Sollner et al., 1993). Subsequent literature data 
showed that this is not absolute truth. SNARE assembly and function is regulated by 
numerous other proteins that provide specificity to the fusion reactions (Bock et al., 
2001; Chen and Scheller, 2001). These SNARE-associated proteins can interact either 
directly or indirectly with SNAREs. The three main groups include Rab GTPases ( 
1.4.4.3), SM proteins (section 1.4.4.2) and other tethering factors. 
 
 
 
1.4.4.2 - SM proteins 
 
 
SM proteins are soluble, 60–90 kDa proteins that interact directly with SNAREs and 
mediate every membrane fusion reaction (Malsam et al., 2008). There are several 
models that show different ways in which SNARE and SM can bind together, but in all 
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of these an SM protein binds specifically to a Qa-SNARE (Gupta and Brent Heath, 
2002). The diverse binding models have been associated with the ambiguous role 
played by SM proteins in the SNARE complex assembly. In-vivo studies have 
demonstrated that this role might be either positive (enhance SNARE complex 
assembly) or negative (inhibit SNARE complex assembly) (Carr and Novick, 2000). 
The SM protein Vps33p (the yeast homolog of VPS33B) is an example of the positive 
role that SM proteins play in the SNARE complex formation (Sato et al., 2000; Seals et 
al., 2000). Recent published data show that Vps33p binds to the 
quaternary SNARE complex Vam3, Vam7, and Nyv1 on their SNARE domains 
(Lobingier and Merz, 2012). The identification of other interacting proteins that bind to 
the SM-SNARE complex can further help in elucidation of the role of specific SM 
proteins (Dulubova et al., 2003). 
 
 
1.4.4.3 - Rab GTPases 
 
 
Ras-Associated Binding (RAB) proteins are small GTPases that are considered a key 
regulatory factor in the intracellular traffic. RAB proteins belong to the RAS 
superfamily. Sec4, the first Rab family member to be discovered in yeast, encodes a 
small GTP-binding protein related to Ras (Salminen and Novick, 1987). Since then, 
more than 60 RAB proteins have been identified in mammals and more than 10 in yeast, 
highlighting the importance of RABs in cell homeostasis and intracellular trafficking 
(Pereira-Leal and Seabra, 2001). In agreement with this, mutations in genes encoding 
RABs have been associated with many human diseases such as immunodeficiency, 
cancer, and neurodegeneration, Carpenter and Griselli syndrome (Bem et al., 2011; 
Corbeel and Freson, 2008; Schwartz et al., 2007; Stein et al., 2003). 
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RAB proteins are specifically located to distinct organelles and associated vesicles 
(figure 1.8). They are involved in all the steps of intracellular trafficking described 
above including vesicle budding, traffic of the vesicle along the cytoskeleton and 
vesicular fusion (Tuvim et al., 2001).  
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Figure 1.8 - The diversity of Rabs in intracellular vesicular pathways (CCV, clathrin-
coated vesicle; CCP, clathrin-coated pit; EC, epithelial cells; M, melanosomes; SG, 
secretory granules; SV, synaptic vesicles; T, T-cell granules; TGN, trans-Golgi 
network.). Figure modified from (Zerial and McBride, 2001). 
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Experimental data show that direct interaction between RABs and SNARE proteins can 
enhance the formation of the trans-SNARE complex (Lian et al., 1994). However other 
published data suggest that this role may be indirect and requires RABs interaction with 
tethering factors (Grote and Novick, 1999; Hutagalung and Novick, 2011; Whyte and 
Munro, 2002). The role played by RABs in vesicular fusion is therefore not completely 
characterised. The diverse functions of RABs originate from their ability to interact with 
different RAB-associated/RAB-effector proteins. RABs regulate the activity of 
downstream effectors through the RAB GTPase cycle (figure 1.9) (Stenmark and 
Olkkonen, 2001). In the active form RABs bind GTP and activate downstream 
effectors. Conversely, the inactive form (GDP-bound) is unable to activate effector 
proteins. This on/off ‘switch’ mechanism is controlled by the RAB-associated proteins 
GEFs (Guanine nucleotide exchange factors) that catalyse the exchange of GTP for 
GDP, and GAPs (GTPase activating proteins), which stimulate the hydrolysis of GTP 
(Pereira-Leal and Seabra, 2000). 
 
 
 
 
 
 
 
 
Figure 1.9 - RAB protein–GTPase cycles: GDP/GTP exchange and membrane 
association/dissociation (Adapted from (Corbeel and Freson, 2008)). 
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RAB proteins are synthesised as soluble proteins into the cytosol where they remain in 
an inactive state until required. In response to intracellular and extracellular signals, 
RABs associate with the lipid bilayer of membranes after being post-translationally 
modified. This modification is mediated by RAB geranylgeranyl transferase (RabGGT), 
which consists of two subunits (RabGGTa and RabGGTß) that catalyse the prenylation 
of two cysteines in the C-terminus of RABs (figure 1.9) (Corbeel and Freson, 2008). 
The RAB protein can therefore bind to the donor membrane where it becomes 
subsequently activated by a specific GEF. In the active state, RAB interacts with its 
specific effectors, performing its function in intracellular trafficking. Once the required 
function is completed, the RAB protein is inactivated by a specific GAP and is removed 
from the membrane by a Rab-GDI (GDP dissociation inhibitor) (figure 1.9). The cycle 
is finally completed with the RAB protein returning to the cytosol and ready for another 
cycle once required. 
 
 
 
1.4.4.3.1 - The RAB11 GTPase subfamily  
 
 
Transport from the trans-Golgi network (TGN) to the cell surface, discussed in section 
1.4.1, requires RAB8 or RAB11 (Ullrich et al., 1996), figure 1.6). 
RAB11 has been detected on a variety of subcellular membranes. In non-polarised cells 
it was found associated with both Golgi and recycling endosomes. In addition, transport 
from sorting endosomes to the recycling compartment has been shown to require 
functional RAB11A (Ullrich et al., 1996). In polarised cells RAB11 has been localised 
to Golgi, recycling endosomes, as well as to apical vesicle populations (Goldenring et 
al., 1996). In regulated secretory cells RAB11 has been associated with TGN and TGN-
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derived vesicles of both constitutive and the regulated secretory pathway (Urbe et al., 
1993). RAB11 might play also a role in the exocytic membrane trafficing and is 
specifically required for TGN–to–plasma membrane transport (Chen et al., 1998).  
The RAB11 GTPase subfamily comprises three members: RAB11A, RAB11B and 
RAB25/RAB11C (Kelly et al., 2012). Unlike universally expressed RAB11A and B, 
RAB25 expression seems to be limited to polarised epithelia such as gastrointestinal 
mucosa, kidney, and lung (Goldenring et al., 1993). RAB25 function is thought to 
mirror that of RAB11A; it associates with the apical recycling endosome (ARE) in 
polarised epithelial cells where it regulates the processes of transcytosis and recycling to 
the plasma membrane (Calhoun and Goldenring, 1997; Casanova et al., 1999). Similar 
to RAB11A, it has been shown that RAB11B associates with recycling endosomes 
(Schlierf et al., 2000) and is associated with the apical recycling compartment where it 
regulates targeting of proteins to the apical plasma membrane (Butterworth et al., 2012; 
Silvis et al., 2009). 
Changes in RAB25 expression, including both up-regulation and down-regulation have 
been associated with breast, ovarian, colon and other types of cancer (Agarwal et al., 
2009; Goldenring et al., 1993; Tong et al., 2012). This is promoted by the interaction 
between RAB25 and α5β1 integrin that leads to loss of polarity and cell migration 
(Caswell et al., 2007). 
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1.4.4.4 - Tethering factors 
 
 
Tethering factors are thought to be the initiators of the fusion reactions between two 
membranes (Pfeffer, 1999; Waters and Hughson, 2000; Whyte and Munro, 2002). In 
association with RAB proteins they stimulate the formation of the initial pairing 
between membranes that precedes the SNARE complex assembly. Indeed many 
tethering factors interact at the same time with SNAREs and RABs, thus facilitating the 
SNARE complex formation (Guo et al., 2000). Therefore tethering factors are other 
essential elements that confer specificity to the fusion reaction.  
Despite their structural diversity, tethering factors are divided into two main groups: 
long coiled-coil proteins and large hetero-oligomeric complexes. The first group 
includes the Golgi protein p115/Uso1 (Waters et al., 1992) and the endosomal EEA1 
(Simonsen et al., 1998). Hetero-oligomeric proteins of 4-10 subunits belong to the 
second group of tethering factors and include the COG (Ungar et al., 2002) and TRAPP 
(Sacher et al., 1998) complexes at the Golgi compartment, the Dsl1p complex at the ER 
(Reilly et al., 2001), the exocyst or Sec6/8 complex at the plasma membrane (Hsu et al., 
1996) and the HOPS and CORVET complexes at the vacuole/lysosomes (Peplowska et 
al., 2007; Sato et al., 2000). Although it is known that many tethering factors interact 
with SNAREs (Ungar and Hughson, 2003), and some, such as the TRAPP complex and 
the Vam6 subunit of the HOPS complex, show RAB GEFs properties (Wang et al., 
2000; Wurmser et al., 2000), the function of many domains and subunits of different 
tethering factors remains unknown.  
This thesis is focusing on the proteins whose yeast homologues are involved in the 
HOPS complex, including the SM protein Vps33p. 
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1.4.4.4.1 - HOPS complex 
 
 
The HOmotypic Fusion and vacuole Protein Sorting complex (HOPS) is a multi-subunit 
complex initially identified as a tethering factor for vacuolar fusion in yeast (Collins et 
al., 2005). There are 6 subunits that form the HOPS complex: Vps11, Vps16, Vps18, 
Vps33, Vps41 (Vam2) and Vps39 (Vam6) (Nakamura et al., 1997; Price et al., 2000) 
(figure 3.3). In yeast the HOPS complex has been shown to interact with the active form 
of the Rab protein Ypt7 (yeast Rab7) and mediate vesicle tethering by binding to 
SNAREs (Collins et al., 2005; Stroupe et al., 2006). This event precedes the trans-
SNARE complex formation.  
The individual subunits are characterised by completely different domains: as 
mentioned above Vps33p contains a Sec1 like domain while Vps11 and Vps18 have 
RING domains at the C-terminus (Rieder and Emr, 1997) (figure 1.10). Both Vps11 and 
Vps18 contain a clathrin domain, a region of about 140 amino acids long composed of 
multiple alpha helical repeats. Clathrin domains occur in the arm region of the clathrin 
heavy chain and are required for clathrin heavy chain self-assembly (figure 1.10). 
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Figure 1.10 - Analysis of VPS11 and VPS18 protein domains using Pfam database. A) 
Domains identified in VPS11 include: -clathrin domain; -the Zinc finger C3HC4 type 
(RING finger), a member of clan RING (CL0229) with a total of 19 members; -the 
VPS11 C of about 50 amino acids in length.  
B) Domains identified in VPS18 include: -clathrin domain; -the Pep3/Vps18/, a region 
found in a number of proteins identified as involved in golgi functions and vacuolar 
sorting of proteins. The members of Pep3/Vps18 contain a C-terminal ring finger 
domain.  
 
 
 
From the other side, Vps41 is involved in tethering (Price et al., 2000) as well as in the 
biogenesis of AP-3 vesicles (Rehling et al., 1999). Vps41 has recently been shown to be 
involved in the fusion of trans-Golgi network-derived lysosome-associated membrane 
protein carriers with late endosomes (Pols et al., 2013).  
Data in literature have shown a direct interaction between Vps11 and activated Rab5 on 
early endosomes (Christoforidis et al., 1999). On the other hand, Vps39 has properties 
of a Rab7 GEF protein and has been shown to act at late endosomes (Wurmser et al., 
2000). However, other studies have not confirmed Vps39 functioning as a Rab7 GEF 
and therefore the GEF activity of Vps39 remains controversial (Peralta et al., 2010). 
A.
B. 
 30 
These findings are consistent with the key role that the HOPS complex plays in the 
conversion of early into late endosomes.  
The mammalian HOPS complex remains poorly understood. The human homologues of 
the yeast HOPS complex components include VPS11, VPS16, VPS18, VPS33A, 
VPS39 and VPS41 that localise to the endosomal compartment (Huizing et al., 2001). 
The above indicates a possible evolutionary conserved role of the HOPS complex in 
intracellular trafficking. Published data suggests that the HOPS complex is required for 
the Rab5 to Rab7 endosomal conversion and also for phagosome maturation in C. 
elegans (Kinchen et al., 2008). Mammalian cells contain two homologs of yeast Vam6: 
hVPS39 (Caplan et al., 2001) and TRAP-1 (Charng et al., 1998) which have both been 
implicated in Smad signalling at the endosome. As mentioned above, VPS16 and 
VPS33A might be part of the mammalian HOPS complex (Kinchen et al., 2008; Zhu et 
al., 2009) but at this point it is not known if this is the case for VPS33B and VIPAR. 
 
 
 
1.4.4.4.2 - The CORVET complex 
 
 
The CORVET (class C cORe Vacuole Endosome Tethering) complex has been recently 
identified as a novel complex involved in endosomal tethering (Peplowska et al., 2007). 
It shares high similarity with the HOPS complex as both complexes contain the class C 
VPS proteins. However the HOPS subunit Vam6/Vps39 is replaced by the homologue 
Vps3 and in the same way Vps8 substitutes for the HOPS subunit Vam2/Vps41 
(Peplowska et al., 2007). Studies in yeast have shown that the CORVET complex 
interacts with Vps21 (Rab5 homologue). Activated Vps21 in association with Vps8 and 
Vps3 mediate endosomal clustering (Solinger and Spang, 2013).  
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It was suggested that HOPS and CORVET complexes could convert from one to the 
other and this process would be associated with the conversion of early (Rab5 positive) 
to late (Rab7 positive) endosomes. If this is correct then whilst the HOPS complex is 
crucial for conversion from early to late endosomes, the CORVET complex could 
mediate the retrograde conversion, i.e. from late to early endosomes (Solinger and 
Spang, 2013).   
 
 
1.5 - Extracellular matrix 
 
 
The extracellular matrix (ECM) is a complex three-dimensional network of precisely 
organised macromolecules that provide a substrate for cell anchorage, scaffolding and 
strength. Furthermore, it has a key role in regulating numerous cellular functions such 
as cell shape maintenance, cell migration and polarity as well as cell differentiation, 
proliferation and apoptosis (Aszodi et al., 2006; Aumailley and Gayraud, 1998) (figure 
1.11). The cell-matrix interactions respond to extracellular stimuli and initiate 
intracellular signal transduction cascades, which ultimately regulate the expression of 
specific genes and affect cell behavior.  
Depending on the type of cell it is associated with, the extracellular matrix can also 
perform other functions such as guidance of the cell migration during embryonic 
development, wound repair, fibrosis and tissue morphogenesis (de Vega et al., 2009). 
Increased synthesis of ECM components can contribute to tumour growth and cancer 
progression (Cox and Erler, 2011). A better understanding of how the cells 
communicate with their environment is changing the way we view cancer. 
Extracellular matrix includes the interstitial matrix, present in the spaces between cells, 
and the basement membrane, adjacent to epithelial cells, that anchors and supports the 
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tissue. The molecular composition of the ECM determines its physical and 
physiological properties and tailors the matrix for different functions.  
 
 
 
1.5.1 - Extracellular Matrix Components  
 
 
The ECM is a dynamic structure. Its constant remodeling implies continuous 
breakdown by proteases and active re-building (Lu et al., 2011). It has three major 
components and their different combinations give specificity to matrix function. 
- Proteoglycans (heparan-sulphate, chondroitin-sulphate and keratan-sulphate) are 
highly glycosylated proteins that play a key role in keeping the ECM and cells hydrated. 
- Insoluble collagen fibres, which provide strength and resilience.  
- Soluble multi-adhesive extracellular matrix proteins, for example fibronectin and 
laminin, that connect cells with components of the ECM and therefore allow the cell to 
move. 
 
 
 
1.5.1.1 - Adhesion molecules 
 
 
Cell adhesion to ECM components occurs according to two main mechanisms: by focal 
adhesions, that connect ECM to actin filaments, and hemidesmosomes, that connect 
ECM to intermediate filaments (Ozawa et al., 2010). 
Specific cell adhesion molecules (CAMs) also known as integrins, mediate this cell-to-
ECM adhesion (Aplin et al., 1998). Indeed CAMs are transmembrane proteins with an 
extracellular domain that binds to a ligand, a transmembrane domain, and an 
intracellular domain that interacts with cytoplasmic proteins (figure 1.11).  
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The main classes of CAMs include integrins, cadherins, selectins and the 
immunoglobulin family. Cd36, cd44 and discoidin domain receptors (DDR) belong to 
the class of integrins that bind to collagens. CAMs, such as cadherins, mediate 
homotypic interactions by binding to CAMs on the surface of other cells.  
In addition to their adhesive functions, cell adhesion molecules modulate signal 
transduction pathways by interacting with molecules such as receptor tyrosine 
kinases, Rho-GTPase and components of the Wnt signalling pathway (Aplin et al., 
1998) (figure 1.11).  
Adhesive interactions are finely regulated quantitatively and temporally, for example in 
some situations such as cell migration, a quick assembly and disassembly is required. In 
others, adhesive contacts (such as in epidermis) need to be strong to resist mechanical 
stress (Hotchin et al., 1995). 
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Figure 1.11 - Interactions between extracellular matrix proteins and integrins. 
Integrins mediate cell-to-ECM adhesion by interacting with multiple intracellular 
proteins that initiate signalling pathways regulating important cellular processes.  
 
 
 
1.5.2 - Adherens Junctions 
 
 
CAMs are essential not only for cell adhesion to ECM components but also for the 
physical cohesion between cells. This is a fundamental requirement for the formation 
and maintenance of tissues and organs. Various types of intercellular junctions exist 
between epithelial cells and each of those serve specific functions and are finely 
regulated during morphogenesis and tissue homeostasis. Adherens junctions and 
desmosomes are primarily involved in the initiation and stabilisation of cell-cell 
adhesion whereas tight junctions serve as physical and ion-selective diffusion barriers. 
Gap junctions form channels between cells and therefore allow intercellular 
communication (figure 1.12). 
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Figure 1.12 - Schematic drawing and electron micrograph of intestinal epithelial cells. 
The junctional complex, which is located at the most apical region of lateral 
membranes, is represented. The tight junction is circled in the electron micrograph of 
the junctional complex. (Mv, microvilli; TJ, tight junction; AJ, adherens junction; DS, 
desmosome.) Figure modified from (Tsukita et al., 2001). 
 
 
 
Adherens junctions together with the apical localised tight junctions and the more 
basally found desmosomes form the Apical Junctional Complex (AJC) (figure 1.12). 
The AJC separates the apical from the basolateral domain of the cell. 
Apart from providing adhesion between cells, adherens junctions have numerous 
functions including regulation of the actin cytoskeleton, intracellular signaling and 
transcriptional regulation (Hartsock and Nelson, 2008). Proteins that constitute adherens 
junctions consist of transmembrane receptors of the cadherin and nectin family that bind 
through their cytoplasmic domain to signaling molecules and actin binding proteins, 
such as vinculin, talin, tensin, and α-actinin, providing the transduction of the signal 
inside the cell and connection to the actin cytoskeleton (figure 1.11). 
Classical cadherins, such as E-cadherin, are type I transmembrane proteins characterised 
by five Ca2+ binding extracellular motif, the so-called extracellular cadherin (EC) that 
interact with E-cadherin molecules from the neighboring cell (Pokutta et al., 1994). 
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E-cadherin is trafficked via the Rab11 positive recycling endosome (RE) in non-
polarised and newly polarised cells. This process is important for E-cadherin trafficking 
in MDCK cells from a non-polarised to fully polarised state (Desclozeaux et al., 2008). 
Based on phylogenetic evolution, cadherins have been classified in vertebrates into two 
major types (Oda and Takeichi, 2011). Type I cadherins are the major components of 
adherens junctions and include E-cadherin, expressed in most epithelial tissues and N-
cadherin, expressed by neuroepithelial cells, neurons, and mesenchymal cells. The E- to 
N-cadherin switching is crucial during embryonic development (Wheelock et al., 2008), 
neuronogenesis, tissue remodeling and wound healing (Dady et al., 2012). This E- to N-
cadherin switch occurs also in pathologic conditions such as in epithelial carcinomas 
with a strong impact on metastatic progression (Hao et al., 2012). 
Type-II cadherins include cadherins-5, -6, -7, -8, -9, -10, -11, and -12 and are expressed 
by various cell types but little is known to date about the type II cadherins (Takeichi, 
1991). 
 
 
 
1.5.2.1 - Regulation of adherens junctions: EMT 
 
 
Regulation of adherens junctions occurs on multiple levels. This includes alteration of 
their gene expression, post translational modifications, alterations in cytoskeletal 
dynamics, regulation of adherens junction trafficking as well as cleavage of their 
components by different proteases.  
Epithelial to mesenchymal transition (EMT) is a biological process in which epithelial 
cells are trans-differentiated to a mesenchymal state. Mesenchymal properties include 
loss of polarity and loss of adherens junctions concomitant with cytoskeletal 
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rearrangements that enable cells to acquire the ability to invade and migrate (De Craene 
and Berx, 2013). Loss of E-cadherin, together with increased expression of vimentin, N-
cadherin and metalloproteinases (MMPs) are key features of EMT. E-cadherin 
transcriptional repressors such as, for example Snail, are up-regulated during EMT 
resulting in reversible silencing of E-cadherin expression. TGF-β signalling has been 
shown to play an important role in EMT. In fact, the addition of TGF-β 
to epithelial cells in culture induces EMT (Xu et al., 2009). Published data show that the 
expression of Snail proteins is induced in response to TGF-β in cells that undergo TGF-
β-induced EMT (Kokudo et al., 2008). 
Recently published data demonstrate that native collagen IV induces down-regulation of 
E-cadherin expression and EMT (Espinosa Neira and Salazar, 2012). 
 
 
 
1.5.3 - Collagens 
 
 
Collagens are the most abundant proteins in the ECM and in the human body with 28 
different types identified to date (Kadler et al., 2007). Thus, various types of collagen 
are the major structural elements of all connective tissues (Kadler et al., 1996). They 
provide tissue scaffold and framework and influence, for example, cell adhesion and 
migration, angiogenesis, tissue morphogenesis and repair. 
Collagens can be classified according to their structure and molecular properties into 
many groups (table 1) including (Gelse et al., 2003; Kadler et al., 2007): 
- fibril-forming collagens (such as types I, II, III and V) which represent the most 
abundant and widespread family of collagens 
- fibril-associated collagens (FACIT) (for example types IX, XII and XIV) 
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- network-forming collagens (type IV) 
- other groups - anchoring fibrils, transmembrane collagens, basement membrane 
collagens and others with unique functions 
The tissue distribution of different collagens is summarised in Table 1. In particular 
type IV collagen is the major constituent of basement membranes and is crucial for its 
function.  
Although the size, function and tissue distribution of collagens vary considerably, all 
members of this family are characterised by three "-chains each consisting of a regular 
arrangement of amino acids (Kuhn et al., 1985): Gly-X-Y. Position X may be any of 
various other amino acid residues, while either proline or hydroxyproline are found in 
position Y. 3-hydroxyproline is found at the X position in -X-4Hyp-Gly-sequences 
(O'Leary et al., 2011). The post-translational modifications that occur in proline and 
lysine residues are specific for collagen type and crucial for collagen stability and 
functions (see next sections).   
Several proteins contain a collagenous domain, but are not classified as collagens. 
These include: macrophage scavenger receptors, adiponectin, acetylcholine esterase, the 
C1q subcomponent of complement, ectodysplasin A, emilins, surfactant proteins A and 
D, colmedins, and mannose binding protein (Franzke et al., 2005; Rautavuoma et al., 
2004). 
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Table 1.1 - Collagen types with corresponding localisation in the genome and tissue 
distribution. Modified from (Gelse et al., 2003). 
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1.5.3.1 - Collagen type IV - the collagen of basement membranes 
 
 
Type IV collagen is the major structural component of basement membrane (BM) that 
inter-connects the other components of the BM (laminins, proteoglycan and 
entactin/nidogens) into a stable reticulum aggregate (Khoshnoodi et al., 2008). 
Type IV is now classified as a protein family of triple helical isoforms consisting of at 
least six genetically distinct chains: the classical al(IV) and a2(IV) chains and the later 
discovered a3(IV), a4(IV), a5(IV), and a6(IV) (Khoshnoodi et al., 2008). 
Mutations of the major isoforms a1(IV) and a2(IV) are embryonically lethal in mouse 
(Content et al., 1980; Rautavuoma et al., 2004). The isoforms a3(IV)-a6(IV) show 
restricted, tissue-specific expression patterns. The recently identified chains have been 
shown to be directly involved in several collagen related diseases such as Goodpasture 
syndrome (Hudson et al., 1993), Leiomyomatosis (Hudson et al., 1993) and Alport 
syndrome (Hudson et al., 1993; Tryggvason, 1996). Alport syndrome, the most 
common form of hereditary glomerulonephropathy, is often caused by mutations in 
a3(IV), a4(IV), a5(IV), and a6(IV) genes that causes lamellation and splitting of the 
glomerulus basement membrane with consequent progressive loss of renal function 
(Hudson et al., 1993; Peissel et al., 1995). Apart from kidney disease, patients with 
Alport syndrome frequently develop sensorineural hearing loss, a common feature of 
ARC syndrome. Type IV collagen is an important component of inner ear structures and 
alterations in type IV collagen often result in abnormal inner ear function. 
Like other type of collagens, the monomer constituent of the type IV collagen network 
is a triple helical molecule (figure 1.13). Three domains characterise each chain: the N-
terminal 7S domain, a C-terminal non-collagenous domain (NC1), and the central triple 
helical part that consists of a long collagenous domain of 1400 residues of Gly-X-Y 
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repeats. This domain is interrupted by short non-collagenous sequences resulting in a 
flexible triple helix (Gelse et al., 2003; Hudson et al., 1993). 
Non-collagenous domains of collagens IV, XV and XVIII have been shown to be 
involved in tumorigenesis and angiogenesis and they might also be important in many 
other biological processes (Ortega and Werb, 2002). Therefore, these domains are 
considered a target for potential therapeutic compounds. 
Specific interactions between the domains are fundamental for the formation of a stable 
network characteristic of collagen IV. Each chain is highly hydroxylated and 
glycosylated. Hydroxylation is essential for the cross-linking of collagen molecules, 
thus ensuring the strength of collagen fibrils (Schegg et al., 2009). Although the role of 
glycosylation is not completely understood, it seems to be crucial for oligomerisation 
and proper secretion of collagen IV (Schegg et al., 2009). 
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Figure 1.13 - Schematic representation of collagen IV structure.  
The electron micrograph in the top panel shows that the basement membrane in the 
renal glomerulus (GBM) is located between the capillary endothelium and the 
epithelium of podocytes. The lower panel schematically represents the association of 
collagen helix in a reticulated suprastructure. The building block is a triple helical 
monomer that self-assemble in dimers by association of monomers at the C-termini, or 
tetramers when they associate at the N-termini. Figure modified from (Hudson et al., 
1993). 
 
 
 
1.5.3.2 - The Biosynthesis of Collagen 
 
 
Transcription and mRNA processing 
The biosynthesis of collagens begins with collagen gene transcription in the nucleus 
(figure 1. 14). There are 45 genes known encoding individual "-chains. Collagen 
molecules can be composed of the same or up to three different gene products forming 
homo- or hetero-trimeric molecules.  
The transcription of collagens is finely regulated and depends on the cell type. 
Numerous growth factors can also control collagen transcription. For example in adult 
bones, collagen formation is stimulated by members of the TGF-β-superfamily as well 
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as insulin-like-growth factors (Chen et al., 2012). The potential to bind growth factors 
and cytokines makes collagen a suitable transport vehicle for therapeutic factor delivery. 
Most collagen genes undergo alternative splicing and possess multiple transcription 
initiation sites that generate different mRNA species. 
 
Translation 
Once the mRNA is mature it is transported to the cytoplasm (figure 1.14) and translated 
on ER membrane-bound ribosomes. The neo-translated protein is called pre-pro-
collagen and it contains a signal sequence recognised by the corresponding receptors in 
the rough endoplasmic reticulum. This mediates the protrusion of pre-pro-collagen into 
the lumen of the ER (Gelse et al., 2003).  
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Figure 1.14 - Schematic representation of the biosynthesis of collagen: collagen gene 
transcription in the nucleus, mRNA processing, translation in the ribosomes and post-
translational modifications in the ER/Golgi, secretion in the extracellular space and the 
final steps of fibril formation. (SP: signal peptidase; GT: hydroxylysyl 
galactosyltransferase; LH: lysyl hydroxylase; PH: prolyl hydroxylase; OTC: 
oligosaccharyl transferase complex; PDI: protein disulphide isomerase; PPI: peptidyl-
prolyl cis-trans-isomerase; NP: procollagen N-proteinase; CP: procollagen C-
proteinase; LO: lysyl oxidase; HSP47: heat shock protein 47, colligin1). Figure 
modified from (Gelse et al., 2003). 
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Posttranslational modifications and secretion into the extracellular space 
Once in the ER the signal peptide is removed by a signal peptidase (figure 1.14) and the 
resultant molecule is called pro-peptide. Numerous and multi-step post-translational 
modifications occur at this stage. Hydroxylation of prolines is catalyzed by prolyl-3-
hydroxylase and prolyl-4-hydroxylase. 4-hydroxyprolines are essential for 
intramolecular hydrogen bonds and therefore contribute to the stability and integrity of 
the triple helical domain (Tiainen et al., 2008). The function of 3-hydroxyproline is not 
known (Sipila et al., 2007). 
Lysyl hydroxylases mediate the hydroxylation of lysine residues. The extent of lysine 
hydroxylation varies between tissues and collagen types (Kivirikko et al., 1973). Most 
lysines in type IV and VI collagens are hydroxylated and glycosylated (Mundy, 1996). 
Hydroxylysine residues are responsible for the formation of stable intermolecular 
crosslinking in collagen fibrils. Additionally they are sites for the attachment of 
glucosyl and galactosyl residues. This reaction is catalyzed by hydroxylysyl 
galactosyltransferase and hydroxylysyl glucosyltransferase enzymes respectively (figure 
1.14) (see next section). 
Before being transported to the Golgi, triple helices, now called procollagen, are formed 
in the ER. From the C-terminus of three-aligned α-chains, the triple helix is folded in a 
zipper-like manner progressing to the N-terminus. Molecular chaperones including PPI 
(peptidyl-prolyl cis-trans-isomerase) (Lang et al., 1987) and collagen-specific 
chaperones like HSP47 (Clarke et al., 1991) mediate the efficient folding of procollagen 
molecules (figure 1.14). 
Procollagen is then transported in vesicles towards the Golgi apparatus. Other models 
have been proposed for collagen trafficking due to the small size of vesicles compared 
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to the large procollagen molecules (Stephens, 2012). 
In the Golgi apparatus procollagen undergoes the last post-translational modifications 
before being secreted. Oligosaccharides are added (not monosaccharides as in the ER) 
before procollagen is packaged within the Golgi compartment into secretory vesicle and 
released into the extracellular space.  
 
Fibril formation 
Following their secretion, C- and N- propeptides are cleaved by specific proteases that 
belong to the family of Zn2+ dependent metalloproteinases (Prockop et al., 1998). The 
cleaved molecule is known as tropocollagen. Several feedback mechanisms have been 
proposed for the control of collagen expression mediated by the internalisation of 
released N- and C-propeptides but the potential mechanisms of regulation are mainly 
unresolved (Gelse et al., 2003). The solubility of procollagen decreases rapidly after the 
removal of the C-propeptide and it starts spontaneously aggregating into organised 
fibrillar structures (Silver et al., 2003). Extracellular enzymes such as lysil-oxidases 
catalyze the oxidative deamination of lysines and hydroxylysines producing aldehyde 
groups (Feres-Filho et al., 1995). This modification causes a spontaneous reaction of 
cross-linking between tropocollagen molecules. The resulting polymer is known as 
collagen fibril. The formation of cross-links is crucial for the physical and mechanical 
properties of collagen fibrils and its role in determining the strength of the collagen 
matrix. The knowledge of the structure, expression and function of the different types of 
collagen is important to better understand embryonic and fetal developmental processes 
as well as diseases based on defects of collagens. 
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1.5.4 - Lysyl hydroxylases: localisation and activities 
 
 
Lysine residues in collagen-like peptides are enzymatically modified into 
hydroxylysine, galactosyl and glucosyl hydroxylysine by specific enzymes, namely 
lysyl hydroxylases (LHs), galactosyl and glucosyltransferase (GT and GGT 
respectively) (Myllyla et al., 2007) (figure 1.15). 
LHs belong to the family of 2-oxoglutarate dioxygenases and therefore their genes are 
named Plod (procollagen lysine 2-oxoglutarate 5-dioxygenase). Like other collagen 
hydroxylases LHs use Fe2+, 2-oxoglutarate, molecular oxygen and ascorbate to catalyse 
the hydroxylation of lysine residues. One atom from O2 is incorporated into the 
hydroxyl group formed in the lysine residue, while the other atom reacts with 2-
oxoglutarate to form succinate and carbon dioxide (Myllyla et al., 2007) (figure 1.15). 
The resultant hydroxylysyl groups are attachment sites for collagen 
galactosyltransferases forming galactosylhydroxylysine residues in collagens that, as 
mentioned previously, are critical for its stability. Galactosylhydroxylysines can be 
further modified to glucosylgalactosylhydroxylysines by the addition of a glucosylic 
group and this reaction is catalyzed by collagen glucosyltransferases. The 
hydroxylysinegalactosylation and hydroxylysineglucosylation enzymes use UDP-
galactose or UDP-glucose respectively in the reaction where galactose or glucose is 
transferred to a hydroxylysine/galactosyl-hydroxylysine substrate (Myllyla et al., 2007) 
(figure 1.15).  
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Figure 1.15 - Enzymatic Reaction catalyzed by (A) lysyl hydroxylases (LHs) that use 
Fe2+,, oxoglutarate, molecular oxygen and ascorbate to catalyse the hydroxylation of 
lysine residues (B) collagen galactosyltransferases (GT) that use UDP-galactose and 
Mn2+ to transfer galactose to hydroxylysines and (C) collagen glucosyltransferases 
(GGT) that use UDP-galactose and Mn2+ to transfer glucose to 
galactosylhydroxylysine. Modified from (Myllyla et al., 2007). 
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The first lysyl hydroxylase enzyme was initially purified from chicken embryos 
(Myllyla et al., 1991) and subsequently three lysyl hydroxylase isoforms LH1, LH2 and 
LH3, also named PLOD1 PLOD2 and PLOD3, have been characterised in vertebrates. 
The D. melanogaster and C. elegans have only one lysyl hydroxylase homologue each 
(Myllyharju and Kivirikko, 2004). The amino acid sequence homology between 
isoforms of the same species is around 60% in both mouse and human (Salo et al., 
2006b). Surprisingly, the most recently identified, but evolutionarily the oldest of the 
PLOD isoforms, PLOD3, also possesses collagen glucosyltransferase and 
galactosyltransferase activity, in addition to the lysyltransferase, whereas PLOD1 and 
PLOD2 can only catalyze the formation of hydroxylysines (Salo et al., 2006b). The N-
terminal part of PLOD3 has been shown to be responsible for the glycosyltransferase 
activity, whereas the lysyl hydroxylase activity is located at the C-terminus of the 
enzyme (Feres-Filho et al., 1995).  
As mentioned previously, collagen glycosylation is essential for basement membrane 
formation. Data from the literature show that PLOD3 is crucial for embryonic 
development and basement membrane formation, possibly because of its unique 
property among PLOD enzymes of possessing collagen glucosyltransferase activity 
(Rautavuoma et al., 2004). In cancordance with the above statement Ruotsalainen et al 
showed that the amount of PLOD3 is higher in embryonic than in adult tissues (Salo et 
al., 2006a). The importance of PLOD3 activity for collagen type IV modification is 
supported by the finding that collagen IV isolated from Plod3 knockout mouse migrates 
faster on SDS-PAGE compared to controls, suggesting a lack of glycosylated 
hydroxylysines (Rautavuoma et al., 2004). 
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PLOD3 has also been shown to possess a critical role in the neuronal growth cone 
migration determined from its glucosyltransferase activity on myotomal type XVIII 
collagen, a ligand for neural-receptor protein tyrosine phosphatases that guide motor 
axons (Schneider and Granato, 2006).  
The expression levels of lysyl hydroxylase isoenzymes differ between tissues and 
organisms (Myllyla et al., 2007). A summary of the expression pattern in selected cell 
lines in human and mouse tissues is shown in Table 2. 
 
Table 1.2 - Expression of lysyl hydroxylase isoforms in adult human and mouse tissues. 
- no, + weak, ++ intermediate. The expression levels are comparable only within the 
same isoform. Modified from (Wang et al., 2000). 
 
 
 
 
 
                   mRNA levels 
  
Human Tissues                              PLOD1             PLOD2                 PLOD3 
Heart + + + +     + + 
Brain + +   +  + 
Placenta + + + + + + 
Lung + +   -   +  
Liver + + + +   +  
Skeletal muscle + + + +   +  
Kidney + +   +    +  
Pancreas + + + + + + 
Mouse Tissues    
Heart + + + + + + 
Brain  -   -   + 
Spleen  -   -   - 
Lung + + + + + + 
Liver + +  - + + 
Skeletal muscle + +  +   +  
Kidney + + + +   + 
Testis  -   +  + + 
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Subcellular localisation   
PLOD isoforms are targeted to the rough endoplasmic reticulum via a signal peptide (of 
18-25 amino acids) even though they lack the typical ER-retention signals such as 
KDEL or double lysine motif (Wang et al., 2012). PLOD1 was shown to be a peripheral 
protein in the ER, weakly bound to the luminal side of the membrane by weak 
electrostatic interactions with unknown proteins (Kellokumpu et al., 1994). 
Interestingly, it has been shown that in addition to the ER, active PLOD3 is also found 
in the extracellular space, in serum and on the surface of cultured cells (Myllyla et al., 
2007; Salo et al., 2006b). Furthermore the distribution of PLOD3 is tissue specific. Salo 
et al showed that PLOD3 was localised both intracellularly and extracellularly in mouse 
muscle, spleen, and kidney, whereas in mouse liver and pancreas was found only in the 
extracellular space (Salo et al., 2006b). The ability of PLOD3 to modify extracellular 
proteins is required for cell growth and viability and is thought to be important for 
matrix remodeling (Salo et al., 2006b).  
The molecular weight of PLOD3 on the cell surface differs from the PLOD3 fraction 
found in the cell culture medium possibly because the two proteins are differently 
glycosylated. This difference suggests that PLOD3 may be secreted through two 
different pathways. PLOD3 secreted into the cell culture medium might pass through 
the Golgi complex for it to be further glycosylated, while PLOD3 that is trafficked and 
remains on the cell membrane might bypass the Golgi (Wang et al., 2012). 
The mechanisms involved in PLOD3 trafficking remain unknown and more studies are 
required.  
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1.5.4.1 - Lysyl hydroxylase 3 deficiency 
 
 
In general, lack of LH activity leads to changes in collagen structure with the 
consequential formation of highly fragile tissues. Mutations in PLOD1 and PLOD2 
have been associated with the kyphoscoliotic subtype of Ehlers-Danlos (Giunta et al., 
2009) and Bruck syndrome (Hyry et al., 2009) respectively. 
Only one patient with mutations in PLOD3 has been identified to date (Hyry et al., 
2009). The two identified mutations were heterozygous with recessive transmission and 
were located in conserved regions of the PLOD3 protein sequence: one nucleotide 
transition c.668ArightarrowG (mutation 1) resulting in the amino acid substitution, p.Asn223Ser, 
and one nucleotide deletion c.2071 delT (mutation 2) causing a translational frameshift 
and generating a premature translational stop codon (Salo et al., 2008). The first 
mutation interfered with the glucosyltransferase activity of PLOD3 and the other with 
the lysyl hydrolase activity. Furthermore, the overall levels of PLOD3 protein were 
reduced (Salo et al., 2008). This resulted in a unique phenotype mostly characterised by 
several collagen related abnormalities that included: joint contracture, congenital 
scoliosis, scleral fragility, right-sided diaphragmatic eventration, knee joints appearing 
prominent, skin, hair, and nail abnormalities (Salo et al., 2008). The patient also showed 
profound bilateral sensorineural deafness, reduced visual acuity with myopia, 
spontaneous vascular rupture and global developmental delay. The common features 
between the PLOD3 deficient patient and individuals with ARC include: joint 
contractures, osteopenia, sensorineural deafness, growth retardation. 
In mouse, PLOD3 null embryos were shown to be lethal at embryonic day 9.5 because 
of the severe deficiency in the synthesis of type IV collagen that lead to the 
fragmentation of BMs. 
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CHAPTER TWO: 
MATERIALS AND METHODS 
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2.1 - Suppliers  
 
 
All chemicals and tissue culture reagents were purchased from Sigma-Aldrich unless 
otherwise stated.   
Tissue culture plastics were purchased from Corning. Lipofectamine 2000 transfection 
reagent was ordered from Invitrogen.  
IMAGE clones were ordered from Geneservice (Cambridge, UK) and purified PCR 
primers were obtained from Sigma. The proofreading Platinum Taq Polymerase kit was 
ordered from Invitrogen. The T4 DNA ligase and buffer were purchased from Promega. 
Restriction endonucleases were purchased from New England Biolabs. Plasmid mini 
and maxi prep kits were purchased from QIAGEN. 
Protein G coupled Dynabeads were ordered from Invitrogen. 
Suppliers for antibodies are listed in table 2. Anti-VPS33B antibody was a gift from 
Guang-dan Zhu from Emory University, Atlanta. 
 
 
 
2.2 - Cloning system 
 
 
PCR inserts for all constructs used in this thesis were first amplified using a 
proofreading DNA polymerase with primers containing restriction sites on the 5’ 
(forward primer) and 3’ end (reverse primer) for ligation into the expression vector. 
Primer sequences used for cloning of plasmid constructs used in this thesis are shown in 
table 2.1. 
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Table 2.1 - List of primes used for cloning of different constructs 
 
 
 
2.2.1 - Proofreading Polymerase Chain Reaction 
 
 
PCR reactions were performed on a GeneAmp 9700 thermocycler using Platinum® Taq 
DNA Polymerase High Fidelity (Invitrogen) with proofreading activity. The reaction 
was set up as follows: 
 
 
   
                                    
 
 
 
 
Table 2.2 - Standard PCR reaction used for cloning of plasmid constructs  
  
   
 
 
Cloning 
primers Direction Sequence 
mCherry-Plod3-F Forward 5´-AAAGAATTCTGATGACCTCCTCGGGGCCTGGACC-3´ 
mCherry-Plod3-R Reverse 5´-TTTGGATCCTTGGGGTCGACAAAGGACACCATGAT-3´ 
mCherry-Plod1-F Forward 5´-AAAGAATTCTGATGCGGCCCCTGCTGCTAC-3´ 
mCherry-Plod1-R Reverse 5´-TTTGGATCCTTGGGATCGACGAAGGAGACTGCGAT-3´ 
Vipar-(N-)-F Forward 5´-AAGAATTCGTGGATCCATGAATCGGACAAAGGGTGATGAGGAGG-3´ 
Vipar-(N-)-R Reverse 5´- AAGGTACCTTAAGCGGCCGCCACTGTATCACTGGGGCTCCAGTCATT-3´ 
VIPAR-(C+)-F Forward 5´- AAGAATTCGTGGATCCGATACAGTGCGACGTCTCCGGAAG-3´ 
VIPAR-(C+)-R Reverse 5´-AAGGTACCTTAAGCGGCCGCATTCTTCCATCGAATTTGCGAGCTGC-3´ 
VIPAR-(C-)-F Forward 5´- AAGAATTCGTGGATCCCTAGAGAGATTCCGCTCCTTACAGGAC-3´ 
VIPAR-(C-)-R Reverse 5´-  AAGGTACCTTAAGCGGCCGCATTCTTCCATCGAATTTGCGAGCTGC-3´ 
Component Volume (µL) Final Concentration 
10X High Fidelity PCR Buffer 5 1X 
10 mM dNTP mixture 1 0.2 mM each 
50 mM MgSO 2 2 mM 
Forward Primer (10 µM) 1 0.2 µM 
Reverse Primer (10 µM) 1 0.2 µM 
Template DNA (35 ng/ul) 1 0.7 ng/ul 
Platinum ® Taq High Fidelity  0.2 1.0 unit 
Nuclease Free Water to 50 Not applicable 
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The reaction was then subjected to the amplification conditions shown below:  
Initial denaturation: 94 ºC for 2 minutes 
25–35 cycles of: 
Denature: 94 ºC for 30 seconds 
Anneal:    60 °C for 30 seconds 
Extend:    72 ºC for 1 minute per kb of PCR product 
Final extension:  72 ºC for 10 minute 
 
 
 
2.2.2 - Agarose Gel Electrophoresis 
 
 
10 µL of the total PCR reaction volume (50 µL) was used to check the success and the 
specificity of each reaction. The remaining 40 µL was PCR-purified before restriction 
digestions were set up. 
A 1 % agarose gel was prepared by dissolving 1 % w/v agarose in 1x TBE buffer (90 
mM tris-base, 90 mM boric acid, and 2 mM EDTA, pH=8.0) and heating, which was 
then supplemented with and 10 ng/mL of ethidium bromide (EtBr). 
 6x DNA loading buffer (2 mM EDTA, 50 % glycerol and 0.1 % orange G) was added 
to the PCR product before loading on the agarose gel. A DNA ladder was loaded on the 
same gel as a size standard. The electrophoresis was run at 110 Volts and the progress 
was monitored by the migration of orange G dye. 
 
 
 
2.2.3 - PCR purification 
 
 
The PCR products were purified using the QIAquick PCR Purification Kit. 
5 volumes of Buffer PB were added to 1 volume of PCR sample and the mix was placed 
in a QIAquick spin column before centrifuging for 1 min at 13,000 rpm. The flow-
through was discarded and the column was washed with 750 µL of Buffer PE and the 
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centrifugation step repeated as above. After the flow-through was discarded, the column 
was centrifuged for an additional minute to remove residual ethanol. 50 µL of nuclease 
free water were added to the centre of the column, which was then centrifuged for 1 min 
at 13,000 rpm. The concentration of the eluted DNA was measured by the NanoDrop 
ND-1000 Spectrophotometer. 
 
 
 
2.2.4 - Restriction Digestion 
 
 
The purified products and appropriate vectors were separately digested with the 
appropriate restriction endonucleases reported in the table below. 
 
 
 
 
 
 
Table 2.3 - List of restriction endonucleases and buffers used during the cloning of 
specific constructs in the respective vectors 
 
 
The reaction was set up using 1 µg of both vector and insert, 10 U of each restriction 
endonuclease (New England Biolabs), 10x specific buffer and 100x BSA where 
applicable, in a total reaction volume of 50 µL. Restriction digestions were carried out 
at 37°C for 4 hours and subsequently run into a 1 % agarose gel as described in section 
2.2.2.  
 
 
 
Construct 5’ Enzyme 3’ Enzyme Vector Buffer 
mCherry-PLOD1 EcoRI-HF BamHI pmCherry-N1 4 + BSA 
mCherry-PLOD3 EcoRI-HF BamHI pmCherry-N1 4 + BSA 
VIPAR N- EcoRI-HF KpnI-HF pCMV-Myc 4 + BSA 
VIPAR C+ EcoRI-HF KpnI-HF pCMV-Myc 4 + BSA 
VIPAR C- EcoRI-HF KpnI-HF pCMV-Myc 4 + BSA 
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2.2.5 - Agarose Gel Extraction 
 
 
Once visualised in the agarose gel, the bands corresponding to the amplified gene size 
were gel extracted using the QIAGEN gel extraction kit. The correct band was excised 
from the gel with a clean scalpel. 3 volumes of Buffer QG were added to 1 volume of 
the gel slice (1 volume ~ 1 weight) and then placed in a heating block at 55 °C until the 
gel had completely melted. Subsequently, one volume of 100 % isopropanol was added 
and the resulting sample was applied to a QIAquick spin column and centrifuged for 1 
min at 13,000 rpm. The following wash and elution steps are common to the PCR 
purification protocol (section 2.2.3). 
 
 
 
2.2.6 – Ligation 
 
 
The gel extracted DNA insert and vector have the same cohesive ends as a result of the 
restriction digestion. To ligate the insert into the expression vector the ligation reaction 
was set up as below, in a reaction volume of 5 µL and incubated either 3 hours at 16 °C 
or overnight at room temperature.     
          
              
 
                                        
 
 
 
   Table 2.4 - Ligation reaction 
 
 
 
Component Volume (µL) 
10X Ligation Buffer 0.5 
T4 DNA Ligase (3 U/ µL ) 0.35 
Insert DNA 1 
Vector DNA 0.5 
Nuclease Free Water to 5 
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2.2.7 - Transformation 
 
 
1 µL of the above ligation products was added to 20 µL of DH5α Escherichia coli 
competent cells and incubated on ice for 30 min. Cells were then subjected to heat 
shock at 42 °C for 45 seconds and immediately placed on ice for 2 minutes. Cells were 
then allowed to grow by adding 500 µL of SOC medium (Invitrogen) and incubating in 
an orbital shaker at 37 °C for an hour at 220 rpm. Subsequently cells were centrifuged at 
5000 rpm for 10 minutes and 360 µL of the supernatant was removed, while the 
remaining 200 µL was resuspended and spread onto LB agar plates supplemented with 
the appropriate antibiotic reported in the table 2.5. Plates were incubated overnight at 37 
°C.    
 
 
Table 2.5 - List of cloning specific antibiotics used in this thesis  
 
 
 
2.2.8 - Colony Screening 
 
 
Bacterial colonies were screened for insert incorporation into the plasmid by Colony 
PCR. Single colonies (~5 per plate) were resuspended in 10 µL nuclease free water and 
1 µL of the mixture was used as a template in the PCR reaction. 5 minutes of the initial 
denaturation was set up to allow bacterial lysis. The forward and reverse primers were 
complementary to the vector and insert sequence respectively to ensure the selection of 
plasmids containing the insert. One of the colonies corresponding to a PCR positive 
reaction was transferred to 5 mL of Luria Broth (LB) medium supplemented with the 
Antibiotic Final Concentration Vector 
Ampicillin 100 µg/mL pCMV-Myc 
Kanamycin 25 µg/mL pmCherry-N1 
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same antibiotic concentration used for plates. The small culture was allowed to grow 
overnight in a shaking incubator (37 °C, 220 rpm). 
 
 
2.2.9 - Plasmid DNA Purification, Miniprep 
 
 
Plasmids were extracted from overnight cultures using the QIAGEN mini-prep kit. 5 
mL of bacterial cultures were pelleted by centrifugation at 5,500 rpm for 15 minutes. 
The resulting pellet was resuspended in 250 µL of Buffer P1 and transferred to a 1.5 mL 
microcentrifuge tube before addition of 250 µL of Buffer P2 to allow cell lysis. The 
tube was carefully inverted several times until a homogeneous blue suspension was 
achieved. Subsequently 350 µL of the alkali Buffer N3 was added, and the solution was 
immediately mixed by inverting the tube until the suspension turned colourless. The 
mixture was then centrifuged at 13,000 rpm for 10 minutes to pellet cellular debris, 
including genomic DNA. The supernatant, which contained the plasmid DNA, was 
transferred to a QIAprep spin column and centrifuged for 1 minute at 13,000 rpm. The 
column, with bound plasmid DNA, was washed with 750 µL of Buffer PE and 
centrifuged as above. The flow through was discarded and the column was centrifuged 
for a further 1 minute at 13,000 rpm to wash away any residual buffer. The QIAprep 
column was then placed into a clean 1.5 mL tube and 50 µL of nuclease free water was 
added to the centre of the column and left to stand for 1 minute. The column was then 
centrifuged at 13,000 rpm for 1 minute to elute the plasmid DNA.   
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2.2.10 - Plasmid Sequencing 
 
 
The plasmid DNA was subsequently sequenced to verify sequence accuracy using 
specific primers mapping in each vector. The dideoxy termination method was used to 
determine the exact sequence of the insert and to verify that it was in-frame. Therefore, 
it was essential to use primers (in the poly-linker region) that would demonstrate the 
sequence of the insert/plasmid interface. 
The DNA was sequenced bi-directionally and the forward and reverse primers were 
kept in separate reactions as shown below.  
                                 
 
 
 
 
 
 
 Table 2.6 - Sequencing reaction 
 
The reaction was then subjected to the following amplification conditions: 
Initial denaturation: 96 ºC for 30 seconds  
30 cycles of:  
Denature:     96 ºC for 30 seconds  
Anneal:        50 °C for 15 seconds  
Extend:        60 ºC for 4 minutes  
 
 
 
2.2.10.1 - Sequencing Reaction: precipitation and analysis 
 
 
The ethanol precipitation method was used to purify sequencing products from the rest 
of the reaction mix (enzymes, ddNTPS). 1 µL of 0.25 M EDTA and 32 µL of 100 % 
ethanol were added to the PCR reaction and incubated at room temperature in the dark 
for 10 minutes. The precipitated DNA was pelleted by centrifugation at 4000 rpm for 30 
minutes at 4 °C. The supernatant was then carefully removed by centrifuging the plate 
Reagent Volume per reaction (µL) 
5x Sequencing Buffer 2.5 
BigDye 0.5 
Primer (2 µM) 1.6 
Plasmid (0.5 µg/µL) 1 
Nuclease Free Water to 10 
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upside down at 500 rpm for 30 seconds. To wash the DNA pellet 125 µL of 75 % 
ethanol were added to each reaction and the centrifugation step was repeated as above. 
The supernatant was again removed by centrifuging the plate upside down and the DNA 
pellet was allowed to air dry for 10 minutes. 10 µL of HiDi formamide were then added 
to each sample before incubating at 95 °C for 5 minutes to denature the DNA. The plate 
was placed on ice for 2 minutes and the DNA was sequenced using the ABI Prism 3700. 
Sequences were analysed with BioEdit Sequence Alignment Editor. 
 
 
 
2.3 - Protein harvesting and quantification 
 
 
2.3.1 - Mammalian protein extraction 
 
 
For knockdown assessment, mIMCD-3 clones were grown to confluence in 25 cm2 
tissue culture flasks, washed with 10mL ice-cold PBS and scraped into 150 µL of RIPA 
lysis buffer (50mM Tris/HCl pH7.5, 1mM EDTA, 150mM NaCl, 0.1% sodium dodecyl 
sulfate (SDS), 0.5% deoxycholic acid, 1% Igepal CA-360 (Mammalian Cell Lysis Kit, 
Sigma), and protease inhibitor cocktail (Roche)) and placed on ice for 30 minutes. The 
suspension was then centrifuged at 13,000 rpm for 15 minutes at 4°C and the 
supernatant transferred to a clean tube.  
For co-immunoprecipitation experiments HEK293 cells grown on 6-well plates were 
lysed as in section 3.3.2. 
For cell-fractionation experiments HEK293, mIMCD-3 and HeLa cells were processed 
as in in sections 5.3.1 and 5.3.2. 
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2.3.2 - Protein detection and quantification 
 
 
Protein concentration was determined either by using the NanoDrop 2000c UV-Vis for 
micro-volume protein quantitation or by the method of Bradford. 
 
 
 
2.3.2.1 - Sodium dodecyl sulphate polyacrylamide gel electrophoresis 
 
 
Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) was used to 
separate proteins according to their electrophoretic mobility, which is dependent on the 
molecular weight of proteins. 
The separation of the proteins was performed in polyacrylamide gels that consist of 
“stacking” and “resolving” gels. The reagent concentration of the resolving gel depends 
on the molecular weight of the proteins to be visualised. A 10 % resolving gel was used 
to visualise all proteins detected in this study. For detection of collagen IV by Western-
blot a 4% resolving gel was used. Both resolving gels and stacking were prepared from 
the following components, volumes stated for one gel solution set up in a 1 mm thick 
glass plate (BioRad).  
 
 
 
 
                
                        
 
 *1.5 M Tris-HCl (pH=8.8) was used for the resolving gel and 0.5 M Tris-HCl (pH=6.8) for the stacking. 
Table 2.7 - Tris-glycine SDS-Polyacrylamide gel preparation 
 
 
Reagent 
Volume (mL) 
Resolving 
gel (10 %) 
Resolving 
gel (4 %) 
Stacking 
gel  
30 % acrylamide Protogel (Geneflow) (mL)  3.16 0.66 0.66 
1.5/0.5 M Tris-HCl (pH=8.8/6.8)* (mL) 2.5 1.25 1.26 
10 % Ammonium Persulfate (mL) 0.1 0.05 0.08 
10 % SDS (mL) 0.1 0.05 0.06 
TEMED (mL) 0.06 0.004 0.01 
Nuclease-free water (mL) to 5 to 5 to 5 
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The resolving gel was poured to within 2 cm of the top of the glass plates and overlaid 
with isopropanol. The resolving gel was left to polymerise before the isopropanol was 
removed and the stacking gel poured on the top. Combs were immediately added to the 
stacking gel to create sample wells. Once the stacking gel polymerised the combs were 
removed and the gel was placed into an electrophoresis chamber (BIORAD Mini). 
Before loaded onto the gel, protein samples were diluted 5-folds with 5x Lamelli 
loading buffer (65 mM Tris/HCl pH 8, 10 % (v/v) glycerol, 2.3 % (w/v) SDS, 0.01 
bromophenol blue, 1 % dithiothreitol (DTT)) and denatured for 3 minutes at 100°C. The 
gel was run in Tris-glycine buffer (192 mM Glycine, 250 mM Tris-Base and 0.1 % 
SDS) for ~1 hour (till the loading dye had reached the bottom of the gel) at 120 V. A 
protein ladder (Page Ruler; Fermentas, York, UK) was loaded on the same gel to 
evaluate the correct size of the protein bands.  
 
 
 
2.3.2.2 - Page Blue protein staining and Drying of SDS-PAGE Gels 
 
 
SDS-PAGE gels were stained using PageBlue (Fermentas). The gel was first washed 
three times with 100 mL distilled water by microwaving each time on high power for 1 
min. This step is required to remove the SDS from the gel as it interferes with the 
staining. Subsequently, the gel was stained for 60 minutes (or overnight) with 20 mL of 
PageBlue, under gentle agitation. Destaining was performed by washing the gel several 
times with distilled water until the protein bands were clearly visualised on the gel. 
The gel was vacuum dried at 80 °C for 60 minutes on a Gel Master Gel Dryer Vacuum 
System (Welch).     
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2.3.3 - Western Blotting 
 
 
2.3.3.1 - Electrophoretic Transfer to PVDF Membranes 
 
 
To complement the gel staining, the resolved proteins were transferred from the SDS-
PAGE gel (section 2.3.2.1) to a PVDF (polyvinylidene difluoride) (GE Healthcare) 
membrane for detection of proteins by Western blot. The PVDF membrane was first 
activated in methanol before the blotting sandwich was prepared in 1 x Transfer Buffer 
(192 mM Glycine, 250 mM Tris-Base and 20 % methanol) in the following order: fibre 
pad, filter paper, PVDF membrane, gel, filter paper, fibre pad. 
The sandwich was then correctly placed into a transfer device in order to allow the 
electrotransfer of proteins from the gel to the PVDF membrane. The transfer was 
performed in 1x Transfer Buffer at 250 mA for 1.5 hours, using an ice pack to cool 
down the apparatus. 
 
 
 
2.3.3.2 - Western Blot detection 
 
 
During the detection process the membrane was first blocked in 10 % dried non-fat milk 
powder in PBST, on a roller, for 1 hour at room temperature (or alternatively overnight 
at 4 °C). The membrane was then incubated with the primary antibody diluted in 5 % 
milk solution for one hour at room temperature. Specific dilutions for all primary 
antibodies used for Western blotting in this thesis are reported in table 2.8. The 
membrane was then washed three times on a shaker (~200 rpm), for 10 minutes each 
time. After the wash, the membrane was blocked with properly diluted secondary 
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antibody (table 2.8) in 5 % milk solution and incubated at room temperature for one 
hour. 
* gift from Guang-dan Zhu from Emory University, Atlanta 
 
Table 2.8 - Antibodies and their dilutions used in this thesis for Western blotting. Other 
information provided includes the species the antibody was raised in (m- mouse, Rb-
rabbit), the company along with the clone number for monoclonal antibodies or 
catalogue number for polyclonal antibodies. 
 
 
 
Membrane washes were repeated as above. The secondary antibodies were all 
conjugated to Horse Radish Peroxidase (HRP) which allows detection once the 
membrane is incubated for 2 minutes with the enhanced chemo-luminescence plus 
(ECL+) western blotting detection system reagents (GE Healthcare) at a ratio of 1:40 
for regent A:B. Exposure of the autoradiography film (Kodak) for the length of time 
that was a function of the signal strength and its subsequent development in an X-ray 
film developer (Konica Minolta) allowed the detection of protein bands.  
 
Antibody Clone / Catalogue nr Supplier  
Primary 
Dilution 
Secondary 
Dilution 
m α myc 9E10 Sigma 1/5000 1/20000 
m α HA HA-7 Sigma 1/1000 1/2000 
m α His RL90 Sigma 1/3000 1/5000 
Rb α VPS33B - Gift *  1/500 1/1000 
Rb α VIPAR HPA003589 Sigma 1/500 1/1000 
Rb α PLOD3 11027-1-AP proteintech 1/500 1/500 
m α PDI RL90 abcam 1/1000 1/2000 
m α LAMP1 CD107a Hybridoma Bank 1/5000 1/10000 
Rb α Collagen I NB600-408 Novus Biologicas 1/1000 1:10000 
Rb α Collagen IV ab6586 abcam 1/1000 1/10000 
m α E-cadherin 4A2C7 Invitrogen 1/2000 1/2000 
m α  β-actin AC15 Sigma 1/15000 1/20000 
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2.4 - Immunoprecipitation 
 
 
For immunoprecipitation experiments Protein G Dynabeads (Invitrogen) were first 
conjugated to the antibody according to the following protocol. 20 µL per reaction of 
well resuspended Dynabeads were washed twice with 500 µL of Citrate Phosphate 
Buffer (24.5 mM Citric Acid and 51.7 mM Dibasic Sodium Phosphate, pH=5.0). During 
all steps of the immunoprecipitation experiment, a magnet block was used to collect the 
beads. The solution was than pipetted out after 1 minute with the tube remaining on the 
magnet. 8 µg per reaction of the specific antibody was diluted in 20 µL of PBS, added 
to the dry beads and incubated for 1 hr at room temperature with rotation. 
After removal of the supernatant, beads were washed three times with 500 µL of Citrate 
Phosphate Buffer followed by three washes with 1 mL of 0.2 M Triethanolamine. 
The beads were then incubated with rotation for 30 min with 20 mM of fresh prepared 
Dimethyl Pimelimidate in order to covalently cross-link the antibody to the immobilised 
beads. The supernatant was removed and the reaction was quenched by incubating the 
beads with 1 mL of 50 mM Tris (pH=7.5) for 15 min with rotation at room temperature. 
The antibody-conjugated beads were washed three times with 500 µL PBST followed 
by three washes with lysis buffer. Beads were then re-suspended in the 20 µL of lysis 
buffer per reaction and were ready to use for the immunoprecipitation experiment. 
HEK293 cells were grown on 6 well plates and once they reached 80% confluence were 
transfected with a total of 4 µg of plasmid DNA per well. 6 hrs after transfection the 
medium was removed and replaced with normal medium where cells were allowed to 
recover for 42 hours prior to immunoprecipitation. 
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Cells were lysed as described in section 3.3.2 and after clarification of the lysates by 
centrifugation at 13,000 rpm for 15 min, the supernatant was added to 20 µL specific 
antibody conjugated to beads and incubated by rotation overnight at 4 °C. 
Supernatants (flow-through) were collected and transferred to a clean tube. The beads 
were washed three times with lysis buffer and then resuspended in 20 µL of lysis buffer 
per reaction before the SDS-PAGE sample buffer was added and samples boiled at 
100°C for 5 min. Beads were removed by centrifugation and samples were analysed by 
SDS-PAGE and Western blotting. 
 
 
 
2.5 - Cell biology  
 
 
2.5.1 - Cell lines culture conditions and maintenance 
 
 
Human Embryonic Kidney (HEK) 293 and HeLa cell lines were cultured in Dulbecco’s 
Modified Eagle’s Medium (DMEM) supplemented with 10% complete fetal bovine 
serum (FBS), 2 mM L-glutamine, 1x MEM non-essential amino acid solution and 1x 
penicillin-streptomycin.   
Murine inner medullary collecting duct, mIMCD-3 cells (CRL2123; ATCC, Manassas, 
VA) were grown in a 1:1 mix of DMEM and Ham’s F12 medium, supplemented with 
10% FBS and penicillin-streptomycin. All cells were grown in incubators at 37 °C in 5 
% CO2 . 
All cell cultures were passaged when they reached ~ 90% confluency. Cells were 
washed twice in sterile PBS and the detached from flasks using 2 mL of 1 x 
trypsin/EDTA per 75 cm² culture flask for 5 minutes at 37 °C. For mIMCD-3 cell lines 
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0.25% trypsin/EDTA was used. New flasks were prepared by diluting 1:10 the 
confluent culture.  
Cell lines were frozen and stored by resuspending aliquots of 4 x 106 cells in 1 mL of 
freezing medium (DMEM supplemented with 10% DMSO, 20% FBS) in cryo-vials (1 
1mL/vial). Vials were slowly frozen in isopropanol and left at –80°C overnight. 
 
 
 
2.5.1.1 - Culture of fully polarised mIMCD-3 cells 
 
 
In order to induce mIMCD-3 cells to fully polarise, cells were seeded onto 0.4 µm pore 
size transwell permeable supports at a density of 1 x 105 cells per cm². Media was 
changed every 2-3 days and cells were grown for 14 days. 
mIMCD-3 cells were grown in medium containing 1.5 µg/mL of G418 sulphate (PAA 
Laboratories) when selection was required.  
To monitor the polarisation process TER (Trans-Epithelial Resistance) was measured 
with an EVOM AC square wave current (+/- 20mA, 12.5Hz) resistance meter (World 
Precision Instruments, Stevenage, UK) after one week of growth. A ‘blank’ 
measurement was done for a filter with no cells. The confluence of the cellular 
monolayer was monitored by the increase in TER. 
For mIMCD-3 culture growing on 3D cultures, Geltrex matrix was used as a support. 
Geltrex (Life Technologies) was prepared according to manufacturer protocol. Geltrex 
was thawed on ice and 50 µL was spread in each well of tissue culture treated 8-well µ-
Slide to form a thick layer, and set at 37°C. 1x105 mIMCD-3 cells were mixed with 
1mL of 2% Geltrex and 200 µL of the mixture was pipetted on the top of the Geltrex 
layer in each well. Slides and plates were incubated at 37°C in a humidified atmosphere 
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of CO2 in air for 4 days. At day 4 the gel in slides was fixed in cold Methanol and 
stained (section 2.5.3). 
 
 
 
2.5.2 - Transfection of HEK293, HeLa and mIMCD-3s using 
Lipofectamine™ 2000  
 
 
The day before transfection HEK293 and mIMCD-3 cells were seeded in the culture 
vessel of choice, so they would reach 50-90% confluency the next day. Cells were then 
transfected with plasmid DNA constructs using Lipofectamine™ 2000 reagent 
(Invitrogen). Before transfection, growing medium was removed and replaced with 
transfection medium (serum free). 
A total of 1 µg of DNA per 2 cm² area per well was added to 50 µL of transfection 
medium, and 10 µL of Lipofectamine 2000 was added to the same volume in separate 
tubes and incubated for 5 min at room temperature. The 2 solutions were then combined 
together and incubated at room temperature for 20 min. 
The 100 µL of DNA-Lipofectamine 2000 complexes were added to the cells and, after 
gentle mixing, were incubated at 37 °C with 5% CO2 for 6 hours. 
Transfection medium was then replaced with normal growth medium and cells were 
allowed to recover for 18hrs before immunofluorescence microscopy experiments, or 
for 42 hrs when immunoprecipitation experiments were performed.   
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2.5.3 - Immunofluorescence microscopy 
 
 
HEK293, HeLa and mIMCD-3 cells were seeded on glass coverslips, transfected 24 hrs 
prior to preparation for immunofluorescence, as described in the previous section. Cells 
were fixed in 4% paraformaldehyde-PBS (pH=7.0) for 20 min at 37°C. After washing 
twice in PBS, cells were permeabilised in 0.5 % Triton-X-100 (diluted in PBS) for 10 
min, followed by blocking in Blocking Buffer (2% BSA in PBS). 
Filters with mIMCD-3 cells were first excised from transwell supports before being 
processed. When Tight Juntions (TJ) and Adherens Junction (AJ) proteins were 
immunostained, mIMCD-3 cells were fixed using ice-cold methanol for 5 minutes and 
permeabilised with 0.1% saponin. 
After blocking, filters and coverslips were further incubated in primary antibodies 
diluted in blocking buffer, for 1 hour at room temperature. Specific dilutions for all 
primary antibodies used for immunofluorescence in this thesis are reported in table 2.9. 
Primary antibodies were fluorescently labeled using Zenon Rabbit IgG Labeling Kit 
(Invitrogen) when two antibodies derived from the same species were used in the same 
application. Cells were then washed 4x in PBS, incubated in the dark in secondary 
antibody solution at the required concentration (table 2.9). Goat anti-mouse IgG and 
anti-rabbit IgG conjugates, as well as donkey anti-sheep IgG conjugates with Alexafluor 
488, 568 and 633 secondary antibodies were used. Nuclei were stained with DAPI or 
TO-PRO-3 (Invitrogen), both diluted 1/2000 in blocking buffer for 2-5 min at room 
temperature. Cells were than washed again 4x in PBS to remove the excess of 
secondary antibodies. Coverslips and filters were then mounted onto microscopy slides 
using ProLong Gold antifade solution (Invitrogen) (5 µL/coverslip). 
Confocal analysis was performed and images were captured using an inverted Leica 
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TCS SP5 AOBS confocal microscope with a 63 x 1.4 oil immersion objective (Leica 
Microsystems) and the pinhole set to 1 Airy unit. 
Series of Z-sections at 0.25 µm intervals were captured and merged into maximum 
projection images when required. Single optical sections were averages of 3 scans at 
1024 x 1024 resolution. Single xz plane images were also obtained where necessary.   
Images were colorized and contrast was enhanced using ImageJ software package. 
 
 
Table 2.9 - Antibodies and their dilutions used in this thesis for immunofluorescence 
experiments. Other information provided includes the species the antibody was raised 
in (m- mouse, Rb-rabbit), the company along with the clone number for monoclonal 
antibodies or catalogue number for polyclonal antibodies. 
 
 
 
 
 
 
Antibody Clone / Catalogue nr Supplier  
Primary 
Dilution 
Secondary 
Dilution 
Sheep α TGN46  AHP500G AbD serotec 1/1000 1/2000 
m α p230 15/p230 BD Biosciences 1/5000 1/6000 
Chicken α Calreticulin ab14234  abcam 1/400 1/400 
Rb α VIPAR HPA003589 Sigma 1/50 1/100 
Rb α PLOD3 11027-1-AP proteintech 1/50 1/100 
m α PDI RL90 abcam 1/100 1/200 
m α LAMP1 CD107a Hybridoma Bank 1/100 1/100 
m α AP-1 100/3  Sigma 1/100 1:100 
Rb α Collagen IV ab6586 abcam 1/200 1/400 
m α E-cadherin 4A2C7 Invitrogen 1/100 1/200 
m α Rab11a 47/Rab11 BD Biosciences 1/50 1/100 
m α GM130 35/GM130 BD Biosciences 1/100 1/100 
Rb α Claudin-1 51-9000 Invitrogen 1/400 1/500 
Alexa Fluor® 488 Phalloidin A12379 Invitrogen - 1/2000 
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2.5.4 - mIMCD-3 stable knockdowns  
 
 
mIMCD-3 stable knockdown cells lines were created by transfecting cells with plasmids 
containing shRNA hairpins for the specific gene. For Vps33b a pSM2c plasmid was 
used and a pRS vector for Plod3 and Vipar. The oligonucleotide sequences for all 
shRNAs are reported in table 2.10. Non-silencing hairpins were used as controls. 
Plasmid shRNA construct for Vps33b was purchased from Open Biosystems 
(V2MM_91195) while plasmids shRNA for Vipar (TR517186) and Plod3 (TR502609) 
were purchased from OriGene. 
mIMCD-3 cells were transfected with 4 µg of plasmid and allowed to recover for 48 h 
before transfected cells were selected using 1.5 µg/ml of Puromycin. Individual clones 
were selected and knockdown levels of each clone were assessed by western blotting.  
 
 
 
 
 
 
 
Table 2.10 - List of shRNA oligonucleotides used for shRNA transfection. 
 
 
 
 
 
 
 
 
 
 
 
Target gene shRNA sequence 
Vps33b CCCTGGCCAGTGCTGAAGTATT 
Vipar CGCGCAGTGAATAGCCTTCGAGACATCGT 
Plod3 ATGACTCGTCCACCTTCACTCTCAATGTC 
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CHAPTER THREE: 
 
VPS33B and VIPAR interact 
forming a stable binary complex 
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3.1 - INTRODUCTION AND OVERVIEW 
 
 
Genetic investigations on patients with ARC syndrome identified mutations in genes 
encoding two proteins: VPS33B or VIPAR. Mutations in VPS33B account for 
approximately 75% of ARC patients while mutations in VIPAR were found in all ARC 
cases where mutations in VPS33B were excluded (Cullinane et al., 2010). The ARC–
LOVD database https://grenada.lumc.nl/LOVD2/ARC reports all known mutations and 
variants for VPS33B and VIPAR (Smith et al., 2012). A summary of the ARC–LOVD 
database reporting pathogenic mutations in VIPAR and VPS33B along their genomic 
sequence is shown in figure 3.1 A and C. ARC patients carrying mutations in VPS33B 
or VIPAR show no difference between them with respect to clinical symptoms, signs or 
disease course (Cullinane et al., 2010). This observation might suggest that VPS33B 
and VIPAR are strongly associated in the cell by regulating the same intracellular 
process or being part of the same intracellular pathway. By analysing the map of known 
pathogenic ARC-mutations along VPS33B and VIPAR genomic sequence (figure 3.1 A 
and C) was noticed that mutations are distributed uniformly along VPS33B genomic 
sequence while they don’t seem to affect the first five exons of VIPAR. Because no 
structural information exists for VPS33B and VIPAR and it is not therefore possible to 
correlate the three-dimensional folding and misfolding of the protein in healthy and 
pathological conditions, I performed structural predictions for both proteins (figure 3.1 
B and D, section 3.6). Predictions of protein secondary structure, globularity and 
disorder were performed using GlobPlot (http://globplot.embl.de/), FoldIndex 
(http://bip.weizmann.ac.il/fldbin/findex), IUPred (http://iupred.enzim.hu/), RONN 
(http://www.oppf.ox.ac.uk/RONN/) and HHPRED 
(http://toolkit.tuebingen.mpg.de/hhpred) (section 3.6). Disordered regions (DRs) are 
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defined as regions of proteins that lack any recognisable secondary structure elements, 
(α-helices, β-strands). These analyses suggest that both proteins contain globular 
regions with well-defined secondary structure elements. In addition, a large disordered 
protein segment has been consistently identified by multiple structure prediction 
software at the N-terminus of VIPAR (figure 3.1 B). Many disordered proteins function 
via binding to a structured partner and undergo a disorder-to-order transition. The N-
terminal of VIPAR might therefore require a binding partner that determines its fold in 
physiologic conditions (Forman and Mittag, 2013). The absence of known pathogenic 
ARC mutations that affect the N-terminal disordered part of VIPAR (figure 3.1 C and 
D) might suggest that mutations in this region are either lethal (and therefore do not 
exist in living patients) or dispensable for VIPAR interaction with other binding 
partners such as VPS33B. 
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Figure 3.1 - Analysis of the structured and disordered regions along VPS33B and 
VIPAR protein sequence related to the map of ARC mutations along the respective 
genomic sequence. Distribution of pathogenic mutations along VIPAR (A) and VPS33B 
(C) genomic sequence. Boxes represent the exons (not to scale). Variants below the 
genogram represent intronic mutations, affecting splice sites. Variants above the 
genogram represent mutations in exons. Purple pointers indicate substitutions; → 
indicates a nonsense mutation, —• indicates a missense mutation. Orange pointers 
indicate deletions/duplications/indels; → indicates a deletion, —• indicates a 
duplication, and —♦ indicates an indel. Analysis of protein sequence with prediction of 
structural disorder for full-length human VIPAR (B) and VPS33B (D). Regions 
predicted as globular are shown as blue ovals. Figure modified from (Smith et al., 
2012). 
 
 
 
The function of VPS33B has not yet been fully characterised in humans but the yeast 
homolog Vps33p is known to belong to the SM family of proteins (Peterson and Emr, 
2001). SM proteins play an important role in conferring specificity to membrane fusion 
events by binding directly or indirectly to Soluble N-ethylmalemide sensitive factor 
Attachment Receptor (SNARE) of the syntaxin family (Chen et al., 2002; Gallwitz and 
Jahn, 2003; Toonen and Verhage, 2003). They are structurally highly conserved in 
evolution, and each SM protein is specialised in a single or a small group of trafficking 
steps. Sec 1 was one of the first SM proteins identified (SM for Sec1/Munc18). Aalto et 
al. (1992) noticed that in Saccharomyces cerevisiae there are two other proteins 
functionally related to Sec1, known as Slyl, and Slpl (Vps33) that altogether form the 
Sec1 family of proteins. Secl, Slyl, and Slpj (Vps33), which share a low 22% of 
sequence homology among them. 
In yeast Sec1 (Sec for secretion mutant) is required for protein secretion to the cell 
exterior and precisely for the fusion of secretory vesicles with the plasma membrane 
and consequent release of the cargo protein (Aalto et al., 1991; Novick et al., 1980). 
Sec1 protein is not soluble and is found in a detergent-resistant subcellular fraction in 
yeast (Egerton et al., 1993). The Sly1 protein instead may act in endoplasmic reticulum 
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to Golgi transport (Ossig et al., 1991) and therefore is also involved in protein secretion. 
The third member of the Sec1 family, Vps33/Slpj, might be involved in transport from 
the Golgi complex to the vacuole (Wada et al., 1990). VPS33B is homologue of the 
yeast Vps33 protein and it is therefore not surprising that protein similarity predictions 
for VPS33B using pBLAST (http://blast.ncbi.nlm.nih.gov/Blast.cgi?PAGE=Proteins) 
against the PDB indicate 22% of identity between VPS33B and the neuronal Sec1 
(nSec1) from the Squid L. Pealei (figure 3.2). Therefore, we can conclude that nSec1 is 
the protein with the highest identity to VPS33B. The crystal structure of nSec1 from the 
Squid L. Pealei (PDB accession number 1FVF) indicates two main functional regions in 
nSec1 structure: one contains the Syntaxin 1a binding site, and opposite to this, a 
potential and yet unspecified effector-molecule binding-pocket which is present in both 
rat nSec1 and homologous squid s-Sec11a. This fold is conserved between VPS33B and 
nSec1 because the two proteins belong to the same family. Consequently, like Sec1, it is 
likely that VPS33B binds to yet unknown SNARE and effector molecules to carry out 
its function.  
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Figure 3.2 - Database sequences identified by pBLAST 
(http://blast.ncbi.nlm.nih.gov/Blast.cgi?PAGE=Proteins) to be similar to the human 
VPS33B protein sequence. In the diagram, the bar color for a hit refers to the alignment 
score, a mathematically derived value that reflects the degree of similarity between hit 
and query sequences. The higher the score, the more similar the two. The Color Key at 
the top of the graphical display gives the range of alignment scores assigned to each 
color. Numbers flanking each bar color correspond to the sequence identified by BLAST 
and listed in the table below. 
The table reports: the description/title of matched database sequence, the highest 
alignment score (Max score) from that database sequence, the total alignment scores 
(Total score) from all alignment segments, the percentage of query covered by 
alignment to the database sequence, the best (lowest) Expect value (E value) of all 
alignments from that database sequence, the highest percent identity (Max ident) of all 
query-subject alignments, and the Accession of the matched database sequence. 
 
 
 
No proteins with known crystal structure that are homologous to VIPAR are known. 
Consequently we cannot deduce structural information on VIPAR based on the 
homology with other proteins. To deduce functional information for VIPAR, pBLAST 
was executed against the UniProt/Swiss-Prot database and found 27% of identity 
between VIPAR and Golgin subfamily A member 5 (GOLGA5) protein. GOLGA5 also 
1
2
3
7 5
4
6
Description Max 
score 
Total 
score 
Query 
cover 
E 
value 
Max 
ident 
Accession 
1. Chain A, Crystal Structure Analysis Of Neuronal Sec1 From The Squid L. Pealei 50.4 50.4 43% 3e-06 22% 1FVF_A 
 
2. Chain A, X-Ray Crystal Structure Of Neuronal Sec1 From Squid 46.2 46.2 43% 6e-05 22% 1EPU_A 
 
3. Chain A, Crystal Structure Of The Unc18-Syntaxin 1 Complex From Monosiga Brevicollis 42.4 42.4 33% 0.001 25% 2XHE_A 
 
4. Chain A, The Crystal Structure Of The Putative Regulator From Escherichia Coli Cft073 31.2 31.2 11% 1.5 32% 3HFI_A 
5. Chain A, X-Ray Structure Of The Death Domain Of The Human Mucosa Associated 
Lymphoid Tissue Lymphoma Translocation Protein 1 
28.1 28.1 9% 8.4 31% 2G7R_A 
6. Chain A, Crystal Structure Of Sly1p In Complex With An N-Terminal Peptide Of Sed5p 29.3 29.3 6% 9.3 31% 1MQS_A 
 
7. Chain A, Crystal Structure Of Human Glcat-P Apo Form 28.9 28.9 10% 9.7 26% 1V82_A 
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known as ‘Cell proliferation-inducing gene 31 protein’ or ‘Golgin-84’ encodes a 
member of the golgin family of proteins, whose members localise to the Golgi. This 
protein is a coiled-coil membrane protein that has been postulated to play a role in 
vesicle tethering and docking (Sohda et al., 2010). Previous data indicate that Golgin-84 
interacts with another tether, the conserved oligomeric Golgi (COG) complex that is 
important in vesicular trafficking and for maintaining Golgi structure and function 
(Sohda et al., 2010; Zeevaert et al., 2008). Translocations involving this gene have been 
found in tumour tissues (Ishizaka et al., 1989; Rabes, 2001). 
Like VIPAR, GOLGA5, belongs to the Golgin_A5 family of proteins whose members 
share a conserved Golgin_A5 domain. Indeed bioinformatics analysis on VIPAR using 
the Pfam, SMART and pBLAST databases finds a large Golgin subfamily A member 5 
domain in the VIPAR protein sequence (section 1.3). As mentioned previously for Sec1 
and VPS33B, members belonging to the same family of proteins share the same fold 
between them. We can therefore conclude that VIPAR shares its protein fold with 
GOLGA5 and like GOLGA5 requires other binding proteins to carry out its function. 
Co-localisation and co-immunoprecipitation experiments have shown that VPS33B and 
VIPAR are physically associated (Cullinane et al., 2010). However these types of 
experiments don’t give any information regarding the interaction between the two 
proteins. This can be either direct or indirect. Indeed positive results in co-
immunoprecipitation experiments may indicate that two proteins interact directly or 
they may interact indirectly via one or more bridging molecules. The aim of this part of 
the work was to establish if VPS33B and VIPAR interact biochemically and directly 
between them. This was achieved by pull-down experiments using over-expressed 
VPS33B and VIPAR. Pull-down assays are in-vitro methods used for both confirmation 
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of previously suspected interactions (such as from co-immunoprecipitation 
experiments) as well as for the identification of unknown protein interactors after 
coupling this technique to mass-spectrometry. The technique requires large amounts of 
the proteins whose direct interaction is being tested and this is achieved by their over-
expression in a protein expression system. This procedure eliminates confusing results 
that could arise from interaction of the bait with other endogenous interacting proteins 
that are not being tested in the study. Another purpose for the large-scale production of 
VPS33B was the generation of an anti-VPS33B antibody. Because the commercially 
available ani-VPS33B antibodies were not suitable for detection of the endogenous 
protein by WB and immunofluorescence and this was therefore a limiting factor in the 
progress of this work. 
To test the direct interaction between VPS33B and VIPAR the two proteins were over-
expressed in several expression systems (bacterial, insect and mammalian). Such efforts 
had to be undertaken because of the initial difficulties with obtaining sufficient amount 
of purified protein present in their native conformation, first in insect and then bacterial 
cells. (Appendix 1). Recombinant protein production in large scale using the 
mammalian systems was the best strategy used to express and successively purify 
VPS33B and VIPAR.  
For a successful confirmation of their interaction, the over-expressed proteins must 
preserve their native conformation. Size exclusion chromatography (section 3.3.5) was 
used as a biochemical tool to test the stability of the proteins alone and in complex and 
also to further confirm the direct interaction between VPS33B and VIPAR. 
The ‘in cell’ confirmation of protein-protein interaction was performed using confocal 
microscopy with Fluorescence Lifetime Imaging in Förster Resonance Energy Transfer 
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(FRET-FLIM) (section 3.4.3). This technique also allows estimation of molecular 
distances separating the proteins.  
Once the direct interaction between VPS33B and VIPAR was confirmed, the work was 
focused on the protein regions involved in this interaction. As mentioned above, no 
mutations have been identified in the N-terminus of VIPAR that corresponds to the 
predicted disordered region at the N-terminus of the protein. I therefore hypothesized 
that this region is not involved in the interaction with VPS33B and tested this 
hypothesis by using short constructs containing different regions of VIPAR (section 
3.4.4). 
Several protein prediction softwares such as PredictProtein 
(https://www.predictprotein.org/) predict a nuclear localisation sequence (NLS) at the 
interface between the disordered and the globular region of VIPAR (section 3.6, figure 
3.13). This result was quite surprising because previous data have localised VIPAR to 
the cytosol of eukaryotic cells (Cullinane et al., 2010; Smith et al., 2012). I questioned 
the role of this sequence in the interaction with VPS33B and/or other interacting 
partners and performed protein-protein interaction experiments using short constructs of 
VIPAR that contain or lack the NLS. 
If VPS33B and VIPAR interact directly, we can interrogate the nature of this complex. 
Can VPS33B and VIPAR co-exist in a stable binary complex or do they require other 
interacting partners for the formation of a stable and functional unit? To answer these 
questions was the second goal of this part of the study. As mentioned above, in order to 
address the question of whether VPS33B and VIPAR co-exist in a stable binary 
complex, pull-down experiments were performed followed by size exclusion 
chromatography. The addition of a MALS (Multi Angle Dynamic Light Scattering) 
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detector coupled downstream to a chromatographic system is a further detection method 
that was used to obtain accurate information regarding the molecular weight and 
aggregation state of the proteins and protein complexes (section 3.3.6).  
Very recently, the EM structure of the HOPS (vacuolar/lysosomal homotypic fusion and 
vacuole protein sorting) complex in yeast (section 1.4.4.4.1) was published (figure 3.3) 
(Brocker et al., 2012). HOPS forms an elongated structure with flexible head formed by 
Vps16-Vps33 (the yeast homologue of VIPAR/VPS33B). Vps41 is localised to the 
remainder of the head and Vps39-Vps11 form the bulky tail while Vps18 constitutes the 
flexible linker that connects the head to the tail regions. This study shows that HOPS 
components can be isolated in sub-complexes formed by 1) Vps16-Vps33 that form a 
very tight sub-complex, 2) Vps39-Vps11-Vps18 and 3) Vps39-Vps11 (figure 3.3).  
As mentioned previously (section 1.3), it is unlikely that VPS33B and VIPAR are part 
of the HOPS complex (Smith et al., 2012), however there might be some conditions in 
the cell under which VPS33B and VIPAR are involved in HOPS (Cullinane et al., 2010; 
Smith et al., 2012; Zlatic et al., 2011). The EM structure shows that the yeast 
homologues of VPS33B and VIPAR (Vps33 and Vps16) can exist as a tight sub-
complex of HOPS. We can therefore hypothesise that in higher organisms this potential 
sub-complex has acquired new functions that go beyond its role of a subunit of the 
HOPS complex. It is therefore of primary importance to establish if in higher organisms 
VPS33B and VIPAR exist as a stable sub-complex, such as their yeast counterpart 
Vps33-Vps16.  
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Figure 3.3 - Organisation of the HOPS complex. (A) Segmented model of the HOPS 
tethering complex. The head domain consists of Vps16-Vps33 (grey) and Vps41 (sandy 
brown), and the bulky tail is composed of Vps11 (light olive green) and Vps39 (dark 
olive green). The head is connected to the tail by the Vps18 linker (pink). (B) Sub-
complexes of HOPS: Vps16-Vps33 (gray), Vps39-Vps11-Vps18 (gold) and Vps39-Vps11 
(brown). Figure modified from (Brocker et al., 2012). 
 
 
Furthermore, if VPS33B and VIPAR do not form part of the HOPS complex in 
physiological conditions, then it is important to identify the intracellular pathway that 
VPS33B and VIPAR are involved in. This can be achieved by identifying VPS33B and 
VIPAR interacting proteins and understanding how these interactions impact the 
phenotype of the cell model for ARC syndrome. For the identification of new 
interactors, the experimental approach undertaken consisted in performing pull-down 
experiments using purified VPS33B/VIPAR as a “bait” followed by mass spectrometry 
for the protein identification. Pull-down experiments are indeed more amenable to an 
Vps16-Vps33 
Vps39-Vps11-Vps18 
Vps39-Vps11 
A. B. 
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initial screening than other biochemical methods such as co-immunoprecipitation as 
they give higher sensitivity and specificity to the interactions detected by the screen. 
 
 
 
3.2 - AIMS 
 
 
Although previous studies suggested that VPS33B and VIPAR interact, the direct 
interaction was not unequivocally confirmed. The aim of the work described in this 
chapter was to biochemically demonstrate direct protein-protein interaction and 
successively determine the regions in VIPAR involved in the interaction. 
Another aim of the work was to reconstitute the minimal VPS33B/VIPAR complex in-
vitro and test its stability.  
 
 
 
3.3 - METHODS 
 
 
3.3.1 - Mammalian expression system 
 
 
VPS33B and VIPAR were expressed using human embryonic kidney 293 cells that 
stably express Epstein-Bar virus nuclear antigen EBNA1 (HEK293-E cells, supplied by 
U-Protein Express BV (U-PE), Utrecht, The Netherlands). An overview of the whole 
process of expression and purification system used in this study is reported in figure 3.4. 
VPS33B and VIPAR genes were cloned using polymerase chain reaction adding 5’ 
BamHI and 3’ NotI restriction sites. The genes were transferred into a pCR8 TOPO 
cloning vector (Invitrogen) using the TOPO cloning protocol, that firstly adds adenine 
overhangs to the blunt PCR product, then ligates the product into a cloning vector that 
bears flanking thymines at 5’ and 3’. After restriction digestion and agarose 
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electrophoresis, the bands corresponding to the VPS33B and VIPAR inserts were 
excised and purified using the Wizard SV Gel and PCR Clean-Up System (Promega), 
and successively ligated into a library of expression vectors bearing various tags for 
solubilisation and optimization of expression conditions. 2 µg of plasmid DNA (either 
using a single VPS33B or VIPAR expression plasmid or a mixture of 1 µg of a VPS33B 
and 1 µg of a VIPAR expression plasmids) were used to perform small-scale transient 
transfections of HEK293 (4 mL) grown in suspension. This procedure was performed 
by the U-Protein Express BV (Utrecht). Six days after transfection cells were harvested 
by centrifugation and the production of recombinant proteins was assayed for each 
expression condition by performing Western blots using antibodies against the 
expression tags selected for the expression tests. This procedure allowed us to identify 
the optimal combination of expression conditions and purification tags for the 
production of the proteins. After experimenting with more than 50 different 
combinations of expression vectors, the best expression condition was determined in a 
co-expression mixture of pUPE.02.09-VIPAR (N-His-Strep3 tag, followed by a 
cleavage site for the Tobacco Etch Virus Protease (TEV) and pUPE.02.13-VPS33b (N-
His-cmyc3 tag, followed by TEV cleavage site). This combination was then used for a 
large scale (1 L) transient transfection of HEK293-E cells in suspension.  
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Figure 3.4 - Expression and purification platform illustration for VPS33B and VIPAR 
comprises the following steps: 1. Generation of coding cDNA via PCR using specific 
cDNA template and gene-specific primers containing standard restriction sites. 2. 
Ligation of this coding sequence into different expression vectors. 3. Small scale 
transient transfection of HEK293E cells cultured in suspension. Six days post-
transfection recombinant protein production was assayed and the most optimal 
expression vector was selected. 4. Large scale protein production in HEK293E cells 
cultured in suspension. 5. Purification and characterization of recombinant proteins. 
Figure modified from http://www.u-proteinexpress.com/media/brochure-r-PEx-
technology.pdf 
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3.3.2 - Mammalian protein extraction 
 
 
The HEK293-E cells were grown in suspension for 6 days after co-transfection with 
VPS33B and VIPAR expression plasmids, and then centrifuged for 10 minutes at 1000 
rpm. Medium was discarded, and a low salt method was used for cell lysis. The cell 
pellet was resuspended in 100 ml of cold lysis buffer (10 mM Hepes pH 8.5, 10 mM 
KCl, 5 mM MgCl2, 1 µg/mL DNase, 5mM DTT, Protease inhibitors). The mixture was 
incubated with gentle rotation at 4 °C for 5-10 minutes, then the Nonidet P-40 detergent 
was added to a final concentration of 0.3% to lyse the cells but preventing the breakage 
of the nuclear membrane. The suspension was incubated for another 15 minutes at 4 °C 
and then the lysate was clarified by centrifugation at 9.500 xg for 1 hour at 4 °C. The 
pellet, containing membrane fragments and insoluble material, was discarded. 
 
 
 
3.3.3 - Mammalian protein purification 
 
 
After centrifugation of the lysate, the soluble fraction was processed using liquid 
chromatography to isolate the VPS33B-VIPAR protein complex. The purification was 
performed using affinity chromatography, by taking advantage of the Strep tag used for 
the recombinant expression of VIPAR in the pUPE.02.09 expression vector. After 
adding NaCl to a final concentration of 250 mM, the clarified lysate was passed through 
a pre-packed StrepTrap FF 1 ml column (GE Healthcare) with a flow-rate of 0.25 
ml/min. The column was then thoroughly washed with 50 ml of wash buffer (25 mM 
HEPES/NaOH pH 8, 250 mM NaCl, 5 mM DTT) to remove non-specifically bound 
contaminants, and then the strep-tagged proteins were eluted with wash buffer + 2.5 
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mM desthiobiotin. The elute fractions were analysed by SDS-PAGE and western blot 
(section 3.4.1, 3.4.2).  
 
 
 
3.3.4 - Dialysis of Recombinant Proteins 
 
 
Dialysis Membrane Tubing (Spectrapor) with 8 kDa molecular-weight cutoff (MWCO) 
was used to exchange the buffer solution in which the proteins were dissolved. Dialysis 
was performed to remove desthiobiotin from the protein elution pool. Proteins were 
dialysed against dialysis buffer (with the same composition of the StrepTrapcolumn 
wash buffer) overnight at 4 °C under agitation.  
 
 
 
3.3.5 - Size exclusion chromatography 
 
 
Size exclusion (also called gel filtration) chromatography separates molecules according 
to their differences in size as they pass through a packed medium (in general sepharose 
or acrylamide-based beads) in a glass column. The elution progress is monitored with 
continuous UV adsorbance detection using an Akta System (GE Healthcare), and the 
protein-containing fractions are collected separately.  
The VPS33B-VIPAR complex eluted from the Strep column was concentrated using a 
Vivaspin 15 concentrator MWCO 30 kDa (Sartorius Mechatronics) to a maximum 
concentration of 5 mg/mL before gel filtration. Protein concentration was evaluated by 
measuring the absorbance at 280 nm using a Nanodrop ND-1000 spectrophotometer 
(Thermo Scientific) and applying a correction of 1.02% as determined from sequence-
based calculations using the Expasy ProtParam tool (Expasy website reference). The 
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sample was injected into a Superdex 200 5/150 gel-filtration column. Elution was 
performed with a flow rate of 0.25 mL/min using a buffer containing 25 mM Hepes pH 
8, 300 mM NaCl, 5 mM DTT.  
 
 
 
3.3.6 - Multi-Angle Laser Light Scattering (MALLS) 
 
 
Multi-angle laser light scattering (MALLS) is an extremely sensitive technique for 
determining the absolute molar mass and the aggregation state of biomolecules in 
solution by measuring the intensity of a laser light scattered at different angles by 
molecular objects passing through the flow cell. This method is highly reproducible and 
does not require calibration with molecular weight standards. Our gel-filtration analysis 
was coupled to MALLS to determine the molecular weight and the oligomeric state of 
the VPS33B/VIPAR complex. 5-10 µL of purified protein complex was injected at 1 
mg/mL. A single gel filtration peak indicated that VPS33B and VIPAR form a stable 
complex that does not dissociate in the column at a salt concentration of 300 mM. 
MALLS analysis was performed using a three-angle light scattering detector (mini-
DAWN TREOS, Wyatt technology) and a refractive index detector (RID-10A, 
Shimadzu). Data points were collected every 0.5 seconds at a flow rate of 0.1 mL/min. 
Data analysis was carried out using the ASTRA software (Wyatt technology). 
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3.4 - RESULTS 
 
 
3.4.1 - VPS33B interacts directly with VIPAR forming a binary 
complex 
 
 
A biochemical approach was used to establish whether there is direct interaction 
between VPS33B and VIPAR. It consisted of large-scale VPS33B and VIPAR protein 
production followed by pull-down experiments using in-vitro purification systems. Pull-
down experiments are strong indication of direct protein-protein interaction because of 
being performed with purified samples present in not-endogenous amounts. The 
mammalian cell system was used for the large-scale expression of VPS33B and VIPAR 
(section 3.3.1). This was done in collaboration with Professor Gros and Dr Federico 
Forneris from the Crystallography laboratory of the University of Utrecht, who 
commonly use the mammalian expression system to over-express human proteins. 
Previous attempts to perform pull-down experiments and reconstitute in-vitro the 
VPS33B-VIPAR complex in insect and bacterial cell system were not successful. Even 
though purification of VPS33B alone was successful in insect cells (Appendix 2) the 
protein formed aggregates and therefore was not suitable for further analysis.  
VPS33B and VIPAR were expressed on large scale in suspension growing human 
embryonic kidney 293 cells that stably express Epstein-Bar virus nuclear antigen 
EBNA1 (HEK293-E cells, supplied by U-Protein Express BV (U-PE), Utrecht, The 
Netherlands) (section 3.3.1). The expression and purification of VPS33B and VIPAR 
alone and in complex was performed. Initially, the reconstitution of VPS33B-VIPAR 
protein complex was attempted from individually produced proteins. However, only 
very low expression levels of VPS33B and VIPAR were detected and therefore it was 
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found impossible to purify these proteins alone using the mammalian expression 
system. 
The best results were achieved from the co-expression and successive co-purification of 
recombinant VIPAR (in fusion with His6-Strep3-TEV tag) with recombinant VPS33B 
(in fusion with His6-cMyc3-TEV tag). This led to an enormous increase in the 
expression of both proteins that reached 2-3 mg/L. Several publications showed that an 
increase in protein expression and solubility can be achieved when proteins that 
normally exist in stable protein complexes are co-expressed together (Hanzlowsky et 
al., 2006; Kerrigan et al., 2011) indicating that this might be the case for VPS33B and 
VIPAR. 
After co-expression in HEK293-E cells, VPS33B was co-purified with VIPAR by 
affinity purification using the StrepTactin™ Sepharose™ resin that specifically binds 
the Strep3 tag of VIPAR. The co-elution of VPS33B in stoichiometric amount 
compared to VIPAR (figure 3.5) is an experimental proof of the direct interaction 
between VPS33B and VIPAR. Indeed only VIPAR, provided with the Strep-tag, is 
capable of affinity binding StrepTactin resin. The presence of VPS33B in the elution 
fractions might be explained either by its binding to VIPAR or by a non-specific 
binding to StrepTactin resin, although this second hypothesis is clearly excluded 
considering that the proteins co-elute stoichiometrically. This second hypothesis was 
further excluded by loading His6-cMyc3-VPS33B on the StrepTactin resin and 
analysing the bound fractions by SDS-PAGE and subsequent Western blot with an anti-
His6 antibody. Western analysis was negative demonstrating that His6-cMyc3-VPS33B 
does not bind to StrepTactin resin. It was therefore possible to conclude that His6-
cMyc3-VPS33B co-elutes with His6-Strep-VIPAR because the two proteins directly 
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interact. The identity of the proteins after purification was confirmed by Western-blot 
using an anti-His6 antibody that specifically recognises the His6-tag of recombinant 
VPS33B and VIPAR (figure 3.5). 
The purified complex was concentred with Vivaspin 15 concentrator (Sartorius 
Mechatronics) before being subjected to size exclusion chromatography (gel-filtration) 
on the Superdex 200 5/150 column for VPS33B-VIPAR complex analysis (figure 3.5; 
section 3.4.2).  
 
 
 
 
 
 
 
 
Figure 3.5 - Recombinant VPS33B-VIPAR complex analysis. (A) SDS-PAGE for His6-
cMyc-VPS33B / His6-Strep-VIPAR complex purification: S (soluble fraction), E 
(StrepTactin Sepharose elution), Conc (concentrated elution pool), GF (elution from the 
peak in gel filtration). (B) Western blot for the soluble fraction (S) with anti-His6 
antibody 
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3.4.2 - VPS33B and VIPAR form a stable complex 
After establishing that VPS33B interacts directly with VIPAR, the next goal was to 
determine the stability of the complex in-vitro. Size exclusion chromatography (or gel 
filtration) was used on Superdex 200 5/150 (figure 3.6) to further confirm the formation 
of a binary complex and to test its stability. In gel filtration, proteins or protein 
complexes are separated from other species by size as they pass through the 
chromatographic column (section 3.3.5). Therefore a single peak in gel filtration is 
equivalent to one protein or one protein complex. The VPS33B-VIPAR purified and 
concentrated complex (figure 3.5 A) elutes as a single peak in gel filtration that 
indicates that proteins are in complex. This complex is quite stable and aggregation 
phenomena were excluded because protein aggregates, too large to enter the exclusion 
range of the gel, normally elute in the void/dead volume of the chromatography column. 
The eluted fractions were analysed on SDS-PAGE confirming the presence of both 
proteins in the elution peak (figure 3.6).  
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Figure 3.6 - Gel filtration chromatogram relative to VPS33B-VIPAR complex on the 
Superdex 200 5/150 column
 
 
 
For an exact and unambiguous determination of the molecular weight of the VPS33B-
VIPAR protein complex, the gel-filtration was coupled to MALS (Multi Angle 
Dynamic Light Scattering molecular weights) (figure 3.7). The system detects a 
molecular weight of 280 kDa in correspondence of the VPS33B-VIPAR elution peak 
(red line) that might correspond to the dimer of VPS33B-VIPAR. The almost horizontal 
orientation of the red line indicates the complex is quite homogeneous.  
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Figure 3.7 - Evaluation of the oligomeric state of the VPS33B-VIPAR complex. SEC-
MALLS elution profile of the VPS33B-VIPAR complex using a Superdex 200 10/300 
analytical column. The complex elutes as a single peak with a molecular weight of 280 
kDa. 
 
 
 
3.4.3 - VPS33B and VIPAR interact in the cell with Fluorescence 
Resonance Energy Transfer (FRET) 
 
 
In-cell analysis of VPS33B-VIPAR interaction was performed using confocal 
microscopy with Fluorescence Lifetime Imaging in Förster Resonance Energy Transfer 
(FRET-FLIM). In FRET-FLIM, the occurrence of FRET can be imaged using 
fluorescence lifetime imaging microscopy (FLIM). For this purpose, HEK293 cells 
were transfected with the fluorescent FRET couple GFP-mCherry. FRET occurs when 
the lifetime of the GFP (donor) is reduced in the presence of an acceptor (mCherry) 
sample. The fluorescence lifetime of the donor was measured in a sample containing the 
donor only (first panel in figure 3.8) and compared it to samples where both donor and 
acceptor are present (figure 3.8). mCherry-tagged VPS33B and GFP-tagged VIPAR 
were used (fourth panel in figure 3.8). In the negative controls the donor GFP-VIPAR 
was coupled first to untagged-VPS33B (second panel in figure 3.8) and secondly to the 
empty mCherry vector only (third panel in figure 3.8). In panels in figure 3.8 the 
lifetime is shown as different colours. The more purple the image, the shorter the 
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lifetime, indicating the presence of FRET. The average fluorescence lifetime is 
calculated for each sample and is represented in the histograms in figure. 3.8. The raw 
data from the FRET analysis are reported in Appendix 3. 
As mentioned previously, a reduction in the lifetime of GFP is associated to FRET and 
figure 3.8 indicates that the lifetime of GFP-VIPAR is reduced only when mCherry-
VPS33B is present, and not in any of the negative controls (figure 3.8). For a positive 
FRET result the 2 fluorophores must be between 1 and 10 nm apart, matching the scale 
at which protein-protein interactions take place. This result unequivocally demonstrates 
that VPS33B and VIPAR interact in the cell. 
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Figure 3.8 - FRET-FLIM of VPS33B-VIPAR interaction. Images are false colour 
lifetime images; the graphs are histograms of the lifetime in the images. Imaging 
experiment performed using a confocal microscope coupled to a FLIM (fluorescence 
life time imaging) detector. The distribution of the mean fluorescence lifetime of the 
GFP donor is displayed using a continuous pseudocolour scale ranging from ‘short’ 
(towards purple) to ‘long’ (towards orange). For each dataset n>5. Significant FRET 
values (P<0.01) were observed when comparing GFP-VIPAR / mCherry couple with 
the GFP-VIPAR / mCherry-VPS33B (P-value = 0.003254, N=3). Experiment performed 
in collaboration with Federico Forneris. 
 
 
 
short long 
 100 
3.4.4 - VPS33B interacts with the globular C-terminal domain of 
VIPAR 
 
 
Two main regions were identified in VIPAR from exploring its protein sequence for 
globularity and disorder (section 3.1), one disordered region at the N-terminus (N) and a 
globular structured region at the C-terminus (C) (figure 3.1). Unlike in the C-region, no 
mutations were identified in the genomic sequence of VIPAR that are located in the 
disordered N-region. Therefore I investigated which of these regions of VIPAR are 
involved in the interaction with VPS33B. For this purpose two constructs of VIPAR 
were used (N and C) including respectively the N- and C-terminal part of the protein, 
and co-immunoprecipiation experiments were performed with VPS33B. Furthermore, 
as mentioned in section 3.1, a nuclear localisation sequence (NLS) is predicted at the 
interface between the disordered and the globular region of VIPAR (section 3.6, figure 
3.13). I investigated if this sequence is crucial or not for the interaction with VPS33B by 
using two constructs for the C-region of VIPAR, C- and C+, that respectively lack or 
include the NLS. The N-construct used in this study does not contain the NLS (N-). The 
co-immunoprecipitation experiment revealed that VPS33B interacts with the C-region 
of VIPAR only. No interaction was detected with the N-region (figure 3.9). This finding 
might explain the lack of known ARC mutations involving the N-terminal of VIPAR. 
Mutations in this region could be dispensable for VIPAR interaction with VPS33B. 
Another possibility is that mutations in the N-region of VIPAR are embryonically lethal 
because they abolish the interaction with other potential binding partners that are crucial 
for VIPAR’s protein function. The hypothesis that the N-region of VIPAR might be 
involved in the binding of other proteins is supported by the evidence that disordered 
regions require the binding of structured partners in-vivo to undergo a disorder-to-order 
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transition. Consequently I hypothesised that also the N-region of VIPAR, not involved 
in the interaction with VPS33B, binds to other interacting proteins in-vivo for its 
stability. 
From figure 3.9 I concluded that C+ and C- constructs bind with similar affinity to 
VPS33B indicating that NLS is not crucial for this interaction (figure 3.9).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.9 - Co-immunoprecipitation of myc-VIPAR constructs with HA-VPS33B. 
HEK293 cells were co-transfected with HA-empty or HA-VPS33B and myc tagged 
VIPAR full-length (FL), N-terminal construct of VIPAR without NLS (N-), C-terminal 
construct of VIPAR without NLS (C-), C-terminal construct of VIPAR with NLS (C+) 
and myc-empty vector. Immunprecipitation was performed with anti-myc antibody and 
it reveals a strong interaction between VPS33B and FL, C- and C+ constructs of 
VIPAR. No interaction with VPS33B was detected for the N- construct. None of these 
proteins were pulled down with HA-empty or myc-empty.  
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3.5 - DISCUSSION 
 
 
Germline mutations in VPS33B or VIPAR have been identified in most patients with 
ARC syndrome. They share the same clinical features and this suggests that VPS33B 
and VIPAR are involved in the same intracellular pathway in higher organisms 
(Cullinane et al., 2010). Published data have confirmed VPS33B and VIPAR 
association by co-localising and co-immunoprecipitating the proteins (Cullinane et al., 
2010). So far there has been no incontrovertible evidence regarding either the direct or 
indirect interaction between the proteins. I performed pull-down experiments and 
demonstrated that VPS33B directly interacts with VIPAR in-vitro. This method 
however, despite giving clear and unambiguous results, lacks spatial and physiological 
information since the proteins expressed are not in their natural environment. Positive 
results in FRET-FLIM experiments excluded the possibility of in-vitro artefacts 
associated with the pull-down system. 
Through biochemical approaches including gel-filtration and SEC-MALLS I 
unequivocally demonstrated that VPS33B and VIPAR form a stable binary complex in-
vitro with a molecular weight of 280 kDa that might correspond to the dimer of 
VPS33B-VIPAR. 
These data are consistent with the suggestion by Bröcker et al, 2012, who published the 
EM structure of the HOPS complex in yeast where VPS33B and VIPAR yeast 
homologues Vps33 and Vps16 were shown to form a tight sub-complex of HOPS. As 
mentioned previously, unlike their yeast counterparts, VPS33B and VIPAR are unlikely 
to form a part of the HOPS complex in physiological conditions (Smith et al., 2012). It 
was therefore hypothesised that in higher organisms the VPS33B-VIPAR binary sub-
complex has acquired new functions separate from HOPS, by interacting with binding 
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partners involved in different intracellular pathways. Consequently our next goal was to 
identify specific intracellular pathways where VPS33B/VIPAR are involved by 
identifying new interacting proteins of the complex. This will allow elucidation of the 
role of VPS33B/VIPAR in the physiological and pathological conditions.  
Another evidence of the possible existence of other VPS33B/VIPAR interactors comes 
from protein predictions of globularity and disorder. This predicts a presence of a large 
disordered protein segment at the N-terminus of VIPAR and it is known that disordered 
proteins require binding to a structured partner in-vivo for their stability. Previously I 
showed that, unlike the C-terminal, the N-terminal region of VIPAR does not co-
immunoprecipiate with VPS33B and therefore is dispensable for this interaction. 
Therefore is possible to conclude that other interactor proteins are likely to be involved 
in the binding to the N-region of VIPAR in-vivo and this hypothesis will be further 
discussed in chapter 4. 
 
 
 
 
 
 
 
 
 
 
 
 104 
3.6 - Supplementary Bioinformatics analysis of VPS33B and VIPAR 
proteins 
 
 
The crystal structure of VPS33B and VIPAR is not yet known. Therefore a preliminary 
bioinformatics analysis was performed to better characterise the proteins subject of this 
study. 
Disordered regions in proteins often lead to difficulties in protein expression, 
purification and crystallisation. Several types of software for prediction of intrinsically 
unstructured/disordered proteins were used including “GlobPlot” 
(http://globplot.embl.de/) “FoldIndex©” (http://bip.weizmann.ac.il/fldbin/findex) and 
“IUPred” (http://iupred.enzim.hu/). All analyses confirmed that the largest predicted 
disordered region is located within the N-terminal portion of VIPAR (figure 3.10 A and 
B). This region is likely to lack any recognisable secondary structure elements, (α-
helices, β-strands). This analysis suggests that the large N-terminal portion of VIPAR, 
as well as some small regions located along the whole sequence of VPS33B (figure 3.11 
A and B), are potentially aggregation-susceptible in the absence of interacting partners.  
Furthermore, a bioinformatics analysis specifically searching for “coiled-coil” regions 
in both proteins was performed using the available on-line software “Coils” (http://npsa-
pbil.ibcp.fr/cgi-bin/npsa_automat.pl?page=npsa_lupas.html). Proteins with coiled-coil 
regions are often insoluble because such regions might be responsible for aggregation in 
absence of interacting partners. VPS33B and in particular VIPAR are predicted to 
contain coiled-coil regions (figure 3.10 C and 3.11 C) that renders the expression and 
purification of those proteins more challenging. 
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Figure 3.10 - Prediction of secondary structures and disordered regions for VIPAR. (A) 
FoldIndex© for VIPAR plotted with window size 51 (scanning windows of 51 
aminoacids). The software gives an estimation of the probability of protein folding 
along the sequence (B) Prediction of the intrinsic protein disorder, domain and 
globularity for VIPAR using GlobPlot. “Up-hills” on the graph are equivalent to 
disorder regions (blue segments) and “down-hills” regions correspond to putative 
globular domains (green segments). C) Prediction of coiled coil regions along VIPAR 
sequence obtained in scanning windows of 14 (green line), 21 (blue line) and 28 (red 
line) residues with Coils software. 
A
B 
C 
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Figure 3.11 - Prediction of secondary structures and disorder regions for VPS33B. (A) 
FoldIndex© for VPS33B plotted with window size 51. (B) Prediction of the intrinsic 
protein disorder, domain and globularity for VPS33B using GlobPlot. (C) Prediction of 
coiled coil regions along VPS33B sequence obtained in scanning windows of 14 (green 
line), 21 (blue line) and 28 (red line) residues with Coils software.  
B 
A 
C 
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Another important parameter to take into consideration during protein expression in a 
different system from the one where the protein is normally expressed, is the codon 
usage (it refers to differences in the frequency of occurrence of synonymous codons in 
coding DNA). Low protein expression or formation of insoluble aggregates may be 
attributed to differences in the codon usage between the target protein and the 
expression host. The available on-line software “the rare codon calculator” 
(http://www.codons.org/) was used to calculate the %Max (percentage of common 
codons) and the % Min (percentage of rare codons) for each amino acid. In figure 3.12 
blue bars correspond to clusters of common codons while red bars indicate clusters of 
rare codons. As evident from figure 3.12, when the “E. coli codon bias” was used, it 
was found that both VPS33B and VIPAR contain large rare codon clusters for E.coli 
along their sequence (figure 3.12 A and B). However the predicted number of clusters 
of rare codons was significantly reduced for VPS33B when the “Homo sapiens codon 
bias” was used (figure 3.12 C), while some rare codon clusters were still predicted 
along VIPAR transcript.   
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Figure 3.12 - Codon clustering calculation using the rare codon calculator software for 
VPS33B and VIPAR genes expressed in E. coli (A and B panel respectively) and Homo 
sapiens (C and D). Blue %Max bars correspond to clusters of common codons; red 
%Min (negative) bars correspond to clusters of rare codons. 
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Figure 3.13 - Results of Nuclear Localisation Signal Prediction (NLS) in VIPAR using 
PredictProtein software (http://www.predictprotein.org/). NLS's found in the query 
sequence are highlighted in red in the output report. The identified NLS motif is found 
in 3 families (protein Swiss Id) with known nuclear localisation (nuc).  
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CHAPTER FOUR: 
PLOD3 is a novel interactor for 
VPS33B/VIPAR 
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4.1 - INTRODUCTION AND OVERVIEW 
 
 
Most biological processes are regulated by multiprotein complexes whose 
characterisation, through the identification of specific protein-protein interactions, is a 
key goal in cell biology.    
As mentioned in the previous chapter, the main goal of this work is to understand the 
role of VPS33B and VIPAR in the cell as well as the underlying intracellular 
mechanisms involved. This can be achieved by identifying VPS33B and VIPAR 
interacting proteins which are part of possible known intracellular pathways and 
understanding how these interactions impact the cell model phenotype for ARC. To 
screen for new protein-protein interactions involving VPS33B and VIPAR, a pull-down 
experiment was performed by using the previously purified VPS33B-VIPAR complex 
as a ‘bait’ to ‘fish’ for novel interacting proteins. This technique was coupled to mass 
spectrometry (MS) for the identification of endogenous proteins bound to the 
VPS33B/VIPAR protein complex. MS was performed at the UCL Mass Spectrometry 
core facility. The specific type of MS employed Liquid chromatography electrospray 
ionisation tandem mass spectrometry (LC-ESI-MS-MS) where the nanoflow liquid 
chromatography is coupled with electrospray ionization to analyse peptides in complex 
mixtures obtained from an enzymatic digest, such as trypsin digestion (section 4.3.2). 
Positive results in MS are strictly dependent on the amount of protein in the original 
sample, therefore coupling this technique to the pull-down, performed with large-scale 
over-expressed proteins was crucial for the success of the whole experimental 
procedure. This work led to the identification of Lysyl Hydroxylase 3 (LH3), also 
named Procollagen-Lysine 2-Oxoglutarate 5-Dioxygenase 3 (PLOD3) as a potential 
binding partner for the VPS33B/VIPAR protein complex. In the next chapters the work 
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to establish the validity of this interaction and its physiological and pathological 
relevance is described.  
PLOD3 is one of the lysyl hydroxylase (LH) enzymes that catalyse the hydroxylation of 
lysyl residues in collagen-like peptides. It belongs to the 2OG-Fe(II) oxygenase 
superfamily that catalyse a wide range of reactions including hydroxylations, 
desaturations and oxidative ring closures. They all require ferrous ion, 2-oxoglutarate, 
molecular oxygen and ascorbate for their activity. In the lysyl hydroxylase reaction one 
atom of oxygen is incorporated into the Lys residue and another one into 2-
oxoglutarate, which is decarboxylated to form succinate and CO2 (Turpeenniemi-
Hujanen et al., 1980) (figure 4.1). Ascorbate is needed to regenerate the enzyme after 
several reaction cycles. 
In vertebrates there are three lysyl hydroxylase isoforms PLOD1, PLOD2 and PLOD3 
while only one (PLOD) is present in invertebrates. D. melanogaster dPLOD is 
homologue to PLOD3, evolutionarily the oldest of the lysyl hydroxylases isoforms 
(Ruotsalainen et al., 1999; Salo et al., 2008). All isoforms are capable of LH activity but 
PLOD3 (and its D. melanogaster homologue dPLOD) has additional 
galactosyltransferase (GT) activity on hydroxylated lysines and 
glucosylgalactosyltransferase (GGT) activity on galactosylhydorxylated lysines (figure 
4.2) (Hudson et al., 1993; Rautavuoma et al., 2002; Ruotsalainen et al., 2006; Wang et 
al., 2002b). The aforementioned post-translational modifications occur during collagen 
biosynthesis (section 1.5.3.2) and are critical for the stability of intermolecular 
crosslinking of collagens and proteins with collagenous domains (Kivirikko and 
Pihlajaniemi, 1998; Sricholpech et al., 2012). The LH and GGT activity have been 
mapped to specific regions of PLOD3 protein sequence by using truncated forms that 
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progressively lose LH or GGT activity (Heikkinen et al., 2000; Wang et al., 2002b). 
These studies located the LH activity in the carboxy-terminal portion of PLOD3 
(Myllyla et al., 2007), the most conserved region among the lysyl hydroxylases 
isoforms, and the GT and GGT activity in the amino-terminal part (Myllyla et al., 2007; 
Wang et al., 2002a; Wang et al., 2002b). Thus, defects in the activity of one catalytic 
domain does not necessarily affect the activity of the other. For example, missense 
mutations affecting the LH activity of PLOD3 do not affect the GGT activity (Wang et 
al., 2002b). 
PLOD3 activity is crucial for the cell secretion of type-IV collagen, the main collagen 
of the basement membranes in humans, mice, zebrafish and Caenorhabditis elegans. 
In this chapter, work to confirm the MS results is described. Co-immunoprecipitation 
was used to validate in-vitro interactions while co-localisation with confocal 
microscopy, as well as Fluorescence Lifetime Imaging in Förster Resonance Energy 
Transfer (FRET-FLIM) were used for in-cell confirmation of protein-protein 
interactions. Additionally, experiments to show whether endogenous PLOD3 co-
localises with VIPAR and VPS33B were performed. These eliminate potential false 
positive results derived from over-expression artefacts. Another purpose for using 
FRET-FLIM technique was to estimate intermolecular distances on an Angström scale 
separating the proteins between them. From this data it is also possible to glean 
information regarding the type of interaction between the proteins in this study. Indeed 
the shorter the distance the more likely it is that a physical direct interaction is occurring 
between the proteins.  
Section 3.4.4 provides evidence that the N-terminal domain of VIPAR, which was 
previously shown to be disordered (section 3.1), is not involved in VPS33B interaction. 
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Thus this domain could to participate in the interaction with other proteins, which 
would facilitate its transition from “disordered” to “ordered”. In this chapter the 
experiments to determine the possibility that the N-terminus of VIPAR is involved in 
the binding of PLOD3 are described. 
 
 
 
 
 
 
 
 
 
 
Figure 4.1 - Hydroxylation reaction catalyzed by lysyl hydroxylases. Fe2+, 2-
oxoglutarate, O2 and ascorbate is required in the lysyl hydroxylase reaction where one 
atom of oxygen is incorporated into the hydroxyl group of the lysyl residue in the 
peptide substrate and another one into 2-oxoglutarate, which is decarboxylated to form 
succinate and liberates CO2. 
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Figure 4.2 - Galactosylation and glycosylation reactions catalysed by peptidyl GT and 
GGT (Modified from (Kivirikko and Myllyla, 1983)) 
 
 
 
4.2 - AIMS 
 
 
The first aim of the work described in this chapter was to identify new interacting 
proteins for VPS33B and VIPAR in order to further investigate the role of VPS33B-
VIPAR complex in the cell. 
The second aim was to validate the novel interaction experimentally and provide a 
hypothesis for the biological importance of this interaction. 
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4.3 - METHODS 
 
 
4.3.1 - Strep-tactin pull-down assay 
!
 
The pull-down assay was performed using the VPS33B/VIPAR purified complex as 
‘bait’ for the identification of new interactors (figure 4.3). VPS33B/VIPAR was purified 
as in section 3.3.3 where the complex was captured on a StrepTrap FF 1 ml column 
taking advantage of the Strep tag on recombinant VIPAR that specifically binds the 
StrepTrap FF. This system generates a secondary affinity support for the binding of 
other proteins that specifically interact with the bait protein once this is incubated with a 
cell lysate that contains putative interactor proteins (prey) figure 4.3. 
After the VPS33B/VIPAR complex was immobilised on the column (section 3.3.3), 
HEK293-E lysate was passed through the column over night with a flow-rate of 0.1 
mL/min. The column was then washed again with 20 mL of wash buffer (25 mM 
HEPES/NaOH pH 8, 250 mM NaCl, 5 mM DTT) to remove the non-specifically bound 
contaminants, before the strep-tagged proteins were eluted with a wash buffer + 2.5 mM 
desthiobiotin (figure 4.3). The collected elution fractions containing both the ‘bait’ and 
putative ‘prey’ proteins were pooled and concentrated using a Vivaspin 15 concentrator 
MWCO 30 kDa (Sartorius Mechatronics) before being analysed by mass spectrometry 
for the determination of the ‘prey’ identity (figure 4.3). This step allowed a further 
enrichment in the ‘prey’ proteins that facilitated its MS identification. 
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Figure 4.3 - Schematic representation of the strep-tactin pull-down assay used as a 
screening tool for the identification of new VPS33B/VIPAR interactors. The affinity 
system consists of strep-tagged VIPAR (in complex with VPS33B) immobilised on a 
strep-tactin affinity column. This protein complex was used as a "bait" to capture 
putative binding partners (prey) once the immobilised bait protein was incubated with 
HEK293-E cell lysate. After washing, the bound protein complexes were selectively 
eluted and the elution fraction containing both the bait and putative ‘prey’ proteins 
were analysed by mass spectrometry 
P 
P 
P 
P 
P 
Cell lysate containing 
the pray (P) protein 
VIPAR 
VPS33B 
Strep-
Tactin  Strep-Tag 
Bait  
Binding and washing 
VIPAR 
VPS33B 
Strep-
Tactin  Strep-Tag 
P 
Elution 
VIPAR 
VPS33B 
Strep-Tag 
P 
Strep-
Tactin  + 
Trypsin digestion 
Mass spectrometry 
Prey protein ID 
 118 
4.3.2 - Liquid chromatography electrospray ionisation tandem mass 
spectrometry ESI-LC-MS/MS 
 
 
Mass spectrometry on the pull-down elution was performed in collaboration with 
Wendy Heywood (Bennett et al., 2010; Bennett et al., 2012).  
Proteins in the concentrated elution pool were firstly precipitated and then denatured by 
re-suspending in 40 µL of 6 M urea containing buffer (100 mM Tris, pH 7.8). To reduce 
disulphide bridges on proteins, 3 µL of 100 mM Tris–HCl buffer, pH 7.8, containing 
5 M DTE (Dithiothreitol) were added and incubated at room temperature for 60 min. 
Free thiol groups were carboamidomethylated by incubating with 6 µL of 100 mM 
Tris–HCl, pH 7.8, containing 5 M iodoacetamide for 30 min at room temperature. This 
mixture was then diluted with H2O to a final volume of 400 µL and vortexed, before 
1 µg of sequence grade trypsin was added to the solution. Trypsin digestion was carried 
overnight at 37 !C in water bath. This trypsin digest was analysed by liquid 
chromatography electrospray ionisation tandem mass spectrometry (ESI-LC-MS/MS). 
ESI-LC-MS/MS couple liquid chromatography to electrospray ionization for the 
analysis of single fragments resulted from the trypsin digestion. This allows the 
measurement of two masses, hence the term tandem mass spectrometry or MS/MS: 
firstly the Nanoflow-HPLC chromatography separates peptides that are directly eluted 
into an electrospray ion source in the mass spectrometer (figure 4.4). This allows the 
protonation of single peptides whose charge and first mass (MS-1) is measured by the 
instrument (figure 4.4). The second mass is measured when single protonated fragments 
pass through a second cell where Argon is used to further fragment single peptides by 
collision-induced dissociation (CID). After their separation, the mass of single 
fragmented ions is recorded (MS-2) (figure 4.4). 
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The fragmentation pattern of a single peptide is based on its sequence and can therefore 
be predicted. Predicted fragment ions for all peptides are available on databases such as 
the Swiss Prot database and experimental data for unknown peptides can therefore be 
searched against those databases using ProteinLynx Global Server (PLGS version 2.2.5, 
Waters, Milford, MA, USA) in order to identify the protein from which the peptide was 
originated. The Protein Lynx Global Server (PLGS 2.2.5) software groups together 
several peptides derived from the digestion of the same protein and compares it to 
theoretical peptides derived from an 'electronic' tryptic digestion of the protein database 
and assigns a PLGS Score (table 3.1), calculated by using a Monte Carlo algorithm. 
This algorithm measures the accuracy for assignment. A higher score implies greater 
confidence of protein identity (Wright et al., 2009). 
 
 
 
 
 
 
 
Figure 4.4 - Liquid chromatography electrospray ionisation tandem mass spectrometry 
ESI-LC-MS/MS illustration. Peptides separated by HPLC (blue and red dots) are eluted 
into an electrospray ion source (ESI) in the mass spectrometer where their first mass 
(MS-1) is measured. These protonated fragments pass through a second cell (collision 
cell) where Argon is used to further fragment peptides and their second mass is 
measured (MS-2). Modified from http://qbab.aber.ac.uk/roy/mss/qtof.htm 
 
 
 
In order to determine the identity of the proteins contained in our pull-down elution 
concentrated fraction, a nanoAcquity HPLC and QTOF Premier mass spectrometer 
(Waters Corporation, Manchester, U.K.) was used (Bennett et al., 2010; Bennett et al., 
2012). Peptides were trapped and desalted before a reverse phase separation was applied 
using a Symmetry C18 5 µm, 5 mm × 300 µm precolumn. Temperature in all columns 
ESI MS-1 Collision 
cell 
MS-2 Detector 
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was constantly kept at 35 °C. The separation of peptides prior to mass spectrometry was 
performed using a 15 cm × 75 µm C18 reverse phase analytical column. Peptides were 
loaded onto the precolumn at a flow rate of 4 µL/min in 0.1% formic acid for 4 minutes 
and eluted before being separated on the analytical column using a gradient of 3−40% 
acetonitrile (0.1% formic acid) for 90 min and at a flow rate of 300 nL/min. The column 
was washed and regenerated at 300 nL/min for 10 min using a 99% acetonitrile (0.1%) 
rinse in order to remove all nonpolar and non-peptide material. The column was then re-
equilibrated for 20 min at the initial starting conditions. Peptides were analysed in 
positive ion mode using a Q-Tof Premier mass spectrometer (Waters Corp., 
Manchester, U.K.) and in v-mode with a resolving power of 10!000 fwhm. The TOF 
analyser was calibrated with [glu1]-fibrinopeptide B fragments obtained using a 
collision energy of 25 V and over the mass range 50−2000 m/z. Post calibration of data 
files were corrected using the doubly charged precursor ion of [glu1]-fibrinopeptide B 
(785.8426 m/z) with a sampling frequency of 30 s. Accurate mass LC-MS data were 
collected in a data independent and alternating, low and high collision energy mode. 
Each low/high acquisition was 1.5 s with 0.1 s interscan delay. Low energy data 
collections were performed at constant collision energy of 4 V, high collision energy 
acquisitions were performed using a 15−40 V ramp over a 1.5 s time period and a 
complete low/high energy acquisition achieved every 3.2 s (Bennett et al., 2010; 
Bennett et al., 2012). 
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4.4 - RESULTS 
 
 
4.4.1 - Mass spectrometry analysis of VPS33B-VIPAR binding proteins 
 
 
To identify novel interactors for the VPS33B-VIPAR protein complex, a pull-down 
assay was set-up combined with a mass spectrometry analysis of the outcome elution 
fraction (section 4.3.1, 4.3.2). Mass-spectrometry was performed in collaboration with 
Wendy Heywood. Trypsin was used to digest the protein mixture into peptides that 
were then subjected to Liquid Chromatography Electrospray Ionisation Tandem Mass 
Spectrometry. ESI-LC-MS/MS outcome results were analysed by The Protein Lynx 
Global Server (section 4.3.2). The proteins identified by this analysis are reported in 
Table 3.1. ESI-LC-MS results confirmed the presence of the ‘bait’, VPS33B and 
VIPAR, in the pull-down elution mixture. H2B-1A and all keratin proteins were 
excluded as potential positive results since these represent the most common 
nonspecific contaminant in the field of protein mass spectrometry and were therefore 
removed from further analysis. Interestingly PLGS 2.2.5 analysis identified PLOD1 and 
3 (Procollagen lysine 2 oxoglutarate 5 dioxygenase 1 and 3) as potential interactors for 
the VPS33B-VIPAR complex. As shown by this analysis, 58 theoretical peptide 
sequences (theoretical peptides) were identified from the Protein Lynx Global Server 
for PLOD3, amongst which 12 sequences showed homology to predicted protein 
fragments. The PLGS score for these proteins suggests reliable identification. 
The experimental work described in this chapter is mainly aimed at confirming or 
excluding the possibility that PLOD3 or PLOD1 interact with VPS33B or VIPAR. 
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Table 4.1. Proteins identified by ESI-LC-MS in the VPS33B/VIPAR pull-down assay. 
Data analysed using Protein Lynx Global Server (PLGS 2.2.5). Indicated are the 
SwissProt accession number, entry and description, expected molecular weight (mW), 
expected isoelectric point (pI), PLGS score, number of peptides identified, number of 
calculated theoretical peptides, percentage of sequence coverage 
 
 
 
4.4.2 - PLOD1 does not co-localise with VPS33B-VIPAR complex 
 
 
Preliminary confocal microscopy experiments were performed to test the possibility that 
PLOD1 or PLOD3 co-localise with the VPS33B/VIPAR complex. HEK293 cells were 
used to over-express the proteins for this preliminary test. This cell line was used to 
remain consistent with the pull-down and mass spectrometry experiment. Over-
expressed mCherry-PLOD1 shows a diffuse cytoplasmic distribution, most likely 
corresponding to ER (Salo et al., 2006a; Schneider and Granato, 2007) that does not co-
localise with over-expressed YFP-VPS33B/myc-VIPAR clusters. In contrast, over-
expressed mCherry-PLOD3 forms distributed cytoplasmic clusters, which co-localise 
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with over-expressed YFP-VPS33B/myc-VIPAR (figure 4.5). These findings suggest 
that PLOD1 might not constitute a true interactor for VPS33B/VIPAR but PLOD3 
might be a novel interactor for this protein complex. This second hypothesis has been 
further investigated in this chapter.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.5 Co-localisation of VPS33B-VIPAR with PLOD1 and PLOD3. Confocal 
immunofluorescence of HEK293 cells co-transfected with myc-VIPAR (unstained), 
YFP-VPS33B (green) and mCherry-PLOD1 (red) show no co-localisation between the 
proteins (upper panel). HEK293 cells co-transfected with myc-VIPAR (unstained), YFP-
VPS33B (green) and mCherry-PLOD3 (red) show co-localisation between the proteins 
in distinct clusters (lower panel).  All images are projection of one optical section at 
0.25 µm Z-spacing. The scale bar represents 10 µm. 
 
 
 
 
YFP-VPS33B  
(myc-VIPAR) 
mCherry-PLOD1 Merge 
YFP-VPS33B  
(myc-VIPAR) 
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4.4.3 - Confirmation of the PLOD3-VIPAR interaction 
 
 
4.4.3.1 - Reciprocal co-immunoprecipitation of PLOD3 and VIPAR 
 
 
As PLOD1 is unlikely to be a real interactor of the VPS33B/VIPAR complex, this study 
was focussed on PLOD3. In order to further substantiate the evidence of an interaction 
between PLOD3 and VPS33B-VIPAR protein complex, the possibility that PLOD3 co-
immunoprecipitates with VPS33B and/or VIPAR was examined. Endogenous PLOD3 
co-immunopreicipitated with myc-VIPAR and VPS33B/VIPAR complex (figure 4.6). A 
very weak co-immunoprecipitation was detected with HA-VPS33B, while endogenous 
PLOD3 was not pulled-down with empty-HA or empty-myc. This result further 
confirms the pull-down and mass spectrometry experiment, as well as the preliminary 
co-localisation of the proteins by confocal microscopy, and suggests that PLOD3 
interacts in-vitro with VIPAR. The weak binding to HA-VPS33B might be explained by 
the indirect binding of endogenous PLOD3 to endogenous VIPAR that in turn interacts 
with over-expressed HA-VPS33B. 
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Figure 4.6 - Co-immunoprecipitation of myc-VIPAR with endogenous PLOD3. HA-
VPS33B and myc-VIPAR were expressed in HEK293 cells separately and in complex 
before immunoprecipitation was performed with anti-HA or anti-myc antibody. One 
control was performed for each of the sets by transfecting with empty-myc and empty-
HA vectors. The immunoprecipitates (bound fraction) and the flow-through (wash 
fraction) were separated by SDS-PAGE, followed by Western blotting using anti-
PLOD3 antibody to detect the presence of endogenous PLOD3 in the fractions. The 
presence of HA-VPS33B and myc-VIPAR in the respective bound fractions was 
confirmed by western blot with anti-HA and anti-myc antibodies. Available antibodies 
to PLOD3 are poor at immunoprecipitating endogenous levels of the protein and 
therefore the reverse co-immunoprecipitation experiment was not successful.  
 
 
 
4.4.3.2 - PLOD interacts with VPS16 in D. melanogaster  
 
 
As mentioned previously (section 4.1) there are three lysyl hydroxylase isoforms in 
vertebrates and PLOD3 is evolutionarily the oldest amongst them, besides being the 
only isoform capable of both LH and GGT activity. In D. melanogaster and other 
invertebrates only one isoform is present (Plod) which is a homologue of PLOD3. 
The novel interaction PLOD3-VIPAR has not been described previously. The only 
evidence in literature for this protein-protein interaction comes from the fly database: 
http://flybase.org/. From anti-tag co-immunoprecipitation and mass-fingerprinting data, 
 126 
Plod was found to be physically associated with Vps16b (the fly homologue of VIPAR) 
(Guruharsha et al., 2011) (figure 4.7). This is a further indication that in higher 
organisms PLOD3 might be involved in the interaction with VIPAR. 
 
 
Figure 4.7 - Plod protein-protein interactions in D. melanogaster. http://flybase.org/ 
Anti-tag co-immunoprecipitation and massfingerprinting data show that Plod is 
physically associated with Vps16b  
 
 
 
4.4.3.3 - Significant co-localisation between VPS33B/VIPAR complex 
and PLOD3  
 
 
For evidence of PLOD3-VIPAR interaction within the cell, immunofluorescence 
experiments were performed with both over-expressed and endogenous proteins.  
Co-localisation between proteins was quantified using Coloc_2 and JACoP (Just 
Another Colocalization Plugin). This are two different ImageJ / Fiji plugins that analyse 
the pixel intensity correlation over space methods of Pearson, Manders, Costes, Li and 
more. They perform scatterplots, analysis, automatic thresholding and statistical 
significance testing. Co-localisation is quantified by the Manders’ M1 and M2 
coefficients. M1 signifies the correlation of pixels from the first channel (green) 
overlapping the second (red) while M2 indicates the overlap coefficient of the second 
channel to the first. M1 and M2 values range between zero and one and values above 
0.6, meaning 60% of pixel overlapping between two channels, are considered proof of 
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co-localisation. A threshold is set for both M1 and M2, which assumes that pixels below 
the threshold are not correlated.  
Another value to consider when performing this type of co-localisation analysis is the P-
value, which represents the percentage of random chance images that had better 
correlation than the real image. Indeed it is common that in images in which the signal 
is localised all over the cell in both channels there will be some random overlap that 
shouldn’t be confused with true co-localisation with biological meaning. The P-value 
should be 1.00 meaning that none of the randomised images had better correlation than 
the real image and therefore the measured co-localisation in the real image is not likely 
to be better than random chance.   
To test for PLOD3 co-localisation with VPS33B/VIPAR, HeLa cells were transfected 
with mCherry-PLOD3, YFP-VPS33B and myc-VIPAR (unstained). Over-expressed 
proteins co-localise (figure 4.8) as demonstrated by Mander's co-localisation 
coefficients M1 and M2 and P1 value (figure 4.8). To exclude the possibility that this 
finding was an over-expression artefact, the co-localisation experiments were repeated 
using a recently available antibody against endogenous VIPAR (Sigma) suitable for 
immunofluorescence experiments together with an anti- rabbit PLOD3 antibody against 
the endogenous protein. Zenon® Labeling kit was used to produce a fluorescently 
labelled anti-PLOD3 antibody that can therefore be used in combination with anti-
VIPAR also produced in rabbit. Endogenous PLOD3 co-localises with endogenous 
VIPAR in the perinuclear region similar to the over-expressed proteins (figure 4.8). 
Because no anti-VPS33B antibody suitable for immunofluerescent experiments was 
commercially available, YFP-VPS33B was used to test co-localisation with endogenous 
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PLOD3. Also YFP-VPS33B, similar to endogenous VIPAR, co-localises with PLOD3 
in the perinuclear area.  
Investigations to determine the intracellular localisation of the interaction between 
VIPAR/VPS33B and PLOD3 will be described in chapter 5. The co-
immunopreciptation and co-localisation experiments further validate the pull-down and 
mass spectrometry results that lead to the identification of PLOD3 as an interactor of 
VPS33B/VIPAR complex. 
Figure 4.8 - Co-localisation of VPS33B-VIPAR with PLOD3. Confocal 
immunofluorescence of HeLa cells co-transfected with myc-VIPAR (unstained) YFP-
VPS33B (green), and mCherry-PLOD3 (red) show co-localisation of the proteins. HeLa 
cells stained with anti-PLOD3 and anti-VIPAR antibodies show co-localisation of the 
endogenous proteins. Endogenous PLOD3 co-localises also with over-expressed YFP-
VPS33B. For each co-localisation analysis of the Manders' overlap coefficients M1 and 
M2, as well as the P-value, are represented as the average of n>6 cells. All images are 
projection of one optical section at 0.25 µm Z-spacing. The scale bar represents 10 µm. 
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4.4.3.4 - Further evidence for VIPAR-PLOD3 intracellular interaction 
from FRET experiments 
 
 
The same approach used for in-cell analysis of VPS33B-VIPAR interaction (section 
3.4.3) was used also to test the newly identified PLOD3-VIPAR interaction. It consists 
of the Fluorescence Lifetime Imaging in Förster Resonance Energy Transfer (FRET-
FLIM) technique that in addition to being a useful tool to test protein-protein 
interactions is also used to measure molecular distances separating proteins. This 
experiment provides the information necessary to deduce the type of interaction 
between the proteins i.e. direct or indirect. As mentioned previously (section 3.4.3) 
FRET occurs when the lifetime of the donor (GFP) is reduced by the presence of an 
acceptor (mCherry) in the sample, and this is imaged using fluorescence lifetime 
imaging microscopy (FLIM). The lifetime of GFP-VIPAR is significantly reduced only 
when mCherry-PLOD3 is present (fifth panel figure 4.9) as compared to the lifetime of 
GFP only (negative control, first panel figure 4.9) or GFP-VIPAR when coupled to 
untagged-VPS33B (negative control, second panel in figure 4.9) or empty mCherry 
vector (negative control, fourth panel in figure 4.9). The occurrence of FRET between 
GFP-VIPAR and mCherry-VPS33B described in section 3.4.3 was used as a positive 
control in this analysis (third panel figure 4.9). The average fluorescence lifetime is 
calculated for each sample and is represented in the histograms in figure. 4.9. The raw 
data from the FRET analysis are reported in Appendix 3. 
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Figure 4.9 - FRET-FLIM of PLOD3-VIPAR interaction. To measure the occurrence of 
FRET between PLOD3 and VIPAR, HEK293 cells were transfected with GFP-VIPAR 
and mCherry-PLOD3 and the fluorescent lifetime of the donor (GFP) was measured by 
using a confocal microscope coupled to a FLIM (fluorescence life time imaging) 
detector. This was compared to the fluorescence lifetime of the donor in a sample where 
only the donor was present. In the panels above the lifetime is shown as different 
colours that are false colour lifetime images. Colours with a shorter wavelength 
(towards purple) correspond to a shorter lifetime, indicating the presence of FRET. 
Negative controls were performed by transfecting cells with GFP-VIPAR and untagged-
VPS33B (second panel) or with GFP-VIPAR and empty-mCherry vector (fourth panel). 
The average fluorescence lifetime is quantified for each sample and reported in the 
histogram above. For each dataset n>5. Significant FRET values (P<0.01) were 
observed when comparing the GFP-VIPAR / mCherry couple with the GFP-VIPAR / 
mCherry-PLOD3 (P=0.009003, N=3). Experiment performed in collaboration with 
Federico Forneris. 
 
 
short long 
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As mentioned in section 3.4.3, for a positive FRET the distance between 2 fluorophores 
must be between 1 and 10 nm, the scale at which protein-protein interactions take place. 
This technique can also be used to measure the nanometer proximity of fluorescent 
labels (mCherry and GFP) attached to proteins, in this case GFP-VIPAR / mCherry-
PLOD3 and mCherry-VPS33B / GFP-VIPAR. The excited state energy of the “donor” 
label (GFP) is transferred to the “acceptor” label (mCherry) with an efficiency (E) that 
is a function of the distance between them (R) (figure 4.10): E = 1 / (1 + (R/R0)6 ) 
where R0 is the Förster distance between donor and acceptor at which the FRET 
efficiency is 50%. For the GFP/mCherry couple, the Förster distance R0 is 5.1nm.  
The simplest way to measure FRET is by the decrease in the intensity of the donor (i.e. 
57% reduction) and the corresponding increase in acceptor intensity. Still, for 
intermolecular FRET in an imaging experiment, the concentration of donor and acceptor 
for each pixel is not known. It is therefore difficult to attribute a certain donor intensity, 
or donor/acceptor intensity ratio to FRET. Therefore, FRET measurement is frequently 
done by monitoring changes in the fluorescence lifetime of the donor. After excitation, 
the fluorescence intensity I(t) decays exponentially (typically with a lifetime τ of a few 
nanoseconds). In case of FRET, the efficiency of the transfer can be calculated from the 
lifetime of the donor in presence (τDA) and absence (τD) of the acceptor: I(t)=I0e-t/τ 
and E= 1 – τDA/τD (i.e. 57% FRET efficiency = 57% reduction in lifetime). The 
concentration of the donor will not change the lifetime, only the accuracy of the 
measurement.  
In FRET/FLIM only the “donor” channel is imaged. For GFP-VIPAR/mCherry-
VPS33B an E=16% decrease in the lifetime of GFP was measured. This reaches E=21% 
in the case of GFP-VIPAR/mCherry-PLOD3. By applying this data to the above 
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mentioned formula E = 1 / (1 + (R/R0)6) and resolving on R, the average distance 
between GFP and mCherry was calculated and it corresponds to 72.3 +/- 4 Å in the case 
of GFP-VIPAR/mCherry-VPS33B and 67.2 +/- 2.5 Å for GFP-VIPAR/mCherry-
PLOD3. This data are consistent after excluding the possibility of FRET signal between 
GFP-VIPAR in presence of VPS33B lacking the mCherry tag (negative control for GFP 
lifetime). It is therefore possible to assume that intra-molecular distances separating 
VIPAR from PLOD3 are shorter than those separating VPS33B from VIPAR. From 
these data we can conclude that PLOD3 and VIPAR are likely to interact directly 
between them. Indeed the distance separating GFP from mCherry in GFP-
VIPAR/mCherry-PLOD3 (67.2 +/- 2.5 Å) is too short to allow the presence of other 
intermediate interactors.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.10 - A plot of the FRET efficiency (E) as a function of the distance (R) between 
a donor fluorophore (green sphere) and an acceptor fluorophore (red sphere) 
according to the E = 1 / (1 + (R/R0)6) where R0 is the Förster distance between donor 
and acceptor at which the FRET efficiency is 50%. 
 
 
 
 
E 
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4.4.3.5 - PLOD3 is likely to interact with the N-terminal domain of 
VIPAR 
 
 
As mentioned in section 3.1, VIPAR consists of two main regions, one N-terminus (N) 
disordered region and a globular structured region at the C-terminus (C). It was 
described in section 3.4.4 that the C region only is involved in the interaction with 
VPS33B. The findings above led to the hypothesis that the N-region of VIPAR might be 
involved in the binding of other interactors, which stabilise its disordered structure in-
vivo. Indeed, disordered regions in proteins require binding of structured partners to 
undergo a disorder-to-order transition in-vivo. Thus, based on the identification of 
PLOD3 as a novel interactor of VIPAR it was suggested that the N-terminal region of 
VIPAR, which is not involved in the interaction with VPS33B, might directly interact 
with PLOD3. This hypothesis was tested by the co-immunoprecipition of PLOD3 with 
the same short constructs of VIPAR that were used to test the interaction with VPS33B: 
the N- and C-terminus containing constructs. Furthermore, two constructs for the C 
region of VIPAR were used, C- and C+, that respectively lack or include a nuclear 
localisation sequence (NLS) (section 3.4.4) that, as mentioned in section 3.1, is 
predicted to be localised at the interface between the disordered and the globular region 
of VIPAR. The N-terminal construct used in this study does not contain the NLS (N-). 
NLS was shown to be dispensable for the interaction of VIPAR with VPS33B (section 
3.4.4). To investigate whether NLS is crucial for the VIPAR-PLOD3 interaction the 
following experiments were performed. The co-immunoprecipitation experiment (figure 
4.11) revealed that PLOD3 interacts mainly with the N-region of VIPAR while only 
weak interaction was detected with its C-region with no major preference for the C- or 
C+ (figure 4.11) indicating that NLS is not crucial for this interaction. Furthermore 
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endogenous PLOD3 binds to full-length myc-VIPAR and also myc-VIPAR in complex 
with HA-VPS33B (figure 4.11), which confirmed previous results (section 4.4.3.1). 
This experimental result confirmed the initial hypothesis that predicted the N-terminal 
disordered region of VIPAR to be involved in the binding of other proteins that stabilise 
its structure in-vivo.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.11 - Co-Immunoprecipitation of myc-VIPAR constructs with endogenous 
PLOD3. HEK293 cells were co-transfected with myc-empty vector (-) and myc tagged 
VIPAR full-length (FL), N-terminal construct of VIPAR without NLS (N-), C-terminal 
construct of VIPAR without NLS (C-), C-terminal construct of VIPAR with NLS (C+) 
and HA-VPS33B/myc-VIPAR complex (CPLX). Immunprecipitation was performed with 
anti-myc antibody and it reveals a strong interaction between endogenous PLOD3 and 
N- construct of VIPAR. Endogenous PLOD3 binds also to full-length myc-VIPAR and 
myc-VIPAR when in complex with HA-VPS33B. A weaker interaction is detected 
between PLOD3 and the C-terminal constructs of VIPAR (C+ and C-). None of these 
proteins were pulled down with myc-empty vector. Available antibodies to PLOD3 are 
poor at immunoprecipitating endogenous levels of the protein and therefore the reverse 
co-immunoprecipitation experiment was not successful. 
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4.5 - DISCUSSION 
 
 
A pull-down experiment followed by mass spectrometry analysis led to the 
identification of two proteins as potential binding partners for the VPS33B/VIPAR 
protein complex. After exclusion of the likely false positives, the interaction with two 
proteins was further tested and included: Procollagen-Lysine 2-Oxoglutarate 5-
Dioxygenase 1 (PLOD1) and Procollagen-Lysine 2-Oxoglutarate 5-Dioxygenase 
(PLOD3). Initial co-localisation experiments were performed to validate these results 
and no co-localisation was seen between over-expressed mCherry-PLOD1 and over-
expressed YFP-VPS33B/myc-VIPAR. Furthermore PLOD1 localisation in the cell has 
been reported to be exclusively at the Endoplasmic Reticulum (Yeowell and Walker, 
2000; Yeowell et al., 2000) and that doesn’t match the previously published data for 
VPS33B/VIPAR intracellular localisation, which identified this protein complex at 
recycling enodosomes, late endosomes, lysosomes and Golgi complex (Akbar et al., 
2011; Cullinane et al., 2010; Flaumenhaft, 2012; Zhu et al., 2009). Thus it was assumed 
that it was unlikely that VPS33B/VIPAR can interact with an exclusively ER localised 
protein such as PLOD1. Altogether these observations led to excluding an interaction 
between PLOD1 and VPS33B-VIPAR. The presence of this protein in the mass 
spectrometry results might be explained by its high homology to PLOD3 and 
consequent fail in the distinction between the isoforms by mass-spec. However more 
experiments, such as co-immunoprecipitation, are required to exclude the possibility 
that PLOD1 is an interactor of VPS33B/VIPAR. 
PLOD3 is the only LH isoform that is found in several locations including 
intracellularly, the cell surface and extracellularly (Myllyla et al., 2007; Wang et al., 
2009; Wang et al., 2012). These locations suggest that different pathways may be 
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involved in PLOD3 trafficking and therefore an interaction with VPS33B/VIPAR 
complex is more plausible. In this chapter several biochemical and cell-biology 
techniques are described that were used to validate the second putative interactor 
identified by mass-spectrometry: PLOD3. All different experimental approaches used in 
this section (co-localisation, co-immunoprecipitation, FRET-FLIM) confirmed that 
PLOD3 is a novel interactor of VIPAR in-vitro and these proteins are likely to interact 
in-vivo. PLOD3 does not co-immunoprecipitate with VPS33B on its own but only when 
VPS33B is in complex with VIPAR. This suggests a high specificity of PLOD3 binding 
to the complex. To further direct this analysis and investigate the regions of VIPAR that 
are specifically involved in the interaction with PLOD3, several short constructs of 
VIPAR were used and PLOD3 was shown to interact with the N-terminal region of 
VIPAR. The N-terminal is a predicted disordered region of VIPAR not involved in the 
interaction with VPS33B. PLOD3 might therefore be crucial to stabilise this region in-
vivo. In addition to the FRET-FLIM analysis, a shorter average distance is calculated 
between GFP and mCherry in GFP-VIPAR/mCherry-PLOD3 than GFP-
VIPAR/mCherry-VPS33B. The proximity of the GFP-mCherry fusion tags might be 
related to the regions of VIPAR involved in the interaction with PLOD3 and VPS33B 
(figure 4.12). Indeed the C-terminal of VIPAR only is involved in the interaction with 
VPS33B. The N-terminal region was found to interact with PLOD3 and therefore the 
fusion tags are expected to be closer in the case of PLOD3-VIPAR. This observation 
indicates that the results obtained are consistent and are confirmed by different technical 
approaches. 
Co-localisation experiments performed with antibodies against endogenous PLOD3 and 
VIPAR found these proteins to co-localise in the perinuclear region of HeLa cells. In 
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the next chapter the intracellular localisation of these proteins will be investigated as 
well as the role of this novel interaction in physiological and pathological conditions. 
 
Figure 4.12 - Diagram for mCherry-VPS33B/ GFP-VIPAR and mCherry-PLOD3/GFP-
VIPAR interaction showing proximity of the mCherry-GFP couple related to FRET 
signal. VPS33B interacts with the C-terminal of VIPAR only and therefore the mCherry-
GFP distance in this couple is higher when compared to the mCherry-GFP located 
respectively on PLOD3 and VIPAR where PLOD3 mainly interacts with the N-terminal 
of VIPAR.
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5.1 - INTRODUCTION AND OVERVIEW 
 
 
In the previous chapter PLOD3 was identified as a novel interactor for VIPAR and this 
interaction was confirmed through several different experimental approaches. In this 
chapter the relevance of this interaction in ARC syndrome will be examined. 
Endogenous PLOD3 and VIPAR were found to co-localise in the perinuclear region in 
HeLa cells (section 4.4.3.3). In this chapter the intracellular localisation of these 
proteins was investigated by performing co-localisation studies with different cellular 
markers.  
During their synthesis, all lysyl hydroxylase homologues are targeted to the rough 
endoplasmic reticulum via a signal peptide, even if they lack the typical ER-retention 
signals such as KDEL or double lysine motif (Kellokumpu et al., 1994). PLOD1, whose 
topology and localisation has been better characterised among the homologues, was 
shown to be a luminal protein of the ER. PLOD1 completely co-localises with the 
protein disulfide isomerase (PDI), an ER resident KDEL-containing protein (figure 5.1) 
and also co-sediments with it after sucrose density gradient fractionation (Kellokumpu 
et al., 1994). Despite lacking ER-specific retention motifs, PLOD1 is a peripheral 
membrane protein of the ER that is retained in its lumen by electrostatic interactions 
with unknown membrane proteins (Kellokumpu et al., 1994). This represents the first 
identified protein with this type of association in the ER (Kellokumpu et al., 1994).  
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Figure 5.1 - PLOD1 and PDI endogenous staining in human skin fibroblasts. The two 
proteins show almost identical localisation except in a few places marked by arrows. 
ER and Golgi complex are stained in the lower panels. The Golgi complex is seen as an 
unstained area in PLOD1, PDI and ER staining panels. Bar, 10 pm. (Modified from 
(Kellokumpu et al., 1994)) 
 
 
 
PLOD2 and PLOD3 have also been thought to localise to the ER because of their 
homology to PLOD1 and because the hydroxylation reaction of lysines is known to 
occur in the ER prior to collagen triple-helix formation (Salo et al., 2006b). 
Overexpressed PLOD3 in COS-7 cells has been localised to the ER, however Golgi 
staining was observed in some cells (figure 5.2 second panel) (Heikkinen et al., 2000).   
 
Figure 5.2 - Intracellular distribution of GFP-PLOD3 in COS-7 cells 48h after 
transfection (green). Rough endoplasmic reticulum is visualised by staining the cells 
with PDI (protein disulfide isomerase) antibody (red) (modified from (Heikkinen et al., 
2000)). 
 
GFP-PLOD3 GFP-PLOD3 PDI 
PDI PLOD1 
ER Golgi complex 
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A part of this chapter describes the co-localisation experiments that were performed to 
identify the intracellular localisation of endogenous PLOD3. Furthermore, the site of 
interaction between VIPAR and PLOD3 was sought using confocal microscopy and 
numerous intracellular markers. Additionally, different cellular fractionation 
experiments were performed to elucidate the topology of this interaction. PLOD3 is 
thought to be located in the lumen of ER, where the modifications of lysine residues in 
collagens take place (Myllyla et al., 2007). To date, the topology of VPS33B/VIPAR is 
not known but the yeast homologue Vps33p is cytosolic (Gerhardt et al., 1998) and it 
interacts directly with Vps16 (VIPAR homologue) constituting the side of the head of 
the HOPS complex (section 3.1). If both VPS33B and VIPAR were located in the 
cytosol, the direct interaction between VIPAR (cytosolic) and PLOD3 (luminal), that 
was established from FRET-FLIM measurements (section 4.4.3.4), would be 
topologically impossible. It was therefore crucial to investigate the topology of 
PLOD3/VIPAR complex to further validate this interaction and FRET-FLIM data. 
It is known that PLOD3 localisation is different from the other PLOD isoforms. Apart 
from being found intracellularly, PLOD3 is secreted into the extracellular space 
surrounding some tissues such as kidney, spleen, muscle and liver (Salo et al., 2006a; 
Salo et al., 2006b). Interestingly PLOD3 is localised exclusively extracellularly in adult 
mouse liver but only intracellularly in the livers of mouse embryos at E13.5 and E15.5 
(Salo et al., 2006a). The ability of PLOD3 to modify proteins in the extracellular space 
has been linked to a potential crucial role of the enzyme in matrix remodelling (Salo et 
al., 2006b). 
Despite being ubiquitous, the expression of PLOD3 differs in tissues and development. 
During mouse embryogenesis PLOD3 is widely expressed but becomes more restricted 
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to specific cells within adult tissues such as brain, lungs, spleen, muscle, pancreas, 
kidney and liver (Salo et al., 2006a). Interestingly these are some of the most affected 
organs in ARC syndrome pathogenesis (section 1.1). Therefore mouse inner medullary 
collecting duct (mIMCD-3) cells lines were chosen to study the impact of 
VPS33B/VIPAR deficiency upon PLOD3 localisation. Stable knockdown of 
Vps33b/Vipar in mIMCD-3 cell lines represent the polarized epithelial cell model for 
ARC syndrome (Cullinane et al., 2010) 
Apart from intra- and extracellular localisation, PLOD3 is also located on the cells 
surface in association with collagenous proteins (Salo et al., 2006b). PLOD3 found on 
the cell surface and intracellularly has different molecular weight from PLOD3 found in 
the cell culture medium, which is though to be due the two isoforms being differently 
glycosylated. This led to the hypothesis that PLOD3 may be secreted from cells through 
two different pathways. The first one passes through the Golgi complex, where the 
protein is further glycosylated and then secreted in the medium, while the second route 
bypasses the Golgi and directs PLOD3 to the cells surface where the protein is 
consequently found to be under-glycosylated (Wang et al., 2012). The mechanisms 
involved in PLOD3 trafficking remain nevertheless unknown. I hypothesised that 
VPS33B/VIPAR are directly involved in one of the routes of PLOD3 trafficking 
throught the direct interaction between VIPAR and PLOD3. 
In order to understand the relevance of PLOD3-VIPAR interaction in the pathogenesis 
of ARC syndrome I analysed the phenotype of mIMCD-3 knockdown cells lines for 
Vps33b/Vipar and its relation to a possible mis-trafficking of PLOD3 in these cells. 
Knockdown of Vps33b-Vipar in mIMCD-3 causes epithelial polarization defects with 
cells undergoing a typical epithelial to mesenchymal transition (EMT) process 
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(Cullinane et al., 2010). Vps33b-Vipar knockdown cells lose their polarity and cell-cell 
contacts, they do not grow in a monolayer but instead grow over the neighbouring cells, 
become migratory, and divide at a faster rate. Loss of polarity in epithelia results in 
mislocalisation of membrane proteins (Fialka et al., 1999; Tanos and Rodriguez-Boulan, 
2008) which has been shown in ARC patient liver and kidney biopsies as well as in 
mIMCD-3 knockdown cell lines for Vps33b and Vipar (section 1.1 and (Cullinane et 
al., 2010)). Loss of polarity in Vps33b-Vipar knockdown cell lines is associated with a 
loss of E-cadherin and, to a lesser extent, claudin-1 expression at adherens and tight 
junctions (Cullinane et al., 2010). In these cell lines E-cadherin is downregulated at a 
protein and mRNA level and this is associated to a reduction in E-cadherin promoter 
activation (Cullinane et al., 2010). The down-regulation of E-cadherin has been 
demonstrated also in Morpholino vipar injected Zebrafish larvae and in ARC patients 
liver biopsies. Loss of E-cadherin is one of the known causes of loss in cell polarity in 
epithelia (Desai et al., 2009; Theard et al., 2007). Therefore investigating the 
mechanism through which the VPS33B/VIPAR complex indirectly regulates the 
expression levels of E-cadherin, is crucial in terms of understanding the pathogenesis of 
ARC syndrome. In order to understand the impact of the novel identified PLOD3-
VIPAR interaction in the phenotype of mIMCD-3 knock down cell lines, I analysed the 
downstream targets of PLOD3 enzyme. As described previously, PLOD3 is a lysyl 
hydroxylase (LH) enzyme that catalyses the hydroxylation of lysyl residues in collagen-
like peptides as well as the galactosylation of hydroxylysines and glucolsylation of 
galacotosylhydroxylysines (sections 1.5.4, 4.1). A considerable number of proteins not 
classified as collagens contain a collagenous domain and therefore constitute a potential 
substrate for PLOD3 (section 1.5.3). Among them adiponectin has been shown to be 
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directly regulated by PLOD3 with regards to its amount and oligomerisation status in 
the cell (Ruotsalainen et al., 2012). However collagen represents the most abundant 
protein in mammals and it constitutes therefore the major substrate of PLOD3 and 
consequently the better characterised target in PLOD3 deficiency (Rautavuoma et al., 
2004; Sipila et al., 2007; Sricholpech et al., 2011). Furthermore, the extent of 
hydroxylated and glucosyl-galacotosylated lysines varies between collagen types. 
Around 90% of all lysines are hydroxylated and hydroxylysines glycosylated in types 
IV and VI collagen but less than 20% of the lysines are hydroxylated in type III 
collagen. In this respect it has been shown that PLOD3 binds preferentially to!type IV, 
VI, XI, and XII collagen peptides, despite there being no strict sequence specificity for 
binding of lysyl hydroxylase isoforms to specific collagenous peptides (Risteli et al., 
2004). Taken together, these data from literature suggested that the best candidate for 
the study of possible effects of PLOD3 mistrafficking in Vps33b/Vipar knockdown 
mIMCD-3 cells is collagen type IV. This represents the major structural component of 
basement membrane (BM) that defines the other components of the BM itself such as, 
laminins, nidogens or perlecan, into highly organised architecture (section 1.5.3.1). The 
basement membrane underlies epithelium and endothelium and is therefore crucial for 
the renal function where it covers the entire outer surface of each individual nephron 
and collecting duct and is involved in filtration, cell adhesion, migration, and 
differentiation (Miner, 1999). Consequently defects in PLOD3 trafficking could be 
reflected in collagen IV structure/expression of inner medullary collecting duct cells 
(mIMCD-3) knockdown for Vps33b/Vipar and this possibility was investigated in this 
chapter. Additionally, a stable knockdown line for Plod3 was created in mIMCD-3 cells 
and compared to Vps33b/Vipar knockdowns in terms of its phenotype, collagen IV and 
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E-cadherin expression. In order to understand the correlation between the phenotype, 
collagen IV and E-cadherin expression in knockdown cells for Vps33b/Vipar or Plod3, 
it is crucial to underline the importance of collagen hydroxylation and their further 
galactosylation/glycosylation in collagen structure and secretion. The formation of 
hydroxylysines is crucial for collagen crosslinking, which stabilises the collagen fibril 
into supramolecular structures (Knott and Bailey, 1998; Reiser et al., 1992). The role of 
the glycosylation of hydroxylysine residues is not completely understood and 
sometimes controversial. Data from literature indicate that glycosylation has a role in 
collagen fibril formation (Notbohm et al., 1999) but this has been contradicted by other 
data (Batge et al., 1997). Glycosylation of type II collagen has been implicated in 
autoimmunity (Myers et al., 2004; Van den Steen et al., 2004) and the glycosylation of 
the collagenous domain in adiponectin is involved in the insulin-sensitising activity of 
the hormone (Wang et al., 2002c). Abnormal glycosylation in collagen IV has been 
shown to be involved in metastasis by preventing the adhesion of melanoma cells and 
consequent invasion (Lauer-Fields et al., 2003). The invasion of the basement 
membrane is indeed a critical step in the metastatic process (Friedl and Wolf, 2003; 
Wolf and Friedl, 2006). Collagen IV of the basement membrane contains glycosylated 
hydroxylysine residues that bind the tumour cell through the CD44/chondroitin sulphate 
proteoglycan receptors located on its surface. This binding is dramatically decreased 
when collagen IV residues were glycosylated, compared to non-glycosylated. These 
findings suggest a role for glycosylated hydroxylysines of collagens in cell-extracellular 
matrix interactions (Lauer-Fields et al., 2003). 
Glycosylation of hydroxylysine residues is crucial for the formation of the embryonic 
basement membranes as shown by the embryonic lethal phenotype of the PLOD3 
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knockout mice (Rautavuoma et al., 2004). This study has shown that the embryonic 
lethality is caused by the block of only the GGT activity of PLOD3. Mice that carried a 
mutation that suppressed the LH activity of the enzyme were viable but with defects in 
the ultrastructure of the basement membrane and in collagen fibril organization whereas 
mice lacking the GGT activity of PLOD3 were embryonically lethal at E9.5 
(Ruotsalainen et al., 2006). This study suggested that PLOD3 is the main isoform 
involved in the biosynthesis of type IV collagen during early vertebrate development, 
because the two other isoforms, PLOD1 and PLOD2 were not able to compensate for 
the lack of PLOD3. Electron microscopy (EM) of the E9.5 embryos revealed 
fragmentation of basement membranes with detachment in some areas. Newly 
synthesised type IV collagen was aggregated in secretion vesicles on the way to the 
cells surface and amorphous type IV collagen particles were evident both intracellularly 
and extracellularly. Part of the intracellular amorphous collagen IV was probably 
degraded in the ER or sent for degradation to lysosomes. Enlarged Golgi complexes and 
lysosomes as well as dilation of the endoplasmic reticulum were shown by immuno EM 
in PLOD3 null embryos (Rautavuoma et al., 2004).  
Successive work demonstrated that the mechanism behind the fragmentation of BM in 
PLOD3 knockout embryos is related to both secretion and intracellular degradation of 
type IV collagen (Sipila et al., 2007). Intracellular accumulation, delayed secretion and 
intracellular degradation of type IV collagen was also seen in PLOD3 knockout 
fibroblasts. It is therefore possible to conclude that glycosylation of hydroxylysine 
residues is critical for assembly and secretion of highly glycosylated collagen types 
(Sipila et al., 2007). Altogether these data demonstrated for the first time a novel crucial 
role of glycosylation of hydroxylysines for collagens (Lauer-Fields et al., 2003; 
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Rautavuoma et al., 2004; Ruotsalainen et al., 2006; Sipila et al., 2007). Complete loss of 
function in PLOD3 has deleterious effects on cells and tissues. There are no known 
patients with homozygous mutations in PLOD3 and the only report of a known case of 
PLOD3 deficiency describes a patient compound heterozygous for two mutations, one 
of which led to a reduction in GGT and the other to a reduction in LH activities (Salo et 
al., 2008). Severe connective tissue abnormalities were seen in this patient with features 
that overlap with a number of collagen defects including joint contractures, growth 
retardation, thin skin with poor healing, osteopenia and talipes equinovarus (Salo et al., 
2008).  
Partial loss of PLOD3 enzymatic activity in human skin fibroblast causes changes in the 
deposition and organisation of the Extracellular Matrix as well as the cytoskeletal 
arrangement of the cell (Risteli et al., 2009). Depletion of GGT activity of PLOD3 in 
HT-1080 cells by siRNA lead to arrest of growth followed by lethality in these cells. 
The glycosyltransferase activity of PLOD3 is therefore crucial for cell growth and 
viability and a complete loss of function of the enzyme is not compatible with life 
(Wang et al., 2009). Additionally, mutations in Caenorhabditis elegans Plod, the only 
isoform present in lower organism, leads to embryonic lethality due to disruption in 
collagen IV secretion and subsequent basement membrane malformation (Norman and 
Moerman, 2000). 
As mentioned in the previous chapter (section 4.1) the LH activity of PLOD3 is located 
in its carboxy-terminal (Myllyla et al., 2007) while the GT and GGT activity in the 
amino-terminal part of the enzyme (Myllyla et al., 2007; Wang et al., 2002a; Wang et 
al., 2002b). Furthermore the LH active site mediates retention of PLOD3 inside the cell 
while the GGT active site is required for its secretion into the extracellular space (Wang 
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et al., 2012). I hypothesised that the VPS33B/VIPAR complex, directly involved in 
PLOD3 trafficking, might therefore indirectly participate in collagen trafficking inside 
the cell. To test this hypothesis, the co-localisation between collagen IV and PLOD3 
was compared between wild-type mIMCD-3 cells and those with Vps33b/Vipar stable 
knockdown. 
As explained above, the phenotype of Vps33b/Vipar knockdown mIMCD-3 is 
characterised by loss in E-cadherin expression and Epithelial to Mesenchymal 
Transition (EMT). Data in literature indicate that native collagen type IV induces down-
regulation of E-cadherin and EMT in mammary epithelial cells MCF10A (Espinosa 
Neira and Salazar, 2012). Furthermore, collagen type IV induces cell migration through 
a DDR1 and CD9-dependent pathway (Castro-Sanchez et al., 2011; Espinosa Neira and 
Salazar, 2012) and is involved in tumour onset and progression (Agarwal and Ballabh, 
2013; Hamano et al., 2003; Ohlund et al., 2013; Rider et al., 2013).  
I hypothesized that loss of E-cadherin and EMT phenotype observed in Vps33b/Vipar 
knockout mIMCD-3 cell lines was caused by an abnormal expression/structure of 
collagen type IV caused by an abnormal PLOD3 trafficking in these cells.  
 
 
"
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5.2 - AIMS 
 
 
In the previous chapter immunofluorescence experiments showed intracellular co-
localisation between PLOD3 and VIPAR in HeLa cell lines. One of the goals of this 
chapter is to identify the intracellular compartment where the interaction of these 
proteins takes place in addition to determining the topology of VPS33B/VIPAR/PLOD3 
interaction. 
Identifying the biological relevance of PLOD3-VIPAR interaction and its role in the 
pathogenesis of ARC syndrome is the main goal of this work. Therefore the main aim 
of this chapter is to identify possible abnormalities related to PLOD3 mistrafficking in 
Vps33b/Vipar knockdown mIMCD-3 cell lines that can elucidate the mechanisms 
behind the EMT phenotype in these cells.  
 
 
 
5.3 - METHODS 
 
 
5.3.1 - Separating cytosol from crude membrane fractions in mIMCD-
3 and HeLa cells 
 
 
Membrane homogenisation of mIMCD-3 and HeLa cells was performed in the cold 
room with samples and homogeniser kept on ice. A 75cm2 flask of HeLa or mIMCD-3 
cells were transferred on ice and rinsed once with 10 mL of ice-cold PBS followed by a 
second wash with 4 mL of Homogenisation Buffer (HB) (20 mM HEPES-KOH, pH 7.5, 
5 mM EDTA, 250 mM sucrose supplemented with protease inhibitors). 
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Cells were scraped on ice with 1mL of HB per T-75 flask and pelleted by centrifugation 
at 500 g for 5 min at 4 °C. The supernatant was discarded and the cell pellet was re-
suspended in HB (~ 4 times the volume of cell pellet). 
For the homogenisation protocol each cell suspension was passed 12 times through a 
ball-bearing homogeniser (10 µm clearance). The homogenates were recovered from the 
chamber and centrifuged at 100,000 xg for 5 min at 4°C for coarse fractionation, that is 
membrane fraction versus soluble fraction (or cytosol). The supernatant (cytosol) was 
recovered and kept on ice. The pellet (membrane fraction) was re-suspended in an equal 
volume of HB until no particulate was visible. To help this process cells were sonicated 
for 10 seconds at 40% amplitude. Both fractions were analysed by WB.  
 
"
"
5.3.2 - Cell fractionation 
 
 
ProteoExtract® Subcellular Proteome Extraction Kit (Merck4Biosciences) was used for 
the extraction of subcellular proteomes from adherent growing HEK293 cells. The kit 
takes advantage of the different solubilities of subcellular compartments in select 
buffers used for cell fractionation into four fractions 1. Cytosolic fraction, 2. 
Membrane/organelle protein fraction, 3. Nucleic protein fraction 4. Cytoskeletal 
fraction. 
A T25 flask of adherent growing HEK293 cells were washed once with 2mL of Wash 
buffer before cells were scraped with 2mL of Wash buffer and pelleted by 
centrifugation for 10 min at 100-330 xg at 4°C. The Wash buffer was discarded and the 
pellet re-suspended in 1mL of Extraction buffer supplemented with 5 µL of Protease 
Inhibitor Cocktail. Cells were gently re-suspended and incubated for 10 minutes at 4°C 
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with gentle agitation before centrifugation was carried out for 10 minutes at 700 xg. The 
collected supernatant constitutes the cytosolic fraction. The pellet was re-suspended in 1 
mL of Extraction buffer II supplemented with 5 µL of Protease Inhibitor Cocktail and 
incubated for 30 minutes at 4°C with gentle agitation then centrifuged for 10 minutes at 
5500 xg. The supernatant, constituting the membrane/organelle fraction, was transferred 
to a clean tube. The pellet was further re-suspended in 500 µL of extraction buffer III 
supplemented with 5 µL of Protease Inhibitor Cocktail and 1.5 µL of Benzonase 
Nuclease and incubated for 10 minutes at 4°C with gentle agitation before 
centrifugation was carried out for 10 minutes at 6,800 xg at 4°C. The supernatant 
contains the nuclear fraction and was therefore collected while the pellet was re-
suspended in 500 µL of Extraction buffer IV supplemented with 5 µL of Protease 
Inhibitor Cocktail. This mixture constitutes the fourth fraction that contains the 
cytoskeletal matrix proteins. All fractions were analysed by Western Blot and stored at -
80°C.  
 
 
5.4 - RESULTS 
 
 
5.4.1 - Endogenous PLOD3 does not co-localise with PDI: PLOD3 
intracellular localisation is different from PLOD1 
 
 
As mentioned above (section 5.1) the intracellular localisation of PLOD1 is the best 
characterised among lysyl hydroxylase isoenzymes. PLOD1 shows an identical co-
localisation with the ER resident protein disulfide isomerase (PDI) in human skin 
fibroblasts (figure 5.1). The same co-localisation has been reported for a GFP tagged 
construct of PLOD3 which co-localises with PDI and in some cells with the Golgi 
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complex (figure 5.2). Here an antibody against PLOD3 was used in order to establish 
the intracellular localisation of the endogenous protein in human skin fibroblasts, the 
same cell type used to demonstrate the complete co-localisation between endogenous 
PLOD1 and PDI proteins. No co-localisation with PDI was seen for endogenous 
PLOD3 (figure 5.3 A). This represents a novel finding regarding PLOD3 intracellular 
localisation that differentiates it from other PLOD isoforms. PLOD3 staining matched 
with the unstained perinuclear area in the PDI staining (figure 5.3 A). This area 
resembles in shape the unstained area in the PDI and PLOD1 staining panels that 
correspond to the Golgi complex (figure 5.1). Therefore TGN-46, a Trans-Golgi-
Network (TGN) protein marker was used to co-localise endogenous PLOD3 in human 
skin fibroblasts. PLOD3 expression pattern completely overlaps with TGN-46 with the 
proteins co-localising in several areas (figure 5.3 B). Co-localisation of PLOD3 was 
observed also with RAB11A (figure 5.3 C). As mentioned previously (section 1.3) 
VPS33B interacts with RAB11A involved in apical membrane protein sorting 
(Cullinane et al., 2010). RAB11A is found associated to the recycling endosomes 
(Ullrich et al., 1996), TGN and post-Golgi vesicles (Chen et al., 1998; Urbe et al., 
1993). Other data suggest that Rab11 influences endosome to TGN trafficking by 
regulating membrane distribution in the early endosomal pathway (Wilcke et al., 2000). 
Therefore I postulated that VPS33B/VIPAR are involved, through RAB11A, in the 
trafficking of PLOD3 from/to TGN. In order to support this hypothesis it is crucial to 
determine the intracellular localisation of endogenous VPS33B/VIPAR that is to date 
not known.  
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Figure 5.3 - Analysis of endogenous PLOD3 localisation in human skin fibroblasts. (A). 
Co-localisation analysis of endogenously expressed PLOD3 with endogenous protein 
disulphide isomerase (PDI) show no co-localisation between the two proteins. PLOD3 
staining overlaps with the unstained area of PDI. PLOD3 co-localises with 
endogenously stained TGN46 (B) and RAB11A (C). All images are projection of one 
optical section at 0.25 µm Z-spacing. The scale bar represents 10 µm. 
"
"
"
"
 
 
 
 
 
 
 
 
 
 
Endogenous PLOD3 RAB11A Merge 
Endogenous PLOD3 TGN46 Merge 
Endogenous PLOD3 PDI Merge A. 
B. 
C. 
 154 
5.4.2 - Endogenous PLOD3 and endogenous VIPAR co-localise with 
TGN markers and RAB11A in HeLa cells 
 
 
To validate the novel finding that PLOD3 is found in the TGN of human skin 
fibroblasts, a different cell type was used to further investigate PLOD3 intracellular 
localisation. It consists of HeLa cells that were co-stained with an antibody against 
endogenous PLOD3 and antibodies against molecules of known cellular compartments 
(figure 5.4). As shown above, PLOD3 does not co-localise with the ER protein PDI. In 
order to exclude the possibility that PLOD3 is located in a different compartment of the 
ER, an antibody against Calreticulin, a more generic ER marker, was used. PLOD3 did 
not co-localise with Calreticulin in HeLa cells (figure 5.4 A) and it is therefore possible 
to conclude that PLOD3, unlike PLOD1, is not an ER resident protein. PLOD3 also did 
not co-localise with LAMP-1, a marker of the lysosomal compartment (figure 5.4 A) 
therefore it is unlikely that this compartment is involved in PLOD3 trafficking in HeLa 
cells. The previously observed PLOD3 localisation in the TGN of human skin 
fibroblasts was confirmed also in HeLa cells where PLOD3 co-localises with TGN-46 
and p230, a different TGN marker used to further validate this data (figure 5.4 B). 
Similarly to what observed in fibroblasts, PLOD3 also co-localises with RAB11A in 
HeLa cells (figure 5.4 B).  
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Figure 5.4 - Subcellular localisation of endogenous PLOD3 in HeLa cells using 
different cell compartment markers. (A). Co-localisation analysis of endogenously 
expressed PLOD3 with the lysosomal protein LAMP1 and the ER protein Calreticulin 
shows no co-localisation between the proteins. (B). PLOD3 co-localises with the TGN 
markers TGN-46 and p230 as well as with endogenously expressed RAB11A. All images 
are projection of one optical section at 0.25 µm Z-spacing. The scale bar represents 10 
µm. 
 
Endogenous PLOD3 TGN46  Merge 
p230 Endogenous PLOD3 Merge 
Endogenous PLOD3 RAB11A Merge 
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As mentioned in the previous Chapter (section 4.4.3.3) endogenous PLOD3 co-localises 
with endogenous VIPAR in the perinuclear area and the aim was to identify the 
intracellular compartment to which this area corresponds. PLOD3 was localised in the 
TGN region in fibroblast and HeLa cells (figure 5.3, 5.4) and therefore it is reasonable 
to assume that VIPAR and PLOD3 co-localise to the TGN area in these cells. Co-
localisation analysis of endogenous VIPAR with TGN-46 and RAB11A provides 
evidence that the intracellular localisation of VIPAR, like PLOD3, is in the TGN area 
(figure 5.5). A partial overlap between VIPAR and TGN46 was observed even if 
VIPAR staining clearly resembles the TGN compartment (figure 5.4, 5.5). A different 
TGN marker, ϒ-Adaptin, was used to co-localise VIPAR and PLOD3 in the TGN 
(figure 5.6). ϒ-Adaptin is a component of the Golgi adaptor protein complex 1 that links 
clathrin to transmembrane proteins (e.g. receptors) in clathrin-coated vesicles (section 
1.4.1). Endogenously expressed VIPAR and PLOD3 co-localise in the perinuclear area 
with ϒ-Adaptin (figure 5.6). This observation suggests the involvement of the 
VPS33B/VIPAR complex in PLOD3 trafficking between the trans-Golgi network 
(TGN) and endosomes (Nakatsu and Ohno, 2003). This is supported by the fact that 
AP-1 is involved in the formation of CCVs that exit the TGN route to endosomes 
(Almomani et al., 2012; Traub and Kornfeld, 1997). 
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Figure 5.5 - Co-localisation analysis of endogenously expressed VIPAR with TGN46 
and RAB11A in HeLa cells. Endogenous VIPAR, TGN46 and RAB11A were detected by 
immunostaining with an anti-VIPAR, anti-TGN46 and anti-RAB11A antibodies 
respectively. Projection of 1 optical Z-section at 0.25 µm is shown. The scale bar 
represents 10 µm. 
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Figure 5.6 - PLOD3 co-localises with VIPAR and AP-1 in HeLa cells. Immunostaining 
was performed using an anti-VIPAR antibody, a fluorescently labelled anti-PLOD3 
antibody and an anti- ϒ-Adaptin antibody for the immunodetection of the endogenous 
proteins. All images are projection of one optical section at 0.25 µm Z-spacing. The 
scale bar represents 10 µm. 
Endogenous VIPAR  Endogenous PLOD3  
Endogenous AP-1  Merge  
Endogenous VIPAR TGN46 Merge 
Endogenous VIPAR Endogenous RAB11A Merge 
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5.4.3 - PLOD3 is abnormally trafficked in Vps33b/Vipar knockdown 
mIMCD-3 cells 
 
 
As mentioned above (section 5.1) PLOD3 is secreted into the extracellular space 
surrounding some tissues such as kidney, spleen, muscle and liver. It is therefore 
reasonable to assume that trafficking of PLOD3 from TGN occurs prevalently in some 
cell types and VPS33B/VIPAR complex is required in one of the PLOD3 trafficking 
routes in these cells. Mouse inner medullary collecting duct (mIMCD-3), a mouse 
polarized epithelial cell line, was therefore used to study PLOD3 trafficking. 
Interestingly the kidney is one of the affected organs in ARC syndrome and 
Vps33b/Vipar knockdown mIMCD-3 cell lines should mimic the effect of 
VPS33B/VIPAR absence in ARC syndrome patient’s epithelial cells. These knockdown 
cells are therefore used as a cell model system for the understanding of the pathology of 
ARC (Cullinane et al., 2010).  
Knockdown of VPS33B in these cells lead to down-regulation of VIPAR (figure 5.11) 
and the same behaviour has been observed in ARC patients’ fibroblasts with mutations 
in the VPS33B gene (Cullinane et al., 2010). Several cases of the co-regulation of 
expression of proteins which are part of the same complexes have been reported in 
literature (Luo et al., 2010), (Tan et al., 2007). Additionally ARC patients carrying 
mutations in VPS33B or VIPAR show no difference between them with respect to 
clinical symptoms, signs or disease course (section 3.1) and mIMCD-3 cells treated 
with Vipar-shRNA have the same phenotype as Vps33b-shRNA treated cells (Cullinane 
et al., 2010). From these data it is possible to conclude that the effect of Vipar or 
Vps33b stable knockdown mIMCD-3 cells have identical defects and can be both used 
in the experiments described in this chapter. As mentioned above, knockdown of 
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Vps33b/Vipar in these cells causes defects in adherens and tight junction formation with 
loss of polarity and cell-cell contacts. Full polarization of wild-type mIMCD-3 cells is 
reached by culturing the cells on transwell supports for two weeks. After 5-days of 
growth, a cavity formation (that resembles the renal tubular structure) is observed in 
wild-type cells but not in Vps33b-Vipar knockdowns. Endogenous PLOD3 staining was 
performed in both wild-type and Vps33b knockdown mIMCD-3 cells after they were 
cultured on transwell supports for two weeks. Additionally a control mIMCD-3 cell line 
(N/S), obtained with an shRNA containing a scrambled sequence, was used as a further 
control in this experiment (figure 5.7). A change in localisation of endogenous PLOD3 
was observed in Vps33b knockdown mIMCD-3 cells when compared to both wild-type 
and control (figure 5.7). It is therefore possible that PLOD3 trafficking is disturbed in 
these cells, which is associated with the absence of VPS33B/VIPAR. This is the first 
indication that the VPS33B/VIPAR complex may be involved in PLOD3 trafficking in 
polarized mIMCD-3 cells. As mentioned above, PLOD3 interacts with VIPAR at the 
TGN compartment, therefore it could be hypothesised that a defect in trafficking 
from/to TGN may be found in Vps33b/Vipar knockdown cells. To further investigate 
trafficking of PLOD3 in these cells, immunofluorescence microscopy experiments were 
carried out by transfecting pre-polarized wild-type and Vipar knockdown mIMCD-3 
cells with mCherry-PLOD3 and GFP-TGN38, a marker of TGN in mouse cells (figure 
5.8). Interestingly the expression levels of endogenous PLOD3 was observed to be 
markedly reduced in pre-polarized wild-type mIMCD-3 compared to fully polarized 
cells, and this was the experimental reason for using overexpressed mCherry-PLOD3 as 
opposed to the endogenous protein. This observed change in PLOD3 expression with 
polarization of mIMCD-3 cells might be an indication of the role of PLOD3 in cell 
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polarity. An accumulation of PLOD3 at the TGN is observed in Vipar knockdown cells 
but not in the wild-type (figure 5.8). In wild-type mIMCD-3 cells PLOD3 did not co-
localise with TGN and therefore further immunofluorescence experiments were 
performed to investigate the localisation of PLOD3 in these cells. Several markers for 
different intracellular compartments (including early and late endosomes and 
lysosomes, endoplasmic reticulum and cis-Golgi and recycling endosomes) were used 
for this purpose and it was found that transfected mCherry-PLOD3 co-localised with 
endogenous RAB11A (figure 5.9). This is in line with the previously shown co-
localisation between PLOD3 and RAB11A in HeLa cells and fibroblasts (figure 5.4, 
5.5). Interestingly mCherry-PLOD3 partially co-localises with endogenous-LAMP1 (a 
marker of late endosomes and lysosomal compartment) that was not seen in HeLa cells. 
No co-localisation was observed between mCherry-PLOD3 and Calreticulin (an ER 
marker), or GFP-RAB4 / GFP-RAB5 (early endosome markers). mCherry-PLOD3 was 
localised in close proximity to GM130, a marker for cis-golgi network, but no co-
localisation between the proteins was observed. Therefore it is possible to conclude that 
VPS33B/VIPAR complex is involved in PLOD3 trafficking from TGN via a RAB11A 
dependent vesicular transport and knockdown of this protein complex causes the 
accumulation of PLOD3 in the TGN compartment (figure 5.8). 
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Figure 5.7 - Endogenous PLOD3 staining in wild-type, Control (N/S) and Vps33b 
stable knockdown mIMCD-3 cells grown on transwell supports for two weeks.  
All images are projection of one optical section at 0.25 µm Z-spacing. The scale bar 
represents 10 µm. 
 
 
 
 
Figure 5.8 - Confocal immunofluorescence of cultured pre-polarized wild-type and 
VIPAR knockdown mIMCD-3 cells transfected with mCherry-PLOD3 and GFP-TGN38. 
Co-localisation of mCherry-PLOD3 with GFP-TGN38 is observed only in VIPAR kd 
mIMCD-3 cells. Endogenous PLOD3 co-localises also with over-expressed YFP-
VPS33B. For each co-localisation analysis of the Manders' overlap coefficients M1 and 
M2, as well as the P-value, are represented as the average of n>3 cells. A rough outline 
around the cells was drawn with ImageJ. All images are projection of one optical 
section at 0.25 µm Z-spacing. The scale bar represents 10 µm. 
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Figure 5.9 - Co-localisation of mCherry-PLOD3 with different intracellular markers in  
pre-polarized wild-type mIMCD-3 cells. mCherry-PLOD3 co-localises with endogenous 
RAB11A and partially with endogenous-LAMP1. No co-localisation with Calreticulin 
or GFP-RAB4 / GFP-RAB5 was seen. mCherry-PLOD3 was localised in close 
proximity to GM130 but no co-localisation between the proteins was observed. For 
each co-localisation analysis of the Manders' overlap coefficients M1 and M2, as well 
as the P-value, are represented as the average of n>3 cells. All images are projection of 
one optical section at 0.25 µm Z-spacing. The scale bar represents 10 µm. 
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5.4.4 - VPS33B/VIPAR and PLOD3 express co-ordinately in mIMCD-3 
cells 
 
 
In section 5.4.3 the expression and localisation of PLOD3 in Vps33b/Vipar knockdown 
mIMCD-3 cells was analysed by immunostaining and mislocalisation of intracellular 
PLOD3 was found in these cells when compared to controls. In this section the 
expression of VPS33B/VIPAR was analysed in mIMCD-3 cells with Plod3 knockdown. 
In order to perform this analysis stable knockdown mIMCD-3 cell lines were created for 
Plod3, Vps33b and Vipar. The level of knockdown for each cell line was tested by 
Western blot (figure 5.10). 76.2% knockdown was achieved for VPS33B and 89% for 
VIPAR (figure 5.10). The survival rate of single clones was very low when stable 
knockdown of PLOD3 was attempted in these cells. This observation is in agreement 
with data in literature that show how the depletion of GGT activity of PLOD3 in HT-
1080 cells by siRNA leads to arrest of growth followed by lethality (Wang et al., 2009). 
Among n>30 clones tested, it was possible to isolate only two that were viable and had 
a decreased intracellular levels in PLOD3. The level of knockdown achieved for each 
clone were respectively 76.8% and 82.6% (figure 5.10). Both clones were tested for 
VPS33B and VIPAR expression by Western blot (figure 5.11). VPS33B and VIPAR 
were both markly down-regulated in Plod3 knockdown mIMCDs (for one Plod3 
knockdown clone VPS33B was down-regulated by 81.2 % and VIPAR by 75.3 %, 
while for the second clone VPS33B was down-regulated by 75.4 % and VIPAR by 
88.2% (figure 5.11). A concomitant down-regulation of VIPAR was observed in 
Vps33b knockdown mIMCD-3 cells (figure 5.11). As mentioned above, the common 
regulation of proteins that interact mutually as a complex to implement a common 
biological function is not unusual and several examples have been reported in literature. 
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Therefore the down-regulation of both VPS33B and VIPAR in PLOD3 knockdown 
cells is a further indication of the crucial role of VPS33B and VIPAR in PLOD3 
trafficking. As shown in section 5.4.3, PLOD3 is mislocalised in Vps33b/Vipar 
knockdown mIMCD-3 cells but its intracellular expression levels are not changed (as 
quantified by Western-blot). Thus PLOD3 expression is not dependent on 
VPS33B/VIPAR interaction. 
 
 
 
Figure 5.10 - Assessment of Vps33b, Vipar and PLOD3 knockdowns in mIMCD-3 cells. 
Knockdown efficiency in Vps33b, Vipar and Plod3 shRNA treated mIMCD-3 cells was 
tested by Western blot and successive densitometry on bands was carried out. Results 
are normalised to !-actin obtained by immune-blotting the same membrane with an 
anti-!-actin antibody. Knockdown efficiency was calculated relative to both wild-type 
(WT) and control (N/S) cells and a mean value is reported. Several clones (n>20) were 
tested and only the clones with the greatest level of knockdown, used for further 
experiments, are shown in each blot. "
An additional non-specific band is recognised by the anti-VIPAR antibody in WT, N/S 
and VIPAR knockdown mIMCD-3. Therefore only the band that disappears in the Vipar 
knockdown clone was considered VIPAR-specific. 
 
 
 
 
 
 
 
 
 
 
 
      OD PLOD3      23863   14125    3134   2395 
      OD &-Actin       28823   22361  18931 19221 
% Knock-down       -           -              76.8    82.6 
      OD VPS33B   26862      8414 
        OD &-Actin    36207   47795 
  % Knock-down       -           76.2 
       OD VIPAR    9742     10105      1451 
      OD &-Actin    30773   36149    40415 
% Knock-down      -              -              89   
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Figure 5.11 - Assessment of VPS33B and VIPAR expression in PLOD3 knockdown 
mIMCD-3 cells. Immnuoblotting with an anti-Vps33b antibody was performed in Plod-3 
knockdown mIMCD-3 and densitometry on bands was carried out. The percentage of 
VPS33B down-regulation in these cells was calculated after -!-actin normalisation (left 
blot). Similarly, the levels of VIPAR expression in Plod3 knockdown mIMCD-3 cells 
were tested by immunoblot with an anti-VIPAR antibody and successive densitometry 
assessment was carried out. The lower recognized band only is VIPAR specific. Results 
were normalized to !-actin (right blot). Additionally the levels of VIPAR expression 
were tested in Vps33b knockdown mIMCD-3 cells and !-actin normalisation was 
carried out as above.  
 
 
The close relationship between co-regulation, co-expression and protein-protein 
interactions between PLOD3, VPS33B and VIPAR was observed also when a cellular 
fractionation experiment was performed in HEK293 for cell subdivision into four 
fractions: cytosol, membrane, nucleus and cytoskeleton (section 5.3.2). The use of 
HEK293 cells was favoured in this experiment due to the high transfection efficiency in 
this cell type compared to HeLa and mIMCD-3 cells. The expression of endogenous 
PLOD3 was markedly enhanced when HEK293 cells were transfected with myc-
VIPAR compared to untransfected cells (figure 5.12). Additionally endogenous PLOD3 
expression was further increased when HEK293 cells were co-transfected with myc-
VIPAR and HA-VPS33B, compared to both untransfected and myc-VIPAR only 
transfected cells (figure 5.12). Only a very faint band for PLOD3 was observed in the 
membrane fraction in untransfected HEK293 cells. This is in agreement with data in 
          OD VPS33B    28802    21644   6331    9925  
            OD &-Actin    43107    36960  40113  48109 
      % Knock-down        -             -         81.2     75.4 
       OD VIPAR    3419   5027    3813     1997 
      OD &-Actin  81626 92567  93839 103329 
% Knock-down               66.9     75.3      88.2 
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literature suggesting that PLOD3 is a membrane-associated protein inside the lumen of 
organelles. The expression of PLOD3 in the membrane fraction is markely increased in 
Vps33b/Vipar transfected cells. This indicates that the over-expression of VIPAR alone 
and more markedly of the VPS33B/VIPAR protein complex, enhances the expression of 
PLOD3 in HEK293 cells. PLOD3 is seen also in the nuclear fraction in transfected cells 
(figure 5.12). This is attributed to a cross-contamination between membrane and nuclear 
fraction that is very common in this type of experiments due to the physical 
communication between nuclei and ER membranes. This was confirmed by 
immunoblotting the fractions with an anti-PDI antibody whose ER location has been 
established in literature (figure 5.14). The presence of PDI in both nuclear and 
membrane fraction confirms the cross-contamination between these two fractions. 
 
 
 
 
 
 
 
 
 
Figure 5.12 - Cell-fractionation of untransfected, myc-VIPAR transfected, and HA-
VPS33B/myc-VIPAR transfected HEK293 cells for analysis of endogenous PLOD3 
presence in each fraction. Cell fractionation was carried out using the ProteoExtract® 
Subcellular Proteome Extraction Kit (Merck4Biosciences) for HEK293 cell subdivision 
into four fractions: cytosol, membrane, nucleus and cytoskeleton. Immunobloting of 
each fraction was performed with an anti-PLOD3 antibody for the detection of the 
endogenous protein. The total cell lysate, prior to the fractionation, of each pool of 
HEK293 cells was blotted with an anti-!-actin antibody. 
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5.4.5 - The topology of VPS33B/VIPAR/PLOD3 interaction: VIPAR is 
a transmembrane protein  
 
 
The fractionation experiments described in the previous section were consistent with the 
intraluminal localisation of PLOD3 previously reported in literature (Myllyla et al., 
2007). To date the topology of VPS33B/VIPAR is not known but cytoplasmic clusters 
of VPS33B/VIPAR complex have been visualised intracellularly by confocal and 
electron microscopy (Cullinane et al., 2010; Smith et al., 2012). In this section 
experiments were performed in order to establish the topology of 
VPS33B/VIPAR/PLOD3 interaction and the possibility, suggested by FRET-FLIM 
measurements (section 4.4.3.4), that a direct interaction between PLOD3 and VIPAR 
can occur. Before proceeding with the experimental work, a bioinformatics analysis was 
performed for all proteins subject of this study, in order to gain more information 
regarding their membrane vs cytosolic localisation. Several prediction servers were used 
to predict putative transmembrane regions along VPS33B, VIPAR and PLOD3 protein 
sequence including: PredictProtein (www.predictprotein.org), Split server 
(http://split4.pmfst.hr/split/4/), "DAS" - Transmembrane Prediction server 
(http://www.sbc.su.se/~miklos/DAS/), TopPred2: Topology prediction of membrane 
proteins file://localhost/(http/::www.sbc.su.se:~erikw:toppred2:), HMMTOP:Prediction 
of transmembrane helices and topology of proteins (http://www.enzim.hu/hmmtop/). 
These servers were all in agreement that no transmembrane helices were present in 
VPS33B and PLOD3, which confirms previous data from literature regarding their 
respective cytosolic and luminal localisation. For VIPAR a different scenario was 
presented. PredictProtein, Split server and DAS databases predict two transmembrane 
helices in VIPAR located around 140-160 amino acid for the first helix and 270-290 
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amino acid for the second helix (figure 5.13). TopPred2 and HMMTOP predicted only 
the second transmembrane domain (amino acid 270-290). Additionally, all the above 
servers predicted the N-terminal region of VIPAR to be located on the luminal side and 
its C-terminal on the cytosolic side. These predictions nicely match with previous 
experiments that identified the N-terminal region of VIPAR interacting with PLOD3 
and its C-terminal with VPS33B (sections 3.4.4, 4.4.3.5). Based on this analysis, it was 
possible to predict the topology of VPS33B/VIPAR/PLOD3 interaction: in this scenario 
VIPAR is a transmembrane protein, with three different hypothesis regarding the 
location of the transmembrane helices along its sequence (figure 5.13), while VPS33B 
is located in the cytosol and interacts with the C-terminal cytosolic domain of VIPAR. 
Thus, according to these predictions PLOD3 interacts with the luminal N-terminal 
domain of VIPAR in the lumen of the organelle/vesicle (figure 5.13). 
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Figure 5.13 - Graphical model of the predicted topology of VPS33B-VIPAR-PLOD3 
interaction with three possibilities in respect to the transmembrane domains (TMD) 
location in VIPAR. Several prediction servers were used to predict putative 
transmembrane regions along VIPAR protein sequence including: PredictProtein 
(www.predictprotein.org), Split server (http://split4.pmfst.hr/split/4/), "DAS" - 
Transmembrane Prediction server (http://www.sbc.su.se/~miklos/DAS/), TopPred2: 
Topology prediction of membrane proteins 
file://localhost/(http/::www.sbc.su.se:~erikw:toppred2:), HMMTOP:Prediction of 
transmembrane helices and topology of proteins (http://www.enzim.hu/hmmtop/). 
PredictProtein, Split server and DAS databases predict two transmembrane helices in 
VIPAR located around 140-160 amino acid for the first helix and 270-290 amino acid 
for the second helix. TopPred2 and HMMTOP predict only the second domain (amino 
acid 270-290). In all three scenarios VPS33B interacts with the C-terminal cytosolic 
domain of VIPAR, while PLOD3 with its luminal N-terminal domain. 
 
 
 
To further validate the model described for VPS33B/VIPAR/PLOD3 topology, 
fractionation experiments were carried out with subsequent Western-blot analysis to 
detect the presence of endogenous VPS33B, VIPAR and PLOD3 in each fraction 
(section 5.3.1). Non-transfected HEK293 cells used in the fractionation experiment 
described in the previous section for the detection of endogenous PLOD3, were also 
used to detect the presence of endogenous VPS33B and VIPAR in the same fractions 
(figure 5.14). The low quality of the blot is related to the dilution of the protein during 
N 
C VPS33B 
PLOD3 
N 
C VPS33B 
PLOD3 
N 
C 
PLOD3 
VPS33B 
1: TM region 270-290 2: TM region 140-160 3: TM regions 
140-160 and 270-290 
cytosol 
lumen 
 171 
the fractionation procedure that consequently lowers the efficency of recognition by the 
antibody. VIPAR, similarly to PLOD3 and PDI protein (used as a cross-contamination 
control protein), is located in the membrane and nuclear fraction and no band was 
detected in the lane that corresponds to the cytosolic fraction (figure 5.14). Endogenous 
VPS33B instead was predominantly located in the cytosolic fraction. As shown 
previously (section 3.4.1) VPS33B interacts directly with VIPAR and therefore the only 
explanation for VIPAR exclusive membrane localisation is its transmembrane nature 
and a possible luminal location was therefore excluded.  
 
 
 
 
 
 
 
 
 
Figure 5.14 - Cell-fractionation of untransfected HEK293 cells and successive Western-
blot analysis for the presence of endogenous VPS33B, VIPAR and PLOD3 in each 
fraction. Cell-fractionation was carried out using the ProteoExtract® Subcellular 
Proteome Extraction Kit (Merck4Biosciences) for HEK293 cell subdivision into four 
fractions: cytosol, membrane, nucleus and cytoskeleton. An additional immunoblotting 
of fractions was carried out with an anti-PDI antibody as a control to assess cross-
contamination between fractions."
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This data were further confirmed by a coarse fractionation experiment for the separation 
of the cytosol from crude membrane fractionation of HeLa and mIMCD-3 cells (both 
wild-type and Vipar knockdown mIMCD-3 cells were used) (section 5.3.2, figure 5.15). 
Endogenous VIPAR is exclusively located in the membrane fraction of HeLa and 
mIMCD-3 cells, both in wild-type and Vipar knockdown, confirming previous data 
(figure 5.15). As shown previously, cells blotted with anti-VIPAR antibody present a 
typical double band with only the lower molecular weight band being VIPAR-specific 
(figure 5.10). To exclude misleading results derived from the presence of two bands in 
the anti-VIPAR blot, unfractionated control and ARC-patient human fibroblast cells 
were loaded on the same blot for confirmation of VIPAR specific band in the 
fractionated samples (VIPAR specific band indeed disappears in ARC-patient fibroblast 
carrying a Vipar missense mutation compared to control cells) (figure 5.15). 
Additionally, the VIPAR-specific band is reduced in the membrane fraction of Vipar 
knockdown mIMCD-3 and this is a further confirmation of band-specificity and 
knockdown efficiency as previously described (figure 5.10). VPS33B is mainly found in 
the cytosolic fraction of HeLa cells and wild-type mIMCD-3 cells. A small fraction of 
VPS33B is found in the membrane fraction and this might indicate that VPS33B cycles 
between soluble and membrane associated (through its interaction with VIPAR), 
similarly to what observed for the yeast Vps33p that cycles between soluble and 
particulate forms in an ATP-dependent manner (Gerhardt et al., 2012). VPS33B was not 
detectable by the anti-VPS33B antibody in Vipar knockdown mIMCD-3 cells. 
PLOD3 was predominantly located in the membrane fraction of all cell lines. A small 
amount of PLOD3 was found in the cytosolic fraction and the same was observed in 
HeLa cells for PDI, a known luminal ER protein, indicating that a small fraction of the 
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internal organelle membranes were disrupted by the homogenisation procedure (section 
5.3.2) causing the release of their content into the cytosol. This observation is however 
very indicative in terms of confirming the transmembrane nature of VIPAR. VIPAR, 
unlike PLOD3 and PDI, is found only in the membrane fraction and possible membrane 
organelle disruption doesn’t cause its release into the cytosol. This further excludes the 
possibility of VIPAR being a luminal protein as an explanation for its presence in the 
membrane fraction. The same behaviour was observed for LAMP1, a known 
transmembrane protein, found exclusively in the membrane pool of HeLa cells (figure 
5.15).  
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Figure 5.15 - Establishment of the cytosolic versus membrane location of endogenous 
VIPAR, PLOD3 and VPS33B in HeLa and mIMCD-3 cells. mIMCD-3 wild-type and 
Vipar knockdown cell lines, as well as HeLa cells, were used in the fractionation 
experiment for the separation of the cytosol from crude membranes. Both fractions for 
each cell-line were blotted with anti-VIPAR, anti-VPS33B and anti-PLOD3 antibody in 
order to determine the cytosolic versus membrane localisation of respective endogenous 
proteins. Due to the presence of two bands in the samples blotted with anti-VIPAR 
antibody, control and ARC-patient human fibroblast cells were loaded on the same blot 
for confirmation of VIPAR specific band (which disappears in ARC-patient fibroblasts 
carrying a Vipar missense mutation compared to Control cells).  
To test for cross-contamination between fractions, cytosolic and membrane fractions 
from HeLa cells were blotted with antibodies against proteins with known intracellular 
localisation. Antibodies against PDI (a known luminal ER protein) and LAMP1 (a 
known transmembrane lysosmal protein) were used for this purpose. The same 
antibodies were not suitable for the recognition of the same mouse proteins in mIMCD-
3 cells.  
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5.4.6 - Collagen type IV and E-cadherin are abnormally expressed in 
Vps33b/Vipar and Plod3 knockdown cell lines 
 
 
PLOD3 is an enzyme that catalyses the hydroxylation of lysyl residues in collagen-like 
peptides as well as the galactosylation of hydroxylysines and glucosylation of 
galacotosylhydroxylysines. Therefore, to examine possible changes in collagen 
expression/modification caused by defects in PLOD3 trafficking/expression, 
immunostaining and immunoblotting of mIMCD-3 cell lines was performed using an 
anti-collagen type IV antibody. Collagen type IV was chosen among the other types of 
collagens for its high content in hydroxylated and hydroxyl-glycosylated lysines and 
also for being the major component of basement membranes of kidneys, remembering 
that the polarized cells used in this study derive from the inner medullary collecting 
duct (mIMCD-3) of mouse kidney (section 5.1). The expression of endogenous collagen 
type IV was analysed in both Vps33b and Plod3 knockdown mIMCD-3 cell lines and 
was compared to wild-type and control cells. Immunostaining and Western blot analysis 
demonstrate a abnourmous increase in the intracellular amounts of collagen IV in both 
Vps33b and Plod3 knockdown mIMCD-3 cells compared to controls (figure 5.16 A and 
B). This is in line with the data in the literature that demonstrate intracellular 
accumulation of collagen IV in PLOD3 deficiency, assigning a critical role to 
hydroxylysine glycosylation in the assembly and secretion of highly glycosylated 
collagen types (Sipila et al., 2007). From the Western-blot analysis, a slightly enhanced 
migration on SDS-PAGE of collagen IV chains is observed in Vps33b and Plod3 
knockdown mIMCD-3 compared to controls, suggesting a possible difference in their 
hydroxylation/glycosylation pattern with consequent molecular weight reduction (figure 
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5.16 B). Similar behaviour was observed in E9.5 PLOD3 null embryo lysates compared 
to wild-type embryo lysates (Rautavuoma et al., 2004).  
As mentioned previously (section 5.1) loss of E-cadherin expression and a typical EMT 
phenotype characterises Vps33b/Vipar knockdown mIMCD-3 cells. The expression of 
E-cadherin was analysed also in Plod3 knockdown cells and similarly to Vps33b/Vipar 
knockdowns, a loss in E-cadherin expression was seen (figure 5.16 B, C). This result 
was quantified by Western-blot (figure 5.16 B) and staining of mIMCD-3 cells cultured 
for 3 days in 3D type I collagen gels. The staining demonstrated a marked loss of E-
cadherin and, to a lesser extent, of Claudin 1 in both Vps33b and Plod3 knockdown 
cells compared to controls (figure 5.16 C). In 3D cultures, control mIMCD-3 cells 
formed spheroid structures with a single layer of epithelial cells defining a well-
established lumen. Vps33b and Plod3 knockdown cells didn’t form the spheroid 
structures and cells did not grow in a monolayer but instead formed a disorganised 
mass. These results lead to the conclusion that an EMT phenotype is observed also in 
Plod3 knockdown mIMCD-3 cells similarly to Vps33b/Vipar knockdowns. Plod3 
knockdown mIMCD-3 cells seem to mimic the phenotype of Vps33b/Vipar 
knockdowns in terms of collagen expression/structure, E-cadherin expression and 
lumen formation. Additionally, and similarly to what was observed in Vps33b and 
Vipar knockdown cells (Cullinane et al., 2010), proliferation was significantly increased 
in Plod3 knockdowns. The maximum level of Trans-Epithelial-Resistance (that 
measures paracellular permeability to ions), reached by Plod3 knockdown cells were 
~40% reduced compared with controls, indicating a defect in junction formation. The 
similar phenotype of Vps33b, Vipar and Plod3 knockdown mIMCD-3 cell lines is a 
further indication of the involvement of these proteins in the same intracellular pathway. 
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Figure 5.16 - Endogenous collagen IV and E-cadherin expression in Vps33b and Plod3 
knockdown mIMCD-3 cell lines compared to control cells. (A). Immunostaining with 
anti-collagen IV antibody of mIMCD-3 cell lines (wild-type, control, Vps33b and Plod3 
knockdown) grown on transwell supports for two weeks. All images are projection of 
one optical section at 0.25 µm Z-spacing. The scale bar represents 10 µm. 
 (B). Western blot analysis of collagen IV and E-cadherin expression in pre-polarized 
mIMCD-3 cell lines with a specific anti-collagen IV antibody that recognasies the !1 
and !2 chains, and an anti-E-cadherin antibody. The same membrane was blotted with 
an anti-!-actin antibody as a loading control. 
(C). mIMCD-3 cells cultured for 3 days in 3D type I collagen gels before staining with 
anti-E-cadherin and anti-Claudin antibodies was carried out. Control mIMCD-3 cells 
formed large spheroid structures with a single layer of epithelial cells that define a 
well-established lumen. Vps33b and Plod3 knockdown cells don’t form the spheroids 
and cells do not grow in a monolayer. Loss of E-cadherin expression is visible in both 
Vps33b and Plod3 knockdown cells compared to control. Experiment carried out in 
collaboration with A Straatman Iwanowska. 
 
 
 
To better understand the relevance of PLOD3 and collagen modifications/expression in 
ARC syndrome, human skin fibroblast derived from ARC patients and age-matched 
controls were analysed by Western blot for collagen type I expression. The importance 
of the GT and GGT activity of PLOD3 has been indeed demonstrated in osteoblasts and 
an impairment of this LH3 function significantly affects type I collagen fibrillogenesis 
(Sricholpech et al., 2011). This study shows an accelerated fibrillogenesis in PLOD3 
knockdown mouse osteoblastic cell lines (Sricholpech et al., 2011). 
A abnourmous intracellular accumulation of collagen I was seen in human skin 
fibroblast derived from ARC patients compared to age-matched controls (figure 5.17) 
Plod3 kd Control Vps33b kd 
Claudin1              
E-cadherin C. 
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similarly to what was previously seen for collagen IV in Vps33b/Vipar and Plod3 
knockdown mIMCD-3 cells (figure 5.16B). The consistency of the data between 
mIMCD-3 cells, the in-vitro cell model for ARC, and cell lines derived from patients 
carrying the disease, indicate plausibility in the observed data and formulated 
hypothesis. 
 
Figure 5.17 - Collagen I expression in human skin fibroblast derived from ARC patients 
and age-matched controls. Collagen I expression in human skin fibroblast cell lines was 
tested by Western blot and then densitometry was carried out. Results are normalized to 
!-actin obtained by immunoblotting the same membrane with an anti-!-actin antibody. 
Levels of collagen I up-regulation in ARC patient fibroblasts were calculated relative to 
the first age-matched control in the figure. 
 
 
 
One of the major goals of this work is to understand the mechanisms that lead to the E-
cadherin down-regulation and consequent EMT phenotype in Vps33b/Vipar mIMCD-3 
cell lines. As mentioned above, similarly to Vps33b/Vipar knockdown mIMCD-3 cells, 
the down-regulation of E-cadherin occurs also in Plod3 knockdown cells. This suggests 
a common mechanism involving VPS33B, VIPAR and PLOD3 that directly or 
   OD Collagen I    2719     250    20989  55541 12445  50717   5551   33349 
        OD &-Actin   38453 39856   40802  40391 39766  37482 43804   46228 
 % up-regulation                              627    1844     342     1813      79        920         
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indirectly regulates the expression of E-cadherin in these cells. A correlation between E-
cadherin down-regulation and abnormal collagen expression has been documented in 
literature (Espinosa Neira and Salazar, 2012), therefore it is possible to hypothesise that 
abnormal collagen formation and secretion in Vps33b/Vipar and Plod3 knockdown in 
mIMCD-3 cells could lead to E-cadherin down-regulation in these cells. In order to 
understand the possible effect of collagen expression on E-cadherin down-regulation in 
Vps33b knockdown mIMCD-3 cells, a time course experiment was performed 
analysing simultaneously the expression of "-actin, E-cadherin and collagen IV on 
transwell plates growing wild-type and Vps33b knockdown mIMCD-3 cell lines (figure 
5.18). From very early stages, at 30 minutes after cells seeding on transwell supports, an 
increase in collagen IV was seen in Vps33b knockdown cells compared to wild-type 
(figure 5.18). At this stage, some E-cadherin was still present in the knockdown cells 
that could not be observed at later stages (figure 5.18). It is therefore possible to assume 
that the progressive accumulation of collagen IV, that can be seen at later time points in 
Vps33b knockdown cells, can lead to the progressive loss of E-cadherin expression in 
these cells. It is important to underline that mIMCD-3 cells with a stable knockdown of 
Vps33b were used in this experiment and it is therefore not possible to monitor the 
expression of collagen and E-cadherin at the very first stages of the knockdown 
establishment. This experiment was useful also for monitoring of the time-course of the 
establishment of polarity in mIMCD-3 wild-type cells. Predominant intracellular E-
cadherin staining was observed at the first stages after cell seeding on transwell supports 
(from 30 minutes to 6 hours) with progressive junctional staining corresponding to cell-
cell contact sites noticeable after 24 hours of growth on transwell supports. The 
complete polarization was reached after 2 weeks when both E-cadherin and "-actin 
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were concentrated at the cell-to-cell adhesion regions. Loss of this typical actin 
cytoskeleton organisation was observed in Vps33b knockdown cells (figure 5.18). 
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Figure 5.18 - Time course experiment analysing the expression of !-actin, E-cadherin 
and collagen IV on transwell growing mIMCD-3 cell lines. Wild-type and Vps33b 
knockdown mIMCD-3 cells were seeded at the same starting point on 7 different 
transwell supports per cell line. Cells were fixed in 4% PFA at different time points that 
range from 30min to 2-weeks. After fixation, staining was performed with anti-!-actin, 
anti-E-cadherin and anti-collagen IV antibodies for each time point of both wild-type 
and Vps33b knockdown cell lines. All images are projection of one optical section at 
0.25 µm Z-spacing. The scale bar represents 10 µm. 
 
 
 
$
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5.4.7 - VPS33B-VIPAR complex is involved in PLOD3 delivery to 
collagen 
 
 
As mentioned early in this Chapter, defects in collagen secretion with its subsequent 
intracellular accumulation, have been associated to loss of GGT activity of PLOD3 
(Sipila et al., 2007). In agreement with this data, an increase in the intracellular 
accumulation of collagen IV was observed in Plod3 knockdown mIMCD-3 cells. The 
same abnormal increase in intracellular collagen IV was seen also in Vps33b/Vipar 
knockdown mIMCD-3 cells. It was therefore possible to propose the existence of a 
novel mechanism for collagen intracellular trafficking involving Vps33b/Vipar/Plod3. 
To test this hypothesis, co-localisation analysis of endogenous collagen IV with 
transfected mCherry-PLOD3 was performed in wild-type and Vipar knockdown 
mIMCD-3 cells. Collagen type IV co-localises with mCherry-PLOD3 in control but not 
in Vipar knockdown cells (figure 5.19). This experiment therefore indicates that 
VPS33B/VIPAR complex is crucial for co-localisation and possibly trafficking of 
PLOD3 to collagen and in the absence of this complex in Vipar knockdown cells, 
PLOD3 does not modify intracellular collagen IV, which affects its intracellular 
trafficking (and possibly secretion). Therefore collagen trafficking is affected in PLOD3 
knockdown cells (due to the reduced amounts of PLOD3 in these cells), as well as in 
Vipar knockdown cells (due to a possible failure in the delivery of PLOD3 to collagen). 
To further validate this data, a rescue experiment was performed by transfecting Vipar 
knockdown mIMCD-3 cells with YFP-VPS33B/myc-VIPAR. The co-localisation 
between collagen type IV and mCherry-PLOD3 was achieved in transfected cells 
confirming the role of VPS33B/VIPAR in the delivery of PLOD3 to collagen (figure 
5.19). 
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Figure 5.19 - Co-localisation analysis of endogenous collagen IV with mCherry-
PLOD3 in wild-type, Vipar knockdown, and Vipar knockdown YFP-VPS33B/myc 
VIPAR transfected, pre-polarized mIMCD-3 cells. Confocal immunofluorescence of 
cultured pre-polarized wild-type and VIPAR knockdown mIMCD-3 cells transfected 
with mCherry-PLOD3 and stained for endogenous collagen IV. Collagen type IV co-
localises with mCherry-PLOD3 in control but not in Vipar knockdown cells. The rescue 
experiment was performed by transfecting Vipar knockdown mIMCD-3 cells with YFP-
VPS33B/myc-VIPAR. Collagen type IV co-localises with mCherry-PLOD3 in 
transfected cells. Endogenous PLOD3 co-localises also with over-expressed YFP-
VPS33B. For each co-localisation analysis of the Manders' overlap coefficients M1 and 
M2, as well as the P-value, are represented as the average of n>3 cells. A rough outline 
around the cells was drawn with ImageJ. All images are projection of one optical 
section at 0.25 µm Z-spacing. The scale bar represents 10 µm. Experiment carried out 
in collaboration with A.Straatman Iwanowska. 
 
 
Furthermore, the same cells in the experiment described in figure 5.8 (performed by 
transfecting cultured pre-polarized wild-type and Vipar knockdown mIMCD-3 cells 
with mCherry-PLOD3 and GFP-TGN38), were additionally stained for collagen IV. 
Round granular structures can be seen by co-localising PLOD3 with collagen IV in 
wild-type cells but the localisation of these granules is not the TGN compartment 
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(figure 5.20). It is therefore possible to hypothesise that PLOD3 binding to collagen 
occurs in correspondence of collagen carriers and not at the TGN level. The co-
localisation between PLOD3 and collagen IV does not occur in Vipar knockdown 
mIMCD-3 cells and additionally an accumulation of mCherry-PLOD3 is observed at the 
TGN compartment of the same cells (figure 5.8, figure 5.20). This further confirms the 
previous hypothesis stating that PLOD3 binding to collagen does not occur at the TGN 
compartment. 
 
 
Figure 5.20 - Confocal immunofluorescence of cultured pre-polarized wild-type and 
Vipar knockdown mIMCD-3 cells transfected with mCherry-PLOD3 and GFP-TGN38 
and stained for collagen IV. Collagen IV co-localises with PLOD3 only in wild-type 
cells but no co-localisation with GFP-TGN-38 was observed. Co-localisation of 
mCherry-PLOD3 with GFP-TGN38 occurs only in VIPAR knockdown mIMCD-3 cells 
and no co-localisation between collagen IV and PLOD3 can be seen in these cells. A 
rough outline around the cells was drawn with ImageJ. All images are projection of one 
optical section at 0.25 µm Z-spacing. The scale bar represents 10 µm. The co-
localisation analysis of the Manders' overlap coefficients M1 and M2, as well as the P-
value, are shown in figure 5.8 and 5.19. Experiment carried out in collaboration with 
A.Straatman Iwanowska. 
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5.5 - DISCUSSION 
 
 
The novel PLOD3-VIPAR interaction, unambiguously confirmed in the previous 
chapter, was here characterised at subcellular level in order to elucidate its potential 
relevance in the pathogenesis of the ARC syndrome. In order to understand the 
trafficking pathway involving VPS33B/VIPAR/PLOD3 it was crucial to determine the 
intracellular localisation of these proteins that is not yet fully characterised. In contrast 
to the previous reports (Heikkinen et al., 2000; Myllyla et al., 2007; Salo et al., 2006a; 
Salo et al., 2006b) it was possible to demonstrate that PLOD3 is not an ER resident 
protein. Unlike the PLOD1 isoform, whose ER-localisation was well-established 
(Kellokumpu et al., 1994), PLOD3 does not co-localise with the luminal ER protein 
PDI but is instead found in the Trans-Golgi-Network compartment as shown by co-
localisation with TGN-46, p230 and AP1 markers in HeLa cells and fibroblasts. This 
finding, despite being a contradiction to the previous statements about PLOD3 
intracellular localisation, is not completely surprising. As mentioned above, PLOD3 is 
unique among PLOD isoforms for its localisation and enzymatic activity. Apart from 
intracellular location, PLOD3 is found also in the extracellular space and at the cell 
surface. Different trafficking pathways that ensure PLOD3 is delivered to these diverse 
locations have been suggested. PLOD1 and PLOD2 isoforms, on the other hand are 
thought to be exclusively ER resident proteins and do not appear to require specific 
trafficking pathways. Additionally PLOD3 is the only isoform that catalyses the 
galactosylation of hydroxylysines and glucolsylation of galacotosylhydroxylysines and 
these post-translational modifications are known to occur in the Golgi complex. The 
identification of VIPAR at TGN demonstrated by the work described in this thesis, 
represent the first evidence that establishes a subcellular compartmentalisation for 
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endogenous VIPAR. This is in agreement with prediction analyses that assign VIPAR to 
a Golgin subfamily A member 5 domain. Members of Golgin family are coiled-coil 
motif proteins that mediate tethering of vesicles to Golgi membranes and cisternal 
membranes to each other (section 1.3).  
Additionally, co-localisation experiments established that both VIPAR and PLOD3 co-
localise in the vicinity of TGN and a co-localisation of both proteins with RAB11A was 
also shown. This supports previous data that see VPS33B interacting with RAB11A and 
their involvement in vesicular trafficking (Cullinane et al., 2010). A trafficking of 
PLOD3, through VPS33B/VIPAR/RAB11A was postulated and further investigated in 
mouse Inner Medullary Collecting Duct (mIMCD3) cell lines, the polarized epithelial 
cell model used for the study of ARC syndrome (Cullinane et al., 2010). Mislocalisation 
of endogenous PLOD3 was observed in Vps33b/Vipar knockdown mIMCD-3 cells after 
culturing for two weeks on transwell supports. This allows wild-type cells to become 
fully polarized but a loss of cell polarity and EMT phenotype is evident in 
Vps33b/Vipar knockdown cells. The accumulation of mCherry-PLOD3 at the TGN is 
seen in Vps33b/Vipar knockdown mIMCD-3 cells where PLOD3 is shown to co-
localise with GFP-TGN38. The co-localisation of mCherry-PLOD3 with TGN38 was 
not seen in wild-type pre-polarized mIMCD-3 cells. Additionally PLOD-3 co-localises 
with RAB11A in wild-type pre-polarized mIMCD-3 cells but not in Vipar knockdown 
cells, strengthening the hypothesis that PLOD3 is trafficked out of TGN by 
VIPAR/VPS33B complex via Rab11a positive endosomes. This route appears to be 
‘blocked’ in the absence of VPS33B/VIPAR and therefore PLOD3 accumulates in the 
TGN of Vipar knockdown mIMCD-3 cells.  
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VPS33B/VIPAR involvement in PLOD3 trafficking was characterized also from the 
topological point of view. The topology of the VPS33B/VIPAR/PLOD3 interaction that 
takes place at the TGN, (or vesicles located in the TGN area) was established. Several 
prediction servers identified two transmembrane domains (TMD) in VIPAR and the 
transmembrane nature of VIPAR was confirmed by different fractionation experiments. 
This is a novel finding that for the first time characterises VIPAR topology in the cell. 
VPS16, the yeast homologue of VIPAR, that constitutes the side of the head of the 
cytosolic HOPS complex, is not a transmembrane protein. This is in agreement with the 
prediction analysis for TMD performed for VPS16 in the same way as for VIPAR. 
These analyses indeed did not identify transmembrane helices in VPS16. As mentioned 
in the previous Chapter, previously published data indicate that it is unlikely that 
VIPAR and VPS33B are constituent parts of the HOPS complex in higher organisms. I 
therefore hypothesised that during evolution VIPAR has acquired a transmembrane 
topology and new functions that are related to PLOD3 trafficking in the cell. A further 
indication of this statement derives from TMD prediction analysis on VPS16B, the 
homologue of VIPAR in D.melanogaster. As mentioned in the previous Chapter, the fly 
database indicates that VPS16B co-immunopreciptates with PLOD, the homologue in 
fly of PLOD3. The TMD prediction servers identify two TMD in VPS16B at the same 
regions where TMD in VIPAR are located. Therefore a strong association can be 
deduced between structure (TMD regions) and function (PLOD3 trafficking) of VIPAR 
in the course of evolution, giving a stronger support to this theory. 
The relevance of PLOD3 in ARC was examined by analyzing the phenotype of 
mIMCD-3 cell lines knockdown for Vps33b/Vipar that as mentioned above is 
characterized by a loss of E-cadherin expression and EMT phenotype. A large increase 
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in the intracellular amounts of collagen IV was observed in these cells. The intracellular 
accumulation of collagen in PLOD3 deficiency has been previously described in 
literature, and was evidenced also in Plod3 knockdown mIMCD-3 cells. Additionally, 
E-cadherin expression was found down-regulated not only in Vps33/Vipar knockdowns 
but also in Plod3 knockdown mIMCD-3 cells, suggesting the existence of a common 
mechanism involving VPS33B/VIPAR and PLOD3 that regulates the 
expression/trafficking of collagen and E-cadherin in these cells. Immunofluorescence 
experiments showed that collagen type IV co-localises with mCherry-PLOD3 in wild-
type mIMCD-3 but not Vipar knockdown cells. This clearly indicates that the 
VPS33B/VIPAR complex is required for the delivery of PLOD3 to collagen. Given the 
established importance of PLOD3 in collagen secretion, it was possible to conclude that 
the intracellular accumulation in collagen IV observed in Vps33b/Vipar and Plod3 
knockdown cell lines is caused by the abrogation of PLOD3/collagen binding in these 
cells. This is caused by the decreased levels of PLOD3 in Plod3 knockdown mIMCD-3 
cells, and by the failure in the PLOD3 delivery to collagen in Vps33b/Vipar 
knockdowns. This crucial role of VPS33B/VIPAR in PLOD3 trafficking could 
constitute a novel mechanism that regulates collagen trafficking. Additionally, the 
abnormal expression/modification of collagen, observed in Vps33b/Vipar knockdown 
mIMCD-3 cells as well as in fibroblasts derived from ARC patients, could explain the 
EMT phenotype and E-cadherin down-regulation that characterises knockdown 
mIMCD-3 cell lines. Indeed data in the literature indicate that exogenous collagen can 
directly lead to E-cadherin down-regulation and EMT (Espinosa Neira and Salazar, 
2012). In conclusion, the newly identified PLOD3-VIPAR interaction was fundamental 
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in elucidating new functions for VPS33B and VIPAR in the cell and getting a better 
understanding of the pathology of the ARC syndrome.  
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CHAPTER SIX: 
 
DISCUSSION 
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6.1 - VPS33B interacts with VIPAR at a protein level forming a stable 
binary complex 
 
 
The co-localisation and co-immunoprecipitation of VPS33B along with VIPAR has 
suggested that these proteins work in a multiprotein complex involved epithelial 
polarisation and apical junction complex formation (Cullinane et al., 2010). 
Fundamentally, this project has added to the growing body of evidence showing that 
VPS33B interacts at a protein level with VIPAR and a direct association between the 
proteins was described. Additionally the work presented here demonstrated through 
different biochemical approaches that VPS33B and VIPAR form a stable binary 
complex in-vitro. This was previously shown for the yeast homologues of VPS33B and 
VIPAR, respectively Vps33 and Vps16 that form a tight sub-complex of HOPS 
(Brocker et al., 2012). Therefore the data in this thesis represent the first evidence 
regarding the interaction involving the mammalian homologues VPS33B and VIPAR.  
Previously published data suggests that VPS33B and VIPAR are unlikely to form active 
parts in the conventional HOPS complex and these proteins may be involved in another 
protein complex (Smith et al., 2012). The work performed in this thesis confirmed that 
this is the case and a novel interacting partner for VPS33B/VIPAR complex was 
identified. Despite being a stable complex in-vitro, instability phenomena including 
degradation with time and protein precipitation after tag removal, initially suggested 
that new binding partners are required to further stabilize the VPS33B/VIPAR complex. 
The instability was related to the presence of a large disordered region at the N-terminus 
of VIPAR that is not involved in the interaction with VPS33B. The fact that disordered 
regions are usually involved in-vivo in binding of structured partners, that determine 
their disordered to ordered transition, suggested that this might be the case for the N-
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terminal of VIPAR. Co-immunoprecipitation experiments demonstrated that indeed the 
N-terminal part of VIPAR is involved in the binding of PLOD3, the novel interactor for 
VIPAR identified in this work. 
 
 
 
6.2 - PLOD3 is a novel interactor for VIPAR 
 
 
The function of VPS33B and VIPAR in the cell is not yet fully characterised. Therefore 
the main goal of this work was to clarify the role of VPS33B and VIPAR and 
understand the pathways and mechanisms in which these proteins are involved. This 
was achieved by identifying new interacting partners for VPS33B and VIPAR through a 
pull-down experiment followed my mass-spectrometry identification. Mass 
spectrometry analysis identified Procollagen-Lysine 2-Oxoglutarate 5-Dioxygenase 1 
(PLOD1) and Procollagen-Lysine 2-Oxoglutarate 5-Dioxygenase (PLOD3) as potential 
interacting partners for VPS33B/VIPAR. The work described in this thesis was focused 
on PLOD3 due to lack of co-localsiation between PLOD1 and intracellular clusters of 
VPS33B/VIPAR. It is however important to stress that further investigation is required 
to exclude the possibility that PLOD1 is also an interactor for VPS33B/VIPAR. All 
experiments performed in this thesis however demonstrated that PLOD3 is a novel 
interactor for VIPAR only, while no interaction with VPS33B was demonstrated. These 
experiments included co-immunoprecipitation, co-localisation of the endogenous 
proteins and Fluorescence Lifetime Imaging in Förster Resonance Energy Transfer 
(FRET-FLIM) analysis using fluorescently-tagged proteins. These last measurements 
provided evidence regarding the intermolecular distance between VPS33B-VIPAR and 
 195 
VIPAR-PLOD3 from which it was possible to deduce that a direct interaction occurs 
between PLOD3 and VIPAR in the cell.  
 
 
6.3 - VIPAR is a transmembrane protein with its luminal N-terminal 
interacting with PLOD3 and its cytsolic C-terminal interacting with 
VPS33B 
 
 
As mentioned above, evidence from this thesis suggests that direct protein-protein 
interactions exist between VPS33B and VIPAR as well as VIPAR and PLOD3. These 
data may seem to contradict the accepted knowledge on the topology of these proteins 
in the cell. PLOD3 is known to be a luminal protein while VPS33B and VIPAR are 
considered cytosolic proteins because of homology to their yeast counterparts Vps33 
and Vps16 that form part of the cytosolic HOPS complex. Bioinformatics analysis 
performed in this thesis led to the identification of two transmembrane helices along 
VIPAR protein sequence located approximately at 140-160 amino acid for the first helix 
and 270-290 amino acid for the second helix. The same TMD were predicted along 
VPS16B, the fly homologue of VIPAR, that co-immunoprecipitates with PLOD (the fly 
homologue of PLOD3). Interestingly no transmembrane helices were predicted for the 
yeast VPS16 that unlike VIPAR, is an integral part of the yeast HOPS complex. The 
transmembrane nature of VIPAR, predicted by several bioinformatics algorithms, was 
confirmed by two different fractionation experiments and represents a novel finding in 
the localisation of VIPAR that was previously uncharacterised. Combined together, the 
data presented here suggest that the function of VIPAR is not related to that of HOPS 
complex and depends on the transmembrane nature of the protein that was acquired 
during evolution of metazoans from single cell organisms. The binomial association 
between protein structure and function is indeed one of the fundamental principles in 
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biology. 
The same bioinformatics analysis that led to the identification of transmembrane helices 
in VIPAR, predicted the N-terminal of the protein targeted to the lumen and its C-
terminal facing the cytosol. Here a mapping of the interaction along VIPAR sequence 
was performed for both VPS33B and PLOD3. VPS33B binds the C-terminal region of 
VIPAR while PLOD3 is involved in the interaction with its N-terminal. These data 
perfectly match with the prediction analysis and allowed us to unambiguously 
determine the topology of the VPS33B/VIPAR/PLOD3 interaction: VPS33B, located in 
the cytosol, interacts with the C-terminal cytosolic domain of VIPAR, while the luminal 
protein PLOD3 is involved in the interaction with the lumen facing N-terminal domain 
of VIPAR (figure 6.1 A).  
However the exact mapping of the TMD in VIPAR is not yet established and on-going 
experiments are aimed at determining their localisation along VIPAR protein sequence. 
As mentioned above, the majority of the prediction servers identify two TMD in 
VIPAR. Therefore VIPAR might constitute a type II membrane-bound protein. 
Differently from type I, type II TM proteins are not targeted in the secretory pathway 
through signal peptides and indeed no signalling sequences have been identified in 
VIPAR. Instead the targeting to the secretory pathway of type II TM proteins occurs 
through their first TMD that resembles the signal sequence, but is different from it 
because it is not cleaved after insertion into the membrane.  
The transmembrane nature of VIPAR, together with the two predicted coiled-coil 
domains, is in agreement with the bioinformatics analysis that identified a large Golgin 
subfamily A member 5 domain in VIPAR. Golgins indeed are found in different parts of 
Golgi stacks and they are typically anchored to the membrane by a transmembrane 
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domain or by binding to a small GTPase (Munro, 2011). We thus concluded that 
VIPAR is associated with PLOD3, and/or other possible cargos, at the TGN 
compartment and this binding stabilises the N-terminal disordered region of VIPAR. 
Fractionation experiment performed in this work showed that VPS33B may be present 
in a soluble and a membrane associated state (through its interaction with VIPAR). 
Therefore this experiment, combined with other evidence, suggested that VPS33B 
binding to VIPAR is associated with formation and trafficking of the vesicles 
containing PLOD3 and other possible cargos (figure 6.1 A and B).  
 
 
 
6.4 - VPS33B/VIPAR complex is involved in PLOD3 delivery to 
collagen 
 
 
The main goal of this thesis to clarify the role of VPS33B and VIPAR in the cell and 
understand the pathways and mechanisms in which these proteins are involved. 
VPS33B and VIPAR function indeed is not yet fully characterised. VPS33B is known 
to belong to the SM family of proteins that bind to Soluble N-ethylmalemide sensitive 
factor Attachment Receptor (SNARE) which in turn mediate all intracellular 
membrane fusion events (Gallwitz and Jahn, 2003; Peterson and Emr, 2001). As 
mentioned above, VIPAR belongs to the Golgin family of proteins because a large 
Golgin subfamily A member 5 domain forms most of its structure. Golgins are coiled-
coil motif proteins that mediate tethering of vesicles to Golgi membranes and cisternal 
membranes to each other (Burguete et al., 2008; Satoh et al., 2003). The discovery of 
PLOD3 as a novel interacting partner for VIPAR lead to a better understanding of the 
role of VPS33B/VIPAR complex in the cells. In agreement with the presence of a 
Golgin domain in VIPAR, the VPS33B/VIPAR complex was localised to the TGN 
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where it carries out its function in PLOD3 (and possibly other cargos) vesicle mediated 
transport from this compartment. The mislocalisation of PLOD3 in Vps33b/Vipar 
knockdown mIMCD-3 cells and its accumulation in the TGN represents a strong 
evidence for this statement. Additionally the work presented here suggested that 
RAB11A is involved in the trafficking of PLOD3 from TGN, given the co-localisation 
of both PLOD3 and VIPAR with this intracellular marker. This confirms previous data 
that identified a VPS33B interaction with RAB11A (Cullinane et al., 2010). 
Additionally this project provided insights into the intracellular localisation of PLOD3. 
The endogenous protein was localised to the TGN compartment in HeLa cells and 
fibroblasts contradicting the previous data that attribute an ER localisation to all PLOD 
isoforms (Heikkinen et al., 2000; Salo et al., 2006a). In support of the data shown in this 
thesis, PLOD3, unlike other PLOD isoforms, is thought to utilise two different 
trafficking pathways for its delivery to the cell surface and for extracellular secretion 
(Wang et al., 2012). Additionally PLOD3 enzymatic activity is peculiar among isoforms 
and as well having the LH activity, common to all three isoforms, PLOD3 is capable of 
collagen glucosyltransferase (GGT) and collagen galactosyltransferase (GT) activities. 
Glycosylation (by GT and GGT) is the type of post-translational modification that is 
known to occur in the Golgi apparatus (Stanley, 2011), which is in agreement with the 
TGN location of PLOD3 established in this work. The post-translational modifications 
performed by PLOD3 in collagens are crucial for determining its stability and 
intracellular trafficking (Sipila et al., 2007). Data in this thesis demonstrate how 
depletion of PLOD3 activity in Plod3 knockdown mIMCD-3 cells leads to an abnormal 
intracellular accumulation of collagen IV, similarly to that observed in Vps33b/Vipar 
knockdown mIMCD-3 cells. Further confirmation of these results was provided by 
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additional experiments that demonstrated a failure in PLOD3 delivery to collagen in 
Vps33/Vipar knockdown mIMCD-3 cells. This therefore suggested that VPS33B and 
VIPAR are required for PLOD3 delivery to collagen and PLOD3-collagen binding is 
crucial for trafficking of collagen inside the cell (confirming previous data) (figure 6.1). 
Abnormalities in collagen IV modifications in Plod3 deficiency have been deduced 
from a ‘band shift’ in Western-blot of collagen IV chains that is caused by a lack in its 
post-translational modifications (Norman and Moerman, 2000). Similarly, Western-blot 
experiments showed a slightly enhanced migration in collage IV chains in 
Vps33b/Vipar and Plod3 knockdown cells. However, further on-going experiments are 
required to confirm these data. 
The lack of co-localisation between PLOD3 and collagen IV in Vipar knockdown 
mIMCD-3 cells, that might cause collagen IV under-glycosylation, can lead to the 
hypothesis that PLOD3 binding to collagen, required for its trafficking, does not occur 
at the TGN level but in the collagen carriers that are responsible for the transport of 
collagen in the cell (figure 6.1). This statement is supported by several experiments 
performed in this thesis. Firstly, the co-localisation between PLOD3 and collagen IV, 
that is lost in Vipar knockdown mIMCD-3 does not occur at TGN level in wild-type 
cells. Round granular structures have been evidenced by co-localising PLOD3 with 
collagen IV and further experiments are required in order to determine their intracellular 
localisation. Secondly, data in this thesis evidence that mistrafficking of PLOD3 in 
Vipar knockdown mIMCD-3 is associated with an accumulation of PLOD3 trafficking 
at the TGN and no co-localisation between PLOD3 and collagen IV occurs in this 
compartment in knockdown cells. It is therefore possible to conclude that 1) PLOD3 
and collagen exit from TGN occurs independently and involves different trafficking 
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routes and VPS33B/VIPAR are responsible for PLOD3 trafficking only 2) PLOD3 and 
collagen binding, that is essential for collagen trafficking, occurs at collagen carrier 
structures (that are either Rab11a or Lamp1 positive) and not at the TGN (figure 6.1). 3) 
Intermediate organelles might be involved in VPS33B/VIPAR mediated delivery of 
PLOD3 towards collagen carrier structures (dashed arrow in figure 6.1) as might be 
suggested by the lack of co-localisation between VIPAR, PLOD3 and collagen in 
correspondence of the round granular structures. Another possibility is that this process 
is fast and VPS33B/VIPAR is recycled back for another fusion cycle. Further 
experiments are required to further investigate the ‘delivery’ of PLOD3 to collagen 
carrier structures in the cell. 
Trafficking of collagen in the cell is not yet fully understood and controversies are 
related to procollagen size (>300nm in length) compare to a typical vesicle size (<100 
nm) (Stephens, 2012). The evidence provided in this thesis and future planned 
experiments could lead to a better understanding on the complex machinery involved in 
collagen trafficking. 
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Figure 6.1. Schematic representation of the VPS33B/VIPAR trafficking pathway 
described in this thesis. (A). Transmembrane VIPAR interacts through its N-terminal 
domain with PLOD3 located at the lumen of the TGN. VPS33B is localised in the 
cytosol. (B). The VPS33B binding to VIPAR is associated with the formation of the 
vesicle containing the cargo protein PLOD3. (C). VPS33B and VIPAR are required for 
the transport of the vesicle to the receiver compartment that might be an intermediate 
organelle (dashed arrow) or collagen carrier structures. (D). The fusion of the PLOD3 
caring vesicle with the collagen carrier structure determines the binding of PLOD3 to 
Pro-collagen that is required for collagen trafficking (E). 
 
 
 
6.5 - Abnormal collagen in Vps33b/Vipar/Plod3 deficiency and its 
relevance to ARC  
 
 
Initial studies by Cullinane at all (2010) described a marked reduction in E-cadherin 
expression in Vps33b/Vipar knockdown mIMCD-3 cell lines. Similarly E-cadherin was 
found down-regulated in ARC syndrome patient liver biopsies and Vipar morfolino 
(MO) knockdown in the zebrafish (Cullinane et al., 2010). Epithelial-to-Mesenchymal 
transition (EMT) has been observed in knockdown cell lines and this transition is often 
caused by a reduced expression of E-cadherin. This suggests that an EMT could be 
occurring in ARC syndrome patient’s polarised epithelial cells (Cullinane et al., 2010). 
The work presented here suggests that abnormal collagen modification and trafficking 
can lead to E-cadherin down-regulation in Vps33b/Vipar and Plod3 knockdown 
mIMCD-3 cells. Further experiments are required to confirm these data. However the 
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mechanism presented here for the first time provides an intracellular pathway for 
VPS33B/VIPAR action that can link their function with the cell phenotype. The better 
understanding of the role of this protein complex in the cell will lead in the future to a 
better characterisation and treatment of the ARC syndrome. 
Additionally, an abnormal intracellular accumulation of collagen type I was described in 
human skin fibroblast derived from ARC patients suggesting an agreement between the 
findings in the cell model of the disease and patients’ phenotype. 
Similarities in the phenotype between Vps33b/Vipar knockdown and Plod3 knockdown 
mIMCD-3 cells suggested that collagen related defects can be observed in ARC patients 
as well as in patients with mutations in Plod3. Only one compound heterozygous patient 
with mutations in Plod3 is known and they lead to a markedly reduction in GGT and 
LH activity of the enzyme (Salo et al., 2008). The common features between the 
PLOD3 deficient patient and individuals with ARC include: joint contractures, 
osteopenia, sensorineural deafness, growth retardation (Salo et al., 2008). 
The bleeding tendency of patients with ARC might be explained by the disruption of 
the capillary basement membranes caused by PLOD3 mistrafficking and consequent 
abnormal collagen formation and secretion. Similarly defects in the glomerular 
basement membranes (GMB) can explain renal tubular dysfunction in ARC patiensts 
such as acidosis and renal tubular dysfunction. The non-complete overlap of symptoms 
between the two conditions suggests that PLOD3 might not be the only cargo of 
VPS33B/VIPAR and further experiments are required to establish this. These features 
include the severe degree of liver and kidney disease in ARC and no blood vessel 
tortuosity in ARC. Indirect secondary effects of PLOD3/VPS33B/VIPAR deficency 
might explain these symptoms but further investigation is required to elucidate the 
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mechanisms involved. In addition VPS33B/VIPAR complex was found to be required 
for platelet α-granule biogenesis  (Urban et al., 2012,). The clinical features in the only 
one patient with PLOD3 deficiency have not been fully investigated and therefore it is 
difficult to judge the full extent of the phenotype. Nevertheless this available data 
strongly suggest that PLOD3 is unlikely to be the only cargo for VPS33B/VIPAR. 
Another hypothesis in that PLOD3 is indirectly involved in these pathways through the 
post-trasnlational modifications of proteins that are directly involved in the α-granule 
biogenesis.   
Finally, the ubiquitous Vps33b knockout mouse developed in our laboratory is 
embryonically lethal at E 8.5 while Plod3 knockout mice at E 9.5 (Rautavuoma et al., 
2004). These data suggests a crucial role for both VPS33B/VIPAR and PLOD3 in 
development and disease. 
 
 
 
6.6 - Future experiments 
 
 
1) As mentioned above, it would be interesting to map the location of the 
transmembrane domains in VIPAR. For this purpose the cloning of new VIPAR 
constructs, based on predictions of TMD servers, is being carried out.  
2) This thesis has established that PLOD3 is a cargo recognised by VIPAR at the TGN 
level. To date is not known if this recognition is PLOD3-specific or if other cargos are 
recognised by VIPAR at the TGN. The mass-spectrometry results identified PLOD1 as 
another possible interacting partner for VPS33B/VIPAR but preliminary co-localisation 
experiments did not confirm this result. However more experiments are required to 
exclude the possibility that PLOD1 is not an interactor of VPS33B/VIPAR. 
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Additionally, different pull-down experiments can be performed by incubating the 
immobilized VPS33B/VIPAR purified complex with a different cell lysate (e.g derived 
from mIMCD-3 cells) in order to identify new possible interactors for this complex and 
answer the question whether PLOD3 is the only cargo recognised by VIPAR in the cell. 
3) According to the model proposed in figure 6.1 for VPS33B/VIPAR role in PLOD3 
and collagen trafficking, there are still questions that need answering. Primarily, it 
would be essential to determine the intracellular localisation of PLOD3 and collagen in 
wild-type mIMCD-3 cells. Secondly, the ‘destiny’ of VPS33B/VIPAR complex after 
cargo delivery is not known and would be interesting to establish. Immunofluorescence 
experiments indeed do not show a simultaneous co-localisation between VPS33B-
VIPAR, PLOD3 and collagen IV in wild-type mIMCD-3 cells but VPS33B/VIPAR co-
localisation with PLOD3 occurs in a different compartment from PLOD3 co-
localisation with collagen. Therefore VPS33B/VIPAR might directly cycle back after 
PLOD3 delivery to collagen or its involved in the cargo sorting only. Thirdly, the route 
followed by PLOD3-collagen after binding in collagen carrier structures, and how this 
is involved in collagen secretion, is not yet known. To answer these questions live cell 
imaging experiments are currently being performed. 
4) On-going mass-spectrometry analysis of collagen IV and collagen I post-translational 
modifications are aimed at identifying changes in the hydroxylation/glycosylation 
pattern of collagens in knockdown cells as well as in tissues derived from our mice 
model for the ARC syndrome. Additionally similar approaches are being performed in 
order to identify other possible proteins with collagen domains whose glycosylation is 
altered in Vps33b/Vipar deficiency. This might help at elucidating other features of the 
ARC syndrome as the mislocalisation of specific proteins in patient’s liver and kidney.  
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5) Mouse model: Experiments are carried out in collaboration with Dr Holly Smith 
involving the use of the ARC mouse model in order to understand the impact of PLOD3 
in the pathophysiology of the ARC syndrome. This indeed is difficult to obtain from 
human samples and represents the closest model to the disease that can additionally be 
useful for trials of potential therapeutic agents. 
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Figure 7.1 - (A) Western blot analysis to identify His6-VIPAR protein soluble (S) and 
insoluble pellet (P) fractions after protein expression and extraction from SF9 insect 
cells. Anti-His6 antibody was used for identification. (B) SDS-Page analysis to identify 
GST-tagged VIPAR expression and solubility in BL21 (DE3)pLysS bacterial cells after 
protein extraction. Soluble (S) and insoluble pellet (P) fractions are shown.  
The molecular weight of VIPAR corresponds to 57 kDa and the molecular weight of the 
GST is 26 kDa.  
 
 
Appendix 2 
 
 
 
 
Figure 7.2  -  SDS-PAGE of Cobalt chromatography elution fractions. His6-VPS33B 
was expressed and extracted from SF9 cells before being affinity purified using cobalt 
(Co2+) resin for the purification of 6x His-tagged VPS33B. The molecular weight of 
VPS33B corresponds to 70 kDa.  
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Appendix 3 
 
 
 
 
 
 
 
 
 209 
 
 
 
 
 
 
 
 
 
 
 210 
 
 
Figure 7.3 - Raw data from FRET data processing. From left to right: intensity image 
recorded using the donor (GFP) channel; fluorescence intensity histogram; false-color 
image representing donor fluorescence lifetime, obtained by processing the intensity 
images using the time-gated phasor plugin for ImageJ; histogram of fluorescence 
lifetime; gaussian fit of the lifetime histogram, used for the determination of the average 
fluorescence lifetime from each image.  
The panels represent 3 measurements for each of the following samples: GFP only; 
GFP-VIPAR + VPS33B; GFP-VIPAR + mCherry; GFP-VIPAR + mCherry-VPS33B; 
GFP-VIPAR + mCherry-PLOD3. 
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